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Abstract 
The purpose of this study was to evaluate the expression patterns of a 
range of cell cycle proteins (MCM2, Ki-67, geminin and cyclin D1) and 
assess the DNA content (ploidy) as diagnostic and prognostic markers in 
oral squamous cell carcinomas (OSCC). Immunohistochemical staining and 
DNA ploidy image cytometry analysis were performed on 86 cases. There 
were 47 primary OSCC that had not metastasised (NM), 39 that had 
metastasised (M) along with their matched positive cervical lymph nodes, 
and 17 normal oral mucosa (NOM) samples. Tissue microarrays (TMAs) 
were prepared with three cores from each of three areas: surface, middle 
and advancing front of each case. Sections were immunostained with 
MCM2, Ki-67, geminin and cyclin D1 antibodies. 
The results revealed that there were no differences in protein expression in 
different areas of the tumours, nor between the metastatic and non-
metastatic carcinomas. None of the cell cycle proteins showed significant 
differences in lymph node metastasis compared to the primary OSCCs, with 
the exception of Ki-67. MCM2 showed higher expression in nodal 
metastses, but this did not reach statistical significance. MCM2/Ki-67 and 
geminin/Ki-67 ratios were significantly different between metastatic and non-
metastatic tumours. 
Analysis of DNA ploidy showed that aneuploidy was detected in all (100%) 
cases of OSCC. Similarly, all lymph nodes samples (39 cases) were 
aneuploid. The results from this project suggest that dysregulation of cell 
cycle regulatory proteins was evident in the studied cohort. MCM2 
expression, MCM2/Ki-67 and geminin/Ki-67 ratios may have prognostic 
significance in oral cancer. Aneuploidy is a common feature of oral 
carcinoma. The results also suggest that primary OSCC lesions may show 
heterogeneity. Greater incidence of abnormal DNA content was observed at 
the surface area of tumours. 
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1. LITERATURE REVIEW 
1.1 Oral cancer - overview 
According to a recent international epidemiological study, cancer is one of 
the leading causes of death in the world (Ferlay et al., 2010) and head and 
neck cancer (HNC) is one of the most common cancers. HNC is the 15th 
most prevalent malignant neoplasm in the United Kingdom (Cancer 
Research UK, 2010). HNCs are located in the upper aerodigestive tract 
encompassing the nasal cavity, paranasal sinuses, pharynx, larynx and oral 
cavity (Argiris et al., 2008). According to the World Health Organisation 
(WHO) (Barnes, 2005) classification system, a wide range of neoplasms 
have been categorised in the head and neck region. However, squamous 
cell carcinoma (SCC) represents the most common epithelial malignancies 
in the region (Cooper et al., 2009). SCC in the oral cavity (oral cancer) is the 
sixth most common malignancy worldwide (Shah and Gil, 2009), 
representing about 3% of all malignancies (Speight et al., 1996). The Larynx 
and pharynx are the next most commonly affected sites for SCC in the head 
and neck region (Mehanna et al., 2010). 
The annual incidence of oral and oropharyngeal squamous cell carcinoma 
(OSCC) accounts for nearly 92,000 new cases in Europe. According to 
Cancer Research UK, 6,539 people were diagnosed with oral cancer in 
2010 and there is a high mortality rate, with approximately 2,056 deaths in 
2011 (Cancer Research UK, 2010). In the last two to three decades the 
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incidence trends have not shown any noticeable improvement. The highest 
incidence across the UK was reported amongst Scottish people. 
In the United States, approximately 22,000 new cases of oral cancer are 
reported each year (Neville et al., 2009). In recent decades a significant 
increase in the incidence of oral cancer, particularly tongue cancer, has 
been documented in young people in the United States as well as the 
United Kingdom (Sherin et al., 2008, Warnakulasuriya et al., 2007). In 2014, 
an estimated 42,440 new oral cavity cases were reported (including 
pharynx) and around 8,390 deaths registered in the United States (National 
Cancer Institute of U.S.A, 2014). It was recently reported that 263,900 
cases were diagnosed as oral squamous cell carcinoma in 2008 around the 
world (Seethalakshmi, 2013). The incidence rate of oral squamous cell 
carcinoma is relatively high in most South Asian nations (Jemal et al., 
2011). Trends in oral cavity cancer incidence have declined over the past 
decades across countries. This decrease is largely due to the decline in 
tobacco use (Chaturvedi et al., 2013). In contrast, oropharyngeal cancer 
(OPC) incidence rates have increased over time (Auluck et al., 2014). 
These contradictory incidence figures for oral and oropharyngeal cancers 
are most likely linked to human papillom virus (HPV) infection (Chaturvedi et 
al., 2013). HPV DNA is frequently detected in oropharyngeal tumours 
(Syrjänen, 2010, Marur et al., 2010). Most importantly the HPV type 16 
(Moody and Laimins, 2010) is highly associated with oropharyngeal cancer 
(Westra, 2015). Consistent with this, a significant increase in the incidence 
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of HPV-associated OPC among men has been reported (Gillison et al., 
2012). 
1.2 Oral squamous cell carcinoma 
Squamous Cell Carcinoma is an invasive epithelial neoplasm which is 
usually well differentiated, showing preponderance in males (2:1), and is 
common over the age of 60 years (Mehanna et al., 2010), with an annual 
incidence of about 8 per 100,000 people in the UK. According to a recent 
report, 6% of people affected with oral cancer are young adults (below 45 
years of age) (Majchrzak et al., 2014). Oral squamous cell carcinoma 
(OSCC) comprises the vast majority (more than 90%) of all malignancies in 
the mouth and oropharynx (Cooper et al., 2009, Marur and Forastiere, 
2008). However, oral (OSCC) and oropharyngeal (OPC) cancers have 
distinct clinical characteristics, and should be regarded as two separate 
entities (Auluck et al., 2014). Clinically, OSCC involves the tongue (anterior 
two third), lower lip, floor of the mouth, buccal mucosa, gingivae and hard 
palate. OPCs can be present in the tonsil area, soft palate, base of the 
tongue and the pharyngeal walls (Chaturvedi et al., 2013). Recent literature 
has reported that OSCC and OPC have different incidence rates, aetiology, 
and clinical outcome (Won et al., 2012, Auluck et al., 2014). The association 
of HPV, mainly type 16, is established as an etiologic cause of OPC, 
whereas its role in OSCC is uncertain (Chaturvedi et al., 2013). Higher HPV 
positivity has been reported in OPC compared to OSCC (Laco et al., 2011). 
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Patients with HPV-associated cancers have more favourable prognosis than 
patients with HPV-negative cancers (Ang et al., 2010, Won et al., 2012). 
Disappointingly, in recent years there has been a marked increase in 
mortality and incidence of oral cancer. This has been documented as due to 
complexities of cancer growth pathways, late diagnosis, and recurrence. 
Overall mortality is about 50% (Johnson et al., 2011). This increases with 
metastasis (Noguti et al., 2012). Thus, the clinical need to prevent 
metastasis is crucial. To date, despite remarkable progression in cancer 
treatment, including surgical techniques and chemotherapy, the prognosis 
remains unchanged. However, the average 5-year survival rates remain at 
approximately 50% of affected people (Fung and Grandis, 2010, González-
Moles et al., 2013), with more than 60% of patients presenting in stages III 
and IV (Lingen et al., 2008). 
OSCC is characterised histologically by frank invasive growth across the 
basement membrane into the connective tissue (Figure 1.1). Keratin pearls 
and individual cell keratinisation are usually seen and are often 
accompanied by stromal reaction (Barnes, 2005). Furthermore, in advanced 
lesions, the malignant cells tend to invade deeply into adipose tissue, 
muscle, nerves, blood vessels and eventually bone. 
Different histopathological classifications have been proposed over time in 
an attempt to increase the objectivity of histopathological parameters to 
predict the biological behaviour of cancer. A histopathologic grading system 
for OSCC was originally developed by Broders (Broders, 1941) in 1920. 
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Broder`s system was based on the resemblance between the neoplasm and 
normal epithelium cells. However, his system lacked correlation between 
histological grade and the prognosis of OSCC (Anneroth et al., 1987). In 
1973, Jakobsson et al. (Jakobsson et al., 1973) introduced a multi-
parameter classification system based on histopathologic characteristics of 
tumour cells, such as nuclear pleomorphism, mitoses, degree of 
keratinization and pattern and depth of invasion. The Bryne et al. (Bryne et 
al., 1992) grading system was proposed in 1992 to evaluate tumour cells at 
the deep invasive margins of OSCC. The World Health Organization (WHO) 
classification system, reviewed in 2005 (Barnes, 2005), is based on 
Broders’ grading system, which takes into account the degree of cell 
differentiation. OSCC is graded into three categories: well, moderately and 
poorly differentiated (Barnes, 2005). Well differentiated squamous cell 
carcinoma resembles the normal epithelial tissues. In contrast, carcinoma 
cells that are difficult to recognise as epithelial (predominately immature 
cells) and show no keratin production are graded as poorly differentiated 
carcinomas. Between these two patterns tumours are graded as moderately 
differentiated (Barnes, 2005).  
OSCC has a distinctive invasion pattern: a cohesive (expansive) pattern and 
non-cohesive (infiltrative) pattern, or combinations of both may be observed. 
The former pattern is characterised by large tumour islands and well defined 
margins. Non-cohesive growth is characterised by scattered individual cells 
or small irregular cords with ill-defined margins (Barnes, 2005). 
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Even though some OSCCs may arise from non-dysplastic epithelium 
(Warnakulasuriya et al., 2008), many are preceded by leukoplakia (white 
patch), erythroplakia (red patch) or speckled leukoplakia (mixed white/red). 
Erythroplakia, in particular, with epithelial alterations such as dysplasia, 
have an increased likelihood of progression to carcinoma (Harrison et al., 
2009). The prevalence of oral premalignant lesions is estimated to be 
between 1 and 5% (Napier and Speight, 2008). The term epithelial 
dysplasia implies cytological changes (cellular atypia) and loss of the normal 
epithelial architecture.  
Generally, dysplasia is graded into three categories: mild, moderate and 
severe. In mild dysplasia the architectural disturbances combined with 
cellular atypia are observed only in the lower third of the epithelium, 
moderate dysplasia is when such changes affect two thirds of the epithelial 
thickness. In severe epithelial dysplasia, loss of individual cell layer 
organisation and atypia involves more than two thirds of the epithelium. 
Carcinoma in-situ is a term used for the most severe dysplasia, in which 
changes of pronounced cytological atypia are seen throughout the full 
thickness of the epithelium, `top- to- bottom`, but invasion is not present 
(Warnakulasuriya et al., 2008). 
Staging of oral cancer depends on the Tumour-Node-Metastasis (TNM) 
classification system, which was recently reviewed and updated in 2010 
(Sobin et al., 2011). This system depends on the extent of the primary 
tumour (T1, T2, T3 and T4), lymph node involvement (N0, N1, N2 and N3) 
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and occurrence of distance metastasis (M0 and M1). The TNM staging 
system has been globally accepted and routinely used in clinical practice to 
facilitate treatment planning and is known as the clinical TNM classification 
(cTNM). Additionally, when this classification is carried out after 
histopathological assessment of tissue samples, it is known as the 
pathologic TNM classification (pTNM) (Takes et al., 2010). The possible 
TNM combinations are grouped into four main categories as follows: stages 
I, II, III and IV. In meta-analysis studies, the TNM system (T value) has 
shown a correlation between tumour thickness and nodal metastasis in 
OSCC (Huang et al., 2009), but it is not a very reliable factor (Akhter et al., 
2011). 
Lymph node metastatic tumours occure in 40% of OSCC patients (Noguti et 
al., 2012). Moreover, up to 25% of OSCC cases have evidence of distant 
metastasis (Woolgar, 2006). Patients with upper aerodigestive tract 
malignancy are more likely to develop second tumours in approximately 
20% of cases (Hunter et al., 2005). This may be related to genetic 
alterations or epigenetic changes in the epithelium around the tumour, the 
so called “field of cancerization”, causing the subsequent recurrences 
(Leemans et al., 2010). Studies also suggest that the primary tumour of 
squamous cell carcinoma and the second tumour develop from separate 
genetic mutations in the same “field of cancerization” (Hunter et al., 2005). 
Unfortunately, tumours that develop in previously irradiated soft tissue tend 
to be more aggressive and have unpredictable survival (Woolgar, 2006). 
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Treatment of OSCC is based on the location and clinical stage of disease 
and consists of radical surgery, radiotherapy or a combination of both. 
Radiation therapy may be accompanied by chemotherapeutic agents. In 
small tumours, surgery alone is preferred, whilst for patients with larger 
lesions and lymph node metastasis, a combined therapy is required. In 
addition, new promising treatments, including gene therapy and 
photodynamic therapy, have been introduced (Agostinis et al., 2011, Shah 
and Gil, 2009).  
Early diagnosis of OSCC is essential in terms of treatment and survival. In 
reality, clinical detection of early invasive carcinoma may be difficult. 
Nevertheless, traditional histological examination combined with biological 
and molecular markers can be useful and special attention should be paid to 
the deepest layers of the epithelium in suspicious lesions (Barnes, 2005). 
Early diagnosis can offer a significant change in clinical outcome and quality 
of life for patients with OSCC. 
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Figure 1.1: H&E section of a well-differentiated squamous cell carcinoma 
(SCC). A: Malignant squamous cells infiltrate through the basement 
membrane deep into connective tissue. B: High power view showing 
neoplastic epithelial cells and keratin pearl formation. 
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1.2.1 Pathogenesis and aetiology of OSCC 
Several variants of OSCC are classified on the basis of the clinical 
presentation and the histological appearance. These variants are important 
in terms of difficulty in diagnosis. Several studies have suggested that oral 
squamous cell carcinomas are associated with, or are preceded by 
precancerous lesions (Pitiyage et al., 2009, Neville et al., 2009). Others 
found that OSCC may arise from clinically normal oral mucosa (Scully and 
Bagan, 2009a). 
The causative agents of oral squamous cell carcinoma have not been fully 
defined and multiple factors may be involved. Nevertheless, the most 
prominent risk factors are tobacco use and alcohol abuse (La Vecchia et al., 
2009). These associated risk factors were reported in approximately 70% to 
90% of head and neck cancers (Brandizzi et al., 2008). Patients who 
combine both tobacco and alcohol consumption have a much higher risk of 
cancer development (Ansary‐Moghaddam et al., 2009). 
Human papilloma virus (HPV) has been shown to be another factor 
associated with carcinogenesis (Marur et al., 2010, Brandizzi et al., 2008, 
Ang and Sturgis, 2012). The viral genome consists of portions that are 
expressed ‘early’ in its lifespan (coding as E1-E7), a further two in the ‘late’ 
stage of its lifspan (coding as L1 and L2), and a non-coding long control 
region (LCR) gene (Ganguly and Parihar, 2009). The HPV genome may 
integrate into the host DNA and its amplification causes high expression of 
the oncoproteins E6 and E7 due to disruption of its E2 sequence; this leads 
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to inactivation of p53 (degraded by E6) and retinoblastoma protein (pRb) 
(degraded by E7) (Chaturvedi and Gillison, 2010). By this mechanism HPV 
can prevent apoptosis and increase DNA replication and cell proliferation 
(Pietsch and Murphy, 2008, Marur et al., 2010). Inactivation of pRb is 
associated with an increase of p16INK4A protein (Westra, 2014). 
Subsequently this will increase the chance of tumour formation in infected 
cells (Figure 1.2). 
Oral cancer is not associated with HPV infection, however, the detection 
rate of HPV DNA in head and neck cancers varies widely between studies. 
It has been identified in 35 to 55% of OSCCs (Jalouli et al., 2012, Castillo et 
al., 2011). This variability in incidence of HPV can be attributed to the 
different detection methods (such as in-situ hybridisation or polymerase 
chain reaction) and the accuracy of the classification of anatomic sites. It 
may also be due to sample preparation, for example, whether formalin-fixed 
or frozen specimens were used (Syrjänen, 2010, Westra, 2015). 
Betel nut chewing, ultraviolet radiation (sunlight), vitamin deficiency and 
candida infection have also been shown to be associated with an increased 
risk of OSCC (Scully and Bagan, 2009a, Muttagi et al., 2012). 
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Figure 1.2: Diagram showing the mechanism by which the HPV genome 
invades and multiplies in the host cell. After E2 disruption, HPV circular 
episome allows HPV DNA integration, leading to higher expression of E6 
and E7 proteins. This over-expression is able to inactivate tumour 
suppressor genes p53 and pRb, which promotes cell growth and possibly 
malignant change. 
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1.2.2 Genetic and molecular changes in oral cancer  
Squamous cell carcinoma lesions arise as a consequence of multiple 
genetic alterations in tumour suppressor genes, which inhibit uncontrolled 
cell division, and oncogenes, which drive the malignancy, involving many 
chromosomes (Scully and Bagan, 2009a). Such genetic alterations are 
considered to be the hallmarks of human cancer. These include cell 
dysregulation, disruption to cell signalling, uncontrolled proliferation, cell 
immortality, apoptosis inhibition, metastasis and induction of angiogenesis 
(Hanahan and Weinberg, 2011). In 1996, Califano and colleagues (Califano 
et al., 1996) proposed a model for pathological genetic progression of head 
and neck carcinoma. They suggested that identification of loss of 
heterozygosity of chromosomes, such as 9q21, can be useful in carcinoma 
diagnosis.  
Much research has been carried out in order to define these genetic 
alterations associated with carcinogenic events, but these events are still 
not clearly understood. Genetic changes have been suggested to be a key 
element in the variable susceptibility for oral carcinogenesis (Leemans et 
al., 2010). Molecular studies have shown that genetic alterations such as 
chromosomal loss at 1p, 3p, 4p, 5q, 8p, 10p ,11q, 13q and 18q with gains at 
1q, 3q, 5p ,7q ,8q ,9q ,11q ,12q ,14q and 15q are frequently detected in 
OSCC, causing cell disturbance (Bauer et al., 2008, Leemans et al., 2010, 
Salahshourifar et al., 2014). In general, the accumulation of genetic 
imbalances such as up-regulation, down-regulation, deletion or mutation is 
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thought to drive the progression of cancer lesions by different mechanisms 
(Stadler et al., 2008). These genetic imbalances can stimulate different 
effects on cells under different conditions and modify interactions with 
neighbouring cells, as well as with stromal cells (Hunter et al., 2011). 
Other molecular studies have indicated that tumour necrosis factor- alpha 
(TNF-α) and increased expression of interleukins (IL-4,-6,-8,-10) are 
strongly associated with an increased risk of OSCC (Brailo et al., 2012, 
Lippitz, 2013). These cytokines help tumour cells to inactivate tumour 
suppressor genes (p53), activate oncogenes (Ras), and escape apoptosis, 
leading to uncontrolled cell growth (Brailo et al., 2012). 
Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that 
regulates cell proliferation, differentiation and migration (Schneider and 
Wolf, 2009). It was claimed that over-expression of EGFR is associated with 
tumour growth, metastasis and poor prognosis (Mitsudomi and Yatabe, 
2010, Normanno et al., 2006). Gene amplification of EGFR is seen most 
frequently in OSCC patients at 7p11.2 region (Sheu et al., 2009). Over-
expression of EFGR was detected in 33% of areca-associated oral 
squamous cell carcinoma cases (Chiang et al., 2008). Combinations of anti-
EGFR antibodies and radiotherapy have been introduced in clinical trials to 
increase the efficacy of cancer treatment (Leemans et al., 2010).  
Activation of oncogenes (proto-oncogenes) is a fundamental step in 
carcinogenesis, and over-expression or dysregulation of these genes can 
lead to malignant transformation. For example, myc (c-myc, N-myc, L-myc) 
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and Ras (H-ras, K-ras, N-ras) genes are frequently associated with solid 
tumours (Garzon et al., 2009). Matrix metalloproteinases (MMPs), especially 
MMP-9, are also thought to play a role in cell proliferation, migration and 
invasion (Vilen et al., 2013). MMPs can induce the release of cytokines and 
cause degradation of the extracellular matrix, leading to changes in cell 
behaviour and promotion of tumour progression (Kessenbrock et al., 2010). 
Briefly, MMPs, integrins and the urokinase Plasminogen Activator (uPA) 
system are proposed to be involved in tumour progression and lymph node 
metastasis (Zhou et al., 2009). 
Tumour suppressor genes (TSG) play a crucial role in normal growth 
control, including cell cycle, proliferation, differentiation and apoptosis; their 
dysfunction can result in uncontrolled growth and cancer development. One 
of the most extensively studied TSG, is the p53 gene, a gene involved in 
cell cycle regulation and programmed cell death (apoptosis). The p53 gene 
is mutated in about 50% of head and neck cancers. However, there is 
debate in the literature about the timing of its role in oral tumourigenesis. 
Some studies have stated that mutations of p53 appear to be late events in 
carcinogenesis and are therefore rare in precancerous lesions (Shahnavaz 
et al., 2000). In contrast, over-expression of p53 has also been reported in 
dysplasia (Campo-Trapero et al., 2008, De Oliveira et al., 2012).  
Additionally, cell cycle checkpoint proteins such as ATM and ATR, play a 
vital role in DNA replication in the cell cycle by promoting senescence and 
apoptosis in cells with damaged DNA (Jackson and Bartek, 2009, Smith et 
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al., 2010). Impairments of DNA repair mechanisms have been observed in 
tumour cells and are associated with carcinogenesis (Cook, 2009, Truong 
and Wu, 2011). Other molecular events associated with oral cancer, for 
example, inactivation of p16INK4A, pRb pathways and aberrations in the 
fragile histidine triad gene (FHIT), have also been identified (Hunter et al., 
2005, Leemans et al., 2010).  
In summary, it has been shown that the carcinogenesis process develops 
as multiple complicated genetic events. Therefore, a full understanding of 
the biologic basis of genetic alterations is essential for proper diagnostic and 
prognostic evaluation. 
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1.3 The cell cycle 
The cell cycle is defined as a series of events that include nuclear DNA 
duplication and mitosis, which lead to cell division. The eukaryotic cell cycle 
traditionally consists of four phases (Figure 1.3): G1 (first gap phase) is the 
growth or synthesis phase and is the interval between the last mitosis and 
the initiation of DNA duplication. During this time the cell decides whether to 
start to proliferate or leave the cycle and enter into G0 (gap 0) or quiescent 
phase to allow more time for growth. The duration of the G1 phase is widely 
variable among different cells and is the longest phase in a typical 
mammalian cell. It has been estimated that in epithelial cells it may last from 
4 to140 hours (Squier et al., 1976). Growth occurs in this phase.  
According to some researchers, the G1 phase in a rapidly proliferating 
tissue such as gut lasts approximately 11 hours out of a total cell cycle time 
of approximately 24 hours (Bury and Cross, 2003). Most cells in this phase 
(G1) are regulated by two cell cycle checkpoints: a restriction checkpoint 
and a DNA damage checkpoint. If a cell escapes from these checkpoints 
with the presence of damaged DNA, cancer may develop. 
S phase (DNA synthesis phase) is when DNA replication takes place and 
typically lasts for 8 hours (Bury and Cross, 2003). The G2 (second gap 
phase) is a period between the completion of DNA replication and mitosis 
(M phase which requires less than an hour). In this stage the cell provides 
the appropriate nutrients and proteins needed for mitosis. Cells in the G1 
phase have a diploid DNA content and cells in the G2 phase are tetraploid 
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with double the normal DNA content. As previously stated, the cell cycle is 
regulated by many molecular events (checkpoints), which may detect and 
repair any damaged DNA and prevent cell division at any specific point (van 
den Heuvel, 2005). However, if repair is unsuccessful, cells may undergo 
apoptosis (Malumbres and Barbacid, 2009).  
 
 
 
Figure 1.3: The four cell cycle phases: G1, S, G2, M. Cells in G0 are in a 
resting stage. G1 is the gap between mitosis and synthesis, while G2 is the 
gap between S phase and the cell division phase (M phase). 
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1.3.1 Initiation of DNA replication 
Precise regulation of DNA replication in eukaryotic cells is crucial for the 
maintenance of genomic integrity. The genome is organised into pairs of 
chromosomes, which are precisely coordinated during S phase. The exact 
duplication of chromosomes is required in each proliferating cell. The 
complex series of events involved in the replication process initiates from 
hundreds of sites along the genome, called origins of replication (OR). In 
mammals, 30,000 to 50,000 origins are activated in each cell cycle 
(Symeonidou et al., 2012). This is tightly controlled by different proteins, 
such as cyclin, cyclin-dependent kinase (CDK) and the pRb pathway 
(Malumbres and Barbacid, 2009). Early studies provided significant 
advances in our understanding of the structure and function of budding 
yeast (Saccharomyces cerevisa). These advances led to the first 
comprehensive studies of the assets of chromosomal DNA replication in 
eukaryotic cells and helped identify molecular regulators of the cell cycle 
(Nieduszynski et al., 2006, Donaldson and Blow, 1999). 
The initiation of DNA replication is an essential step during cell proliferation 
which is regulated by a series of multiprotein recruitments. It begins with the 
construction of a pre-replication complex (pre-RC) known as ‘‘licensing’’, 
which loads chromatin that is required for DNA synthesis (Karnani et al., 
2010). This regulatory mechanism ensures that DNA replication is fired 
once per cell cycle by temporally separating the assembly of the pre-RC 
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(which occurs during G1 phase and late M phase in the cell cycle) from the 
initiation of DNA synthesis (Figure 1.4).  
In eukaryotes, DNA replication is established by a sequence of events in a 
stepwise manner that begins with the origin recognition complex (ORC) 
binding to protein Cdc6 on chromatin which is required for the association of 
minichromosome maintenance (MCM) proteins (Aparicio, 2013). The ORC 
is constantly present throughout the cell cycle, providing an ideal location for 
the serial conjunction of the pre-replicative proteins (Newlon, 1997, Aparicio, 
2013). In early G1 phase, ORC, MCM10, Cdc6, along with Cdt1, together 
load inactive MCM2-7 helicase complexes at origins. At this stage the MCM 
complex interacts with MCM10 to form the pre-replicative complex, resulting 
in the origin being licensed for replication in the subsequent S phase 
(Symeonidou et al., 2012). Nevertheless, to proceed to DNA replication cell 
cycle kinases need to be activated, including Dbf4-Dependent kinase (DDK) 
and cyclin-dependent kinase (CDK), which are sequentially activated during 
the G1/S phase transition (Aparicio, 2013). Cdc7 (cell division cycle 7) 
kinase is another key kinase that acts in association with Dbf4-Dependent 
kinase for full activity. Cdc7/Dbf4 complex kinase, Cdc7 and Cdk2 are 
required for MCM complex phosphorylation and recruit throughout the S 
phase to activate origins of replication (Labib, 2010). Next, the MCM 
complex is converted to an active stable helicase (Figure 1.4) and DNA 
replication starts with recruiting additional factors, including DNA 
polymerase α-primase and the replication protein A (single-strand specific 
DNA-binding protein), into the unwound ORC as a first step in forming 
                                                                         Chapter 1: Literature review 
22 
 
replication forks and initiation of DNA synthesis (Blow and Gillespie, 2008, 
Aparicio, 2013). 
Once DNA replication is initiated, the pre-RCs are disassembled, Cdc6 is 
degraded, while Cdt1 is targeted for proteolytic degradation by geminin at 
the G1/S border. Cdt1 proteolysis suggests the importance for inactivating 
Cdt1 function during S phase and G2 to prevent re-replication (reviewed by 
(Aparicio, 2013, Truong and Wu, 2011). Inhibition of Cdt1, prevents pre-RC 
reassembly and loading of MCM2–7 complex in the same cell cycle. This is 
a very conserved mechanism among eukaryotic cells to prevent DNA re-
replication in order to maintain genome stability (Labib, 2010). 
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Figure 1.4: Sequence of events of DNA replication in the cell cycle. In G1 
phase: ORC, cdt1 and cdt6 recruit MCM2-7 to replication origins to establish 
the pre-replication complex (pre-RC). In late G1, Cdc7-Dbf4 and other 
CDKS mediate MCM phosphorylation events (soluble state), followed by 
interactions of Cdc45 with the MCM2-7 complex to activate the DNA 
helicase. RPA and DNA polymerase α are then recruited to the replication 
origin and this initiates DNA synthesis. 
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1.3.2 Disorders of the cell cycle and oral cancer  
OSCC pathogenesis is believed to be a multistep process in which several 
genetic alterations take place in the early stages of disease and disrupt cell 
growth control. Defects in the cell regulation system may lead to 
chromosomal missegregation, with loss and gain of chromosomes leading 
to aneuploidy. The literature suggests that continuous chromosomal 
missegregation could accelerate or induce tumourigenesis (Ricke et al., 
2008, Baker et al., 2009). Some researchers believe that genetic instability, 
as a result of loss of heterozygosity (LOH) and expression of damaged or 
mutated suppressor genes, may be the first step in cancer development 
(Bester et al., 2011, Scully and Bagan, 2009b). Although, the exact 
mechanisms that mediate such structural chromosomal changes in different 
tumours are not fully described. 
Alterations in cell cycle regulators such as CDKs, licensing proteins and 
their regulators (e.g. geminin) may contribute to the carcinogenesis process 
(Blow and Gillespie, 2008). Several investigators believe that mutations in 
proto-oncogenes and inactivation of tumour suppressor genes (eg. p53 and 
pRb) can trigger tumour growth (Baker et al., 2009, Scully and Bagan, 
2009b, Oliveira and Ribeiro-Silva, 2011). Mutation of genes encoding CDK, 
cyclins, CDK-activating enzymes, CDK substrates, CKI and check point 
proteins, and over-expression of cell cycle regulating proteins are 
recognised in dysplastic and malignant lesions (Tsantoulis et al., 2007, 
Weaver et al., 2007, Pitiyage et al., 2009). Cell cycle aberration and 
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dysregulation of apoptosis as a result of oncogenic transformation have 
been suggested as useful therapeutic targets for oral cancer (Senderowicz, 
2004, Mishra, 2010). 
Furthermore, the minichromosome maintenance proteins (MCM) may be a 
valuable proliferation marker in tumour screening (Scott et al., 2006). Ki-67 
and proliferating cell nuclear antigen (PCNA) are also useful markers of 
tumour proliferation, but no single cell cycle regulatory protein has yet 
emerged as an ideal biomarker. 
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1.4 Mini-Chromosome Maintenance proteins (MCM) 
Minichromosome maintenance proteins (MCM) are considered to be 
essential for the initiation of DNA replication (serving as DNA helicases) in 
eukaryotic cells (described in Section 1.3.1) (Bochman and Schwacha, 
2009). The MCM complex is a conserved protein family comprising six 
unique subunits, initially discovered via mutations in the yeast 
Saccharomyces cerevisiae. These proteins are composed of polypeptides, 
ranging from 600 to 1200 amino-acid residues (Costa and Onesti, 2009). 
They are considered to be ubiquitous regulators of chromosomal replication 
as MCM proteins exist in all eukaryotes (Lei, 2005). Analogous classes 
have been found in Xenopus and in human cells with significant conserved 
gene sequences (Remus and Diffley, 2009). 
In all eukaryotic cells the replicative DNA helicases possess at least six 
related proteins (MCM2-7) that work together as a hexameric ring (Labib, 
2010), which interact in dimeric complexes MCM5/3, MCM3/7, MCM7/4, 
MCM4/6, MCM6/2 and MCM2/5 (Vijayraghavan and Schwacha, 2012). The 
architecture model of MCM in Saccharomyces cerevisiae showed that the 
two subunits comprising dimeric complexes are neighbouring in the 
hexamer. The predicted structure also highlights a gap between MCM2 and 
MCM5. The MCMs are enzymes with a characteristic form of the AAA+ 
domain superfamily which is responsible for the catalytic activity. MCM 
proteins comprise two consensus ATP-binding motifs: ‘Walker A and B’. The 
Walker A motif, including the P-loop (phosphate-binding loop) of the active 
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site, contains the invariant lysine. Walker B motif is a hydrophobic amino 
acid, and best known to contribute to ATP hydrolysis rather than binding 
(Davey et al., 2003, Costa and Onesti, 2009, Bochman and Schwacha, 
2009). 
MCM proteins are present throughout the proliferative cell cycle and play a 
vital role in DNA licensing as part of the pre-RC (described in Section 1.3.1). 
They have been shown to be chromatin-bound around origins of replication 
during the G1 phase, displaced during replication in S phase, but remain in 
soluble form until the end of mitosis (Figure 1.4) (Kuipers et al., 2011). 
However, they are not expressed in differentiated somatic cells that have 
entered into the quiescent phase (G0) and senescent status (Tachibana et 
al., 2005). 
The MCM complex is required to ensure that each initiation during DNA 
synthesis occurs only once during cell division within each cell cycle (Diffley, 
2011). Among the MCM family, MCM2 has been widely studied in a range 
of malignancies. However, very few studies have evaluated the expression 
of other MCM members. Unlike other MCM subunits, MCM2 binds 
specifically to chromatin (Bochman and Schwacha, 2007). This protein may 
be involved in replication forks formation, and has been shown to regulate 
the replicative helicase activity of the complex (Samel et al., 2014). 
Several lines of evidence suggest that MCM2 function may be regulated by 
S phase regulating kinases (Cdc7/Dbf4) during DNA replication events 
(Chuang et al., 2009). The Cdc7/Dbf4 complex phosphorylates MCM2 at the 
                                                                         Chapter 1: Literature review 
28 
 
G1/S transition phase. Thus, phosphorylation of MCM2 is a critical step in 
initiation of DNA replication (Tsuji et al., 2006, Charych et al., 2008). Recent 
genetic evidence suggests that down-regulation of MCM2 subunits could 
lead to growth inhibition and cell cycle arrest in cancer cell lines (Magatti et 
al., 2012, Jin et al., 2014). MCM2 has been investigated in oral lesions and 
the results suggest that MCM2 may be used as a prognostic marker in 
OSCC (Torres-Rendon et al., 2009a, Kodani et al., 2003, Szelachowska et 
al., 2006, Gueiros et al., 2011). Therefore, it has also been proposed as a 
therapeutic target in human cancer (Liu et al., 2013). 
1.4.1 Licensing factor and “Out of cell cycle” phases 
Cell proliferation is controlled by initiation of DNA replication where 
chromatin is ‘licensed’ in the synthesis phase to regulate the growth process 
(Sun and Kong, 2010). Both in vivo and in vitro studies (Bochman and 
Schwacha, 2008, Moyer et al., 2006) have revealed that down-regulation of 
pre-replicative complex proteins such as Cdc6 and MCM is a common 
downstream mechanism for loss of proliferative ability in human cells. 
Down-regulation also appears to be a powerful growth regulatory 
mechanism that prevents cell proliferation. However, components of DNA 
replication licensing machinery are negatively regulated in senescent, non-
proliferating quiescent, and differentiated cells (Blow and Gillespie, 2008). It 
has previously been mentioned that there is likely antagonism between 
proliferation and differentiation, hence raising the possibility that DNA 
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replication and differentiation cannot occur at the same time (Stoeber et al., 
2001, Olson, 1992). 
This orchestrated down-regulation mechanism is considered as an 
absolutely vital step in self-renewing and permanent human tissues, 
coinciding with the concept of antagonism between the cellular paths that 
regulate proliferation and differentiation (Myster and Duronio, 2000). 
1.4.2 MCM as novel biomarkers of growth 
Human cell proliferation proteins have been identified as essential to 
determine the growth fraction and proliferation in any given cell population. 
These proteins are indispensable through the active phase in the cell cycle, 
are present in all cell types, and are absent from resting or quiescent cells 
(Williams and Stoeber, 2007). 
Stem cells of the proliferative compartment in human tissue have the 
capacity for unrestricted self-regeneration. These stem cells can produce 
highly differentiated descendants. In fact, there is an intermediate 
population of committed progenitors between the stem cell and its terminally 
differentiated progeny. This intermediate population can be characterised by 
limited proliferative ability and restricted differentiation capacity; these cells 
are identified as transit amplifying cells (Watt and Hogan, 2000). In addition, 
some human cell types (e.g. hepatocytes) have reversible withdrawal from 
the G0 phase. Other cells have irreversible (e.g. epithelial cells in surface 
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mucosa) withdrawal from cell division and proceed into differentiation 
(Williams and Stoeber, 2012a). 
MCM origin licensing factors have recently been recognised as critical 
regulators of growth and differentiation. In addition, silencing of MCM2 may 
lead to cell growth inhibition and apoptosis in cancer cell lines (Liu et al., 
2013). In normal human tissues, expression of MCM proteins is generally 
restricted to the basal proliferative compartment as epithelial cells undergo 
differentiation. Down-regulation of the MCM proteins is associated with 
transition from progenitor to terminally differentiated cells. The progenitor 
cells, which are located above the stem cell area, are known to express 
MCM licensing factors where persistent uncontrolled differentiation of cells 
occurs (Stoeber et al., 2001). 
MCM proteins are essential for the initiation of DNA replication, serving as 
licensing components for the S phase of the cell cycle. The importance of 
MCM protein expression in proliferating cells, in all cell cycle phases, and 
their absence in the non-cycling phase (G0) reinforces their potential as cell 
proliferation markers (Williams and Stoeber, 2012a, Tamura et al., 2010). 
MCM2 expression levels have been recognised as powerful diagnostic and 
prognostic markers in a variety of human neoplasms, including bladder 
cancer (Saeb-Parsy et al., 2012), colorectal cancer (Wang et al., 2009) and 
laryngeal carcinoma (Lian et al., 2013). In this respect, recent studies 
demonstrate that MCMs have higher specificity and sensitivity to detect cells 
in the cell cycle than the conventional proliferation markers in a variety of 
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tissues (Giaginis et al., 2010). Thus, MCM proteins have an ability to 
ascertain diagnosis and/or prognosis of clinical significance in several types 
of human malignancy (Giaginis et al., 2009), especially in rapidly dividing 
cells (Wojnar et al., 2010). 
1.4.3 Prognostic potential of MCM in cancer  
Since MCM proteins have an essential role in the initiation of DNA 
replication, their expression may be associated with carcinogenesis (Das et 
al., 2013). The MCM proteins are highly expressed in malignant cells and 
possibly in pre-cancerous cells but not in differentiated somatic cells (Costa 
and Onesti, 2009, Karimi and Sadr, 2011). Numerous studies have reported 
that MCM2 nuclear expression is dysregulated in dysplastic epithelial cells 
(Torres-Rendon et al., 2009a) and in a large number of malignancies, 
including oesophageal (Tao et al., 2011), colorectal (Guzińska-Ustymowicz 
et al., 2009), laryngeal (Cai et al., 2012), ovarian (Levidou et al., 2012) and 
Hodgkin’s lymphoma (Karimi et al., 2008). These alterations of expression 
were also more frequently seen in cells from malignant samples than those 
from normal human tissues (Toyokawa et al., 2011). For instance, 
expression of MCM2-7 proteins was much higher in HeLa cells and SV40-
transformed human fibroblasts than in normal human fibroblast cells (Ishimi 
et al., 2003).  
The first possibility why premalignant and malignant cells express licensing 
proteins is that it may reflect cell failure to exit the cell cycle. This could be 
the consequence of oncogene induced cell division that decreases the 
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number of cells in a quiescent state. In fact, oncogenes can either stimulate 
the re-licensing of replicated DNA, or can permit cells to enter S phase. The 
second possibility is that dysregulation of the licensing program may have a 
fundamental role in cancer growth (Blow and Gillespie, 2008). High 
expression of MCM proteins was found to be associated with more invasive 
tumours in oesophageal squamous cell carcinoma (Ahn and Chang, 2010). 
Interestingly, only MCM2 and MCM3 have recognisable nuclear localization 
sequences, providing nuclear targeting to the other MCM members (Karimi 
and Sadr, 2011). Likewise, antibodies against MCM, especially MCM2, 
demonstrated an association between over-expression and lymph node 
metastasis in tongue squamous cell carcinoma (Gueiros et al., 2011) and in 
colorectal carcinoma (Guzińska-Ustymowicz et al., 2009). Similarly, high 
MCM2 expression has been seen in areas of malignant transformation in 
recurrent pleomorphic adenoma (Soares et al., 2011). Nuclear MCM2 
expression, recognised by immunohistochemistry, showed increased 
expression in dysplastic and malignant lesions of OSCC (Scott et al., 2006, 
Torres-Rendon et al., 2009a). Kodani et al. (Kodani et al., 2003) evaluated 
the immunoexpression of cell cycle proteins in 46 OSCC samples. Their 
results suggested there was no significant difference in MCM2 and Ki-67 
labelling index (LI) in tumours with or without metastasis. Elevated LI of 
MCM2 was observed in moderately differentiated OSCCs compared to well 
differentiated OSCCs (Kodani et al., 2003). In a recent similar study, MCM2 
immunoreactivity was shown to increase with histological grade of OSCC 
(p=0.000), with higher expression in poorly differentiated tumours (Shalash 
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et al., 2012). The authors also claimed that positive correlation between 
MCM2 LI and lymph node metastasis was significant (Shalash et al., 2012). 
A high LI of MCM2 identified in the lymph node metastasis lesions suggests 
that MCM2 may predict the proliferation rate of malignant tumours (Shalash 
et al., 2012, Guzińska-Ustymowicz et al., 2009). In 63 tongue squamous cell 
carcinomas, immunoexpression of proliferation markers (MCM2, Ki-67 and 
geminin) and their clinicopathological features were evaluated (Gueiros et 
al., 2011). Over-expression of MCM2 and Ki-67 was related to nodal 
metastasis and disease stage. A high immunoreactivity of geminin was 
associated with neural invasion (Gueiros et al., 2011). Moreover, 
association between MCM2 expression and histological grade of tumours 
was reported, indicating a wide spectrum of growth potential within each 
tumour grade (Dudderidge et al., 2005, Shalash et al., 2012). In OSCC, high 
levels of MCM proteins may indicate poor clinical outcome (Karimi and 
Sadr, 2011, Gonzalez et al., 2005). However, patients with low MCM2 LI 
have better survival rates than those with high MCM2 LI (Giaginis et al., 
2010). Thus, inhibition of these proteins has been suggested as an anti-
cancer drug target in various types of tumours (Costa and Onesti, 2009, 
Toyokawa et al., 2011, Zhang et al., 2015). Transient inhibition of the 
replication licensing system causes a transit cell cycle in normal cells. 
Likewise, inhibition can cause apoptosis in tumour cells (Shreeram and 
Blow, 2003, Liu et al., 2013). Positive correlation between the proliferation 
marker, MCM2, and tumour stage, has been demonstrated. Inhibition of the 
replication licensing biomarkers may provide a potential therapeutic target 
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against regulators of DNA replication (Gonzalez et al., 2005, Blow and 
Gillespie, 2008, Karimi and Sadr, 2011). Using existing proliferation markers 
along with licensing replication biomarkers may allow more accurate 
diagnosis and treatments of tumours. These observations suggest that 
MCM2 protein is likely to be a promising and reliable marker for cancer 
diagnosis and suggest further investigation of its prognostic value. 
Therefore, MCM2 will be the focus of this project rather than other MCM 
members. 
In summary, the MCM proteins have been suggested to be more sensitive 
in detecting cells that are going through the cell cycle than existing 
proliferation markers such as Ki-67 and PCNA (Giaginis et al., 2010). This is 
discussed further in the next section.  
1.4.4 Advantage of MCM proteins over conventional 
proliferation markers 
Ki-67 protein is expressed in all phases of the cell cycle (G1, S, G2, and 
mitosis) and has been used to estimate the fraction of the tumour growth as 
a proliferation marker. The prognostic value of Ki-67 has been controversial 
with regard to its ability to differentiate tumours with a good or poor 
prognosis. The first reason for this controversy could be that Ki-67 shows 
some variation in its expression in G1 phase and may be absent in cells 
entering G1 from G0 (Bubán et al., 2009). Secondly, it has been shown that 
Ki-67 expression levels can be altered in nutritionally deprived cells 
(Verheijen et al., 1989). Claims have been made in the literature regarding 
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whether it is essential for cell proliferation or not (Brown and Gatter, 1990, 
Wojnar et al., 2010). Detection of Ki-67 by immunohistochemistry may 
therefore vary and show inconsistencies. 
Proliferating cell nuclear antigen (PCNA) is a nuclear protein essential for 
cell division and is associated with DNA repair mechanisms. Its expression 
starts at the S phase of the cell cycle, but it has limited use as a proliferation 
marker (Myoung et al., 2006, Mahler et al., 2012). Moreover, immune 
staining of PCNA can be affected by a variety of factors, such as fixation 
time. 
Notably, in normal tissue MCM2 is higher than Ki-67, and many studies 
have confirmed the superiority of MCM2 as a proliferation marker when 
compared to Ki-67 and PCNA, allowing better distinction between normal 
and neoplastic cells (Lei, 2005, Maiorano et al., 2006, Szelachowska et al., 
2006). The most important advantage or characteristic of MCM2 is its ability 
to identify those cells that are licensed to enter the cell cycle, including 
licensed cells in G0 (Stoeber et al., 2001, Costa and Onesti, 2009, Gouvêa 
et al., 2013) (Figure 1.5). This property makes MCM2 an exceptional 
marker to assess the growth fraction in malignant tumours. 
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1.4.5 Ki-67 protein as a prognostic marker 
Ki-67 is a non-histone protein that is expressed in proliferating cells. It was 
described in 1983, after mice were immunised with nuclei from cell line L 
428 (Gerdes et al., 1983). Even though its exact biological role remains 
unclear, the expression of Ki-67 protein has been linked to cell proliferation 
and its nuclear antigen was detected in all active phases (Figure 1.5) of the 
cell cycle (G1, S, G2 and mitosis), but not in the G0 resting phase (Scholzen 
and Gerdes, 2000, Gerdes et al., 1984). This protein can be assessed by 
immunohistochemistry using monoclonal antibody (clone MIB-1) that reacts 
with different epitopes (Del Sordo and Sidoni, 2008). This simple technique 
has been used to estimate cell proliferation in fixed tissues (Cuevas et al., 
1993). 
Generally, the cellular expression of Ki-67 protein is not consistent, and its 
presence in early cell cycle phases has not been confirmed. It is widely 
accepted that its expression increases during S phase and the highest 
staining intensity is seen in metaphase (Scholzen and Gerdes, 2000). MIB-1 
monoclonal antibody is the most frequently used proliferation marker in 
prognostic and diagnostic studies. These studies have shown that the Ki-67 
labelling index can serve as a prognostic evaluation biomarker in some 
neoplasms (Tojo et al., 2005, Park et al., 2007, Tawfik et al., 2013). On the 
other hand, MIB-1 antibody alone did not correlate with disease outcome 
and therefore may not be beneficial as a prognostic indicator (Okamoto et 
al., 2002, Gonzalez-Moles et al., 2010, Massano et al., 2006, Shah et al., 
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2009). Generally, the majority opinion is that Ki-67 antibody can differentiate 
cells in late G1, S, G2 and M phases (Figure 1.5) and be considered as a 
marker of the total growth fraction of proliferating cells. 
1.4.6 MCM2/Ki-67 ratio  
The MCM2/Ki-67 ratio represents the proportion of cells that are licensed to 
replicate (Shetty et al., 2005). The value of this ratio may go from 1 to 
infinity since MCM2 expression is always higher than Ki-67 (Figure 1.5). 
MCM protein expression also recognises non-cycling cells with proliferative 
potential (Stoeber et al., 2001, Eward et al., 2004, Wharton et al., 2004). A 
low MCM2/Ki-67 ratio, close to 1, means less cells are in the G1 phase, and 
cells in a given tumour population are actively proliferating (Torres-Rendon 
et al., 2009a). On the other hand, when this ratio increases, it means that a 
greater number of cells reside in a licensed state with proliferative capacity, 
but are not cycling (Eward et al., 2004, Wharton et al., 2004). Low values of 
this ratio have been associated with higher grade tumours and an 
unfavourable outcome (Dudderidge et al., 2005). 
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1.5 Geminin 
Geminin was originally discovered in metazoans and first cloned in Xenopus 
(Xouri et al., 2004), but was also found in higher eukaryotes (Machida and 
Dutta, 2005). It is recognised by the anaphase promoting complex (APC) 
system and targets the protein for ubiquitin mediated proteolysis (McGarry 
and Kirschner, 1998). Its degradation was observed in transition from 
metaphase to anaphase, allowing DNA replication licensing in the cell cycle. 
Geminin expression is absent during the G1 phase, but at high level through 
the rest of the cell cycle until the onset of mitosis (Figure 1.5) (Williams and 
Stoeber, 2012b). Once the cell is licensed for DNA replication, geminin 
interacts with Cdt1 during S and G2 phase to inhibit DNA re-replication in 
the same round (Tamura et al., 2010), thus maintaining genome stability in 
normal cells. Inactivation of geminin expression has been found to induce 
re-initiation of DNA synthesis in normal and tumour cells in the presence of 
functional p53 (Melixetian et al., 2004).  
Numerous lines of evidence have suggested that over-expression of 
geminin is associated with poor prognosis and it could be used as a reliable 
prognostic maker in different cancers (Moraes et al., 2012, Tamura et al., 
2010, Torres-Rendon et al., 2009a). The biological function of geminin was 
thought to be an inhibitor of the cell cycle, but recent studies have 
suggested that geminin may not be involved in suppressing cell proliferation 
(Zhu and Pamphilis, 2009, Guo and Sun, 2013). 
                                                                         Chapter 1: Literature review 
39 
 
Geminin is characterised as a bi-functional molecule as it stimulates cell 
proliferation and also regulates the DNA replication licensing process to 
prevent over-replication in the cell cycle (Seo and Kroll, 2006). Its 
phosphorylation is CDK-dependent and previous studies suggested that 
geminin may be part of the checkpoint control that links CDK activity to the 
next round of replication (Nishitani and Lygerou, 2002). Additionally, 
geminin is responsible for the proliferating-differentiated transition process 
during nervous tissue development (Seo and Kroll, 2006).  
Immunohistochemistry and immunoblotting studies have shown that, in 
contrast with carcinomas, geminin expression is very minimal or hardly 
detectable in normal tissue (Wohlschlegel et al., 2002, Torres-Rendon et al., 
2009a). Geminin is over-expressed in tumours compared to normal and 
dysplastic tissues (Torres-Rendon et al., 2009a, Tamura et al., 2010). 
Geminin physically interacts with the replication factor Cdt1 necessary for 
MCM loading. In high eukaryote cells, geminin inhibits Cdt1 protein during 
the S, G2 and late mitosis phase, however, this mechanism is currently 
unclear. Inhibition of Cdt1 protein prevents the abnormal assembly of pre-
RC on chromatin (Klotz-Noack et al., 2012). Experimentally, high expression 
of Cdt1 can cause re-replication (Nishitani et al., 2004, Li and Blow, 2005). 
Interestingly, the absence of geminin and MCM expression may identify 
cells in the G0 phase that are out of cycle and not licensed to proliferate 
(Kingsbury et al., 2005). 
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With respect to Cdt1, geminin can bind to other proteins such as Six3 and 
Hox, which indirectly regulate cell cycle progression (proliferation) by 
displacing geminin from Cdt1 before pre-RC is formed (Li and Rosenfeld, 
2004, Klotz-Noack et al., 2012). It was recently shown that geminin interacts 
with different proteins when bound on chromatin, including cyclins E, A1 and 
B1 (Nakuci et al., 2006). It was also shown that depletion or silencing of 
geminin in human cell lines induces DNA re-replication (Melixetian et al., 
2004, Zhu and Pamphilis, 2009, Zhu et al., 2004). 
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Figure 1.5: MCM2, Ki-67 and geminin expression during the cell cycle. 
MCM2 protein is present in all cell cycle phases, including G0. Ki-67 is 
expressed in all phases with the exception of early G1 phase. Geminin acts 
between G1/S transition stage and metaphase-to-anaphase transition.  
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1.5.1 Geminin/Ki-67 ratio 
In several human tumours the presence of geminin is directly proportional to 
the cell proliferation index, quantified by Ki-67 expression (Wharton et al., 
2004). Ki-67 is expressed in all active cell cycle phases (G1, G2, S and M) 
and absent in quiescent stages (G0, early G1) (Figure 1.5), while geminin is 
absent in the G1 phase (Figure 1.5). The geminin/Ki-67 ratio has therefore 
been suggested to estimate the length of the G1 phase (Wharton et al., 
2004). As geminin identifies less positive cells than Ki-67, this ratio goes 
from 0 to 1 (e.g. 0.2, 0.3 0.4, 0.5 …etc.). The indication is that the higher the 
ratio (close to 1), the less cells in G1 and the higher the rate of proliferation. 
Cells with an increased geminin/Ki-67 ratio, have a shorter G1 phase 
(Torres-Rendon et al., 2009a), which indicates an accelerated rate of 
proliferation and a worse clinical prognosis (Wharton et al., 2004, Shetty et 
al., 2005, Quaglia et al., 2006). Accordingly, the geminin/Ki-67 ratio has 
been proposed as a marker of prognosis in some neoplasms (Wharton et 
al., 2004). 
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1.6 p16INK4A (CDKN2A) 
p16INK4A is the best characterised tumour suppressor protein of the INK-
4/ARF family (Queiroz et al., 2010). In humans it is encoded by the 
CDKN2A gene (Cyclin-Dependent Kinase Inhibitor 2A), and is mapped on 
chromosome 9p21. The CDKN2A locus encodes for two overlapping, but 
structurally different proteins: p16INK4A and p14ARF (Figure 1.6). 
The p16INK4A protein has a role in the regulation of the cell cycle. p16INK4A 
interacts with cyclin D1 to inhibit cyclin dependent kinase activity (CDK4 and 
CDK6), and subsequently prevents the phosphorylation of pRb protein 
during the G1 phase (Figure 1.6) (Chien et al., 2011, Nasser et al., 2011). 
Inhibition of phosphorylation of pRb prevents the cell cycle progressing into 
S phase and stops cell cycle progression (Queiroz et al., 2010, Pérez-
Sayáns et al., 2011). 
The consequence of these interactions is suggestive of its role as a tumour 
suppressor gene. Therefore, inactivation or reduction of p16INK4A 
encourages abnormal growth in tissues. In addition, inactivation of p16 INK4A 
by genetic or epigenetic alterations, including promoter methylation and 
homozygous deletion or mutation, is frequently found in head and neck 
malignancies (Sailasree et al., 2008, Reed et al., 1996, Lang et al., 2002). 
Inactivation of p16INK4A is therefore defined as an early event in 
carcinogenesis (Ai et al., 2003, Karsai et al., 2007, Demokan et al., 2012). 
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Inactivation or elimination of p16INK4A by hypermethylation has been 
reported to increase proliferative activity and promote cell migration and 
invasion in head and neck cancer (Mariatos et al., 2000, Su et al., 2010). 
However, activation or an increase in expression suppresses angiogenesis 
by restoring wild-type p16INK4A gene and arrests cell growth in some other 
tumours (Harada et al., 1999). In contrast to its reduced expression in some 
SCC (see section 1.6.1), p16INK4A may be activated and increased in HPV-
associated tumours due to inactivation of pRb by E7 protein. In addition, 
malignant tumours over-expressing p16INK4A have been suggested to have 
higher radiosensitivity (Romagosa et al., 2011). 
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Figure 1.6: The CDKN2A locus structure and its protein pathways during 
cell cycle control. p16INK4A inhibits CDK4 and CDK6 activity, with 
consequent inhibition of pRb phosphorylation. (Adapted from Pérez-Sayáns 
et al., 2011). 
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1.6.1 Evaluation of p16INK4A expression in oral squamous 
cell carcinoma  
Expression levels of p16INK4A have been extensively studied in oral 
squamous cell carcinoma (Abrahao et al., 2011, Gologan et al., 2005, 
Bradley et al., 2006, Nemes et al., 2006, Ohta et al., 2009, Buajeeb et al., 
2009, Queiroz et al., 2010, Montebugnoli et al., 2010, Nasser et al., 2011, 
Chandarana et al., 2013). The p16INK4A pathway contributes to tumour 
induction and differentiation (Queiroz et al., 2010). Down-regulation of 
expression has been found to be highly associated with disease recurrence, 
metastasis and worse clinical outcome in HNC (Danahey et al., 1999, 
Suzuki et al., 2006, Kumar et al., 2008), while over-expression of p16INK4A 
protein might be an indicator of better prognosis in HPV-positive HNC 
patients (Lassen et al., 2009). On the other hand, others have reported that 
no association was found between expression of p16INK4A and the grading of 
OSCC (Abrahao et al., 2011, Reuschenbach et al., 2013). 
Chen et al. (Chen et al., 1999) showed a significant association between 
immune positivity for p16INK4A and CDK4 in OSCC. In the same way, Karsai 
et al. (Karsai et al., 2007) reported that loss of p16INK4A expression seems to 
be associated with aberrant expression of p53. Further, using combinations 
of proliferation markers such as Ki-67 and cyclin D1 with p53 or p16INK4A has 
been suggested to improve prognostic predicative value in OSCC 
(Montebugnoli et al., 2010, Nasser et al., 2011). Immunohistochemical 
studies of p16INK4A in the oral cavity have reported both low (Pande et al., 
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1998, Bradley et al., 2006, Isayeva et al., 2014) and high expression (Dong 
et al., 2012, Duncan et al., 2013, Reuschenbach et al., 2013, Lingen et al., 
2013). Interestingly, over-expression of p16INK4A has been found to be 
associated with increased sensitivity to chemotherapy in OSCC (Suzuki et 
al., 2006). Silencing of p16INK4A is detected in approximately 70% of oral 
squamous cell carcinomas (Mascolo et al., 2012) that increase death risk 
(Barros-Angueira and Gandara-Vila, 2015). It is important to mention that 
HPV-associated HNCs have genetic alterations that are consistent with the 
functions of viral oncoproteins (E6 and E7). These cancers are 
characterised by wild-type p53 and wild-type p16INK4A (Isayeva et al., 2014). 
Conversely, p53 mutations and p16INK4A inactivation in HNCs have been 
shown to be mediated by tobacco and alcohol consumption (Ai et al., 2003). 
These observations support the possibility of at least two distinct pathways 
for tumour progression in the head and neck region: one driven mainly by 
the mutagenic effects of tobacco and/or alcohol mediated and the other 
driven by HPV infection (Westra, 2015). 
Bova et al. (Bova et al., 1999) revealed that loss of p16INK4A expression was 
detected in 55 % of studied samples and 68% showed high expression of 
cyclin D1 protein. The results from this study suggested that loss of p16INK4A 
and increased expression of cyclin D1 was associated with a reduced five-
year survival rate; this co-appearance of both proteins can be utilised as an 
independent prognostic marker in tongue carcinoma. These observations 
were consistent with other studies (Jayasurya et al., 2005, Pande et al., 
1998) and the same correlation was reported. 
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More recently, studies have shown p16INK4A protein levels to be elevated in 
OSCC. This has been credited to HPV induced OSCC (Leemans et al., 
2010), where inactivation of pRb by the HPV oncoprotein E7 results in 
increased p16INK4A expression (Romagosa et al., 2011). In recent published 
studies the prevalence of HPV positivity was recorded in approximately 6% 
of OSCC (Lingen et al., 2013, Krüger et al., 2014). Therefore, it is difficult to 
compare the results of different studies evaluating p16INK4A expression 
levels in OSCC, since results are variable and may depend on HPV status. 
There is no wide agreement in the literature on the potential role of HPV in 
OSCC (Lingen et al., 2013, Samman et al., 2014). Studies have confirmed 
an association between high expression of p16INK4A and HPV in 
oropharyngeal cancers (OPC) (Jordan et al., 2012, Singhi and Westra, 
2010, Westra, 2015). Hence, p16INK4A over-expression has been considered 
as an HPV surrogate marker in OPC (Seiwert, 2014, El‐Naggar and Westra, 
2012), but not in pre-malignant and malignant oral lesions (Nankivell et al., 
2014). This over-expression can be simply determined by 
imunohistochemical means. The high sensitivity and low cost of this 
technique make it a more practical and alternative method to in situ 
hybridisation (ISH) or polymerase chain reaction (PCR) (Westra, 2014). 
Since p16INK4A can also function as a tumour suppressor gene, its 
expression can be altered secondary to gene mutation or methylation 
(Romagosa et al., 2011). However, while most non HPV-associated 
carcinomas are p16INK4A negative, some can express p16INK4A by other 
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mechanisms (Hunt et al., 2014). Therefore, it is essential to detect strong 
and diffuse nuclear and cytoplasmic staining in more than 70% of cells for 
p16INK4A to be a surrogate marker of active HPV (Lewis et al., 2012, Hunt et 
al., 2014, Nankivell et al., 2014). 
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1.7 Cyclin D1 
Cyclins are important proteins in the regulation of the cell cycle. The cyclin 
D family is composed of D1, D2 and D3, which drive cell cycle progression. 
In humans, D1 protein is encoded by the CCND1 gene (linked tightly to the 
bcl-1 oncogene) and is located on chromosome 11q13, also sometimes 
known as PRAD1 (benign parathyroid adenoma D1) (Donnellan and Chetty, 
1998). The cyclin D proteins reach their maximum level during the G1 
phase, and are thought to be responsible for the G1/S phase transition 
(Figure 1.7). Cyclins activate their cyclin dependent kinases (CDK4/CDK6) 
to phosphorylate the pRb protein (Pestell, 2013), which then releases 
transcription factors (EF2) necessary for the DNA replication initiation 
process. Cyclins, along with their partners, cyclin dependent kinases 
(CDKs), have been linked with proliferation and differentiation in different 
tissues (Agarwal et al., 2012) and are frequently altered in neoplasms (Kim 
and Diehl, 2009). 
The amplification of cyclin D1 associated with loss of p16INK4A function has 
been widely seen in HNCs (Hall and Peters, 1996, Arora et al., 2012). 
Hanken et al. (Hanken et al., 2014) have recently shown that cyclin D1 over-
expression and gene amplification correlated with decreased survival in 
OSCC patients. In most instances, high expression of cyclin D1 with or 
without gene (CCND1) amplification is frequently seen in primary tumours 
and cell lines (Huang et al., 2002, Miyamoto et al., 2003). In a study of 106 
patients with laryngeal squamous cell carcinoma, increased cyclin D1 
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expression was associated with poor prognosis (Gibcus et al., 2008). 
Likewise, in OSCC, high expression of cyclin D1 was detected in 95% of 
studied samples and p53 positivity was seen in 65%. The results of this 
study have shown a positive correlation between increased cyclin D1 and 
p53 expression in OSCC samples (Swaminathan et al., 2012). High 
expression of cyclin D1 was also observed in previous studies (Kuo et al., 
1999, Lam et al., 2000), and may be an independent prognostic marker for 
oral squamous cell carcinoma (Huang et al., 2012, Hanken et al., 2014). In 
a recent meta-analysis study of oral cancer, correlation between high 
expression of cyclin D1 and clinicopathological parameters, such as size of 
tumour, differentiation status, nodal metastasis, and clinical stage of disease 
has been reported (Zhao et al., 2014). 
Molecular studies of cyclin D1 have highlighted possible new functions, for 
instance, it has a role in promoting cell adhesion and migration (Figure 1.7) 
by inhibition of Rho-associated (RhoA) protein kinase (Li et al., 2008). In 
contrast, cyclin D1 protein can indirectly inhibit cell migration by inhibiting 
epithelial/mesenchymal transition (Tobin et al., 2011). 
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Figure 1.7: Presence of cyclin D1 in the cell cycle and its different protein 
interactions. In the G1 phase, cyclin D1 binds to cyclin dependent kinases 
(CDK4 and CDK6), with the help of cyclin E/DK2 complex, to phosphorylate 
tumour suppressor pRb protein. The phosphorylation of pRb is associated 
with release of the transcription factor E2F, which can then drive cell-cycle 
progression. 
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1.8 DNA content (ploidy) 
DNA ploidy is a measure of the DNA content in a cell population. Normally, 
a non-dividing somatic cell contains 23 pairs of chromosomes (diploidy). 
During S phase, without subsequent cell division, the somatic cell will have 
double the amount of DNA (tetraploid or 4 copies). 
The term polyploidy is applied when multiple copies of DNA exist. In cases 
of partial or total genetic damage, unequal distribution of chromosomes that 
causes chromosomal segregation is called aneuploidy (Sen, 2000). It has 
been shown that the best approach to evaluate potentially malignant lesions 
is to measure the DNA status (DNA ploidy). However, a variety of methods 
have been used to determine the ploidy status, including karyotyping, flow 
cytometry, image analysis and fluorescence in situ hybridisation. These 
measurements are performed by staining the nuclear material in the cell 
with stoichiometric stains (such as Feulgen) and comparing the intensity of 
staining to control cells by means of integrated optical density (IOD), which 
may be performed by flow cytometry (FCM) or image cytometry (ICM). 
The method is validated by using internal control cells which must have a 
known DNA content. Normal cells, such as lymphocytes, are usually used 
(Haroske et al., 1997). 
Estimation of the DNA index (DI) in populations of cells of interest by image 
cytometry can be performed on cell suspensions (cytospin) or directly on 
histological sections (Huang et al., 2008). In contrast, standard FCM can 
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only be achieved by suspending disaggregated cells and passing them 
through a flow cytometer. The advantage of FCM is that it can anlyse 
thousands of cells. 
1.9 Aneuploidy 
Aneuploidy is defined as numeric chromosomal aberrations in which the 
number of chromosomes is either more or less than the normal cell content 
(diploid). Caspersson (Caspersson et al., 1963) was the first investigator to 
describe abnormal genetic material in cancer cells (reviewed by (Shackney 
et al., 1989, Pihan and Doxsey, 1999)). Since then aneuploidy has become 
one of the main features of human cancer, particularly in solid tumours 
(Weaver et al., 2007). According to the European Society of Analytical and 
Cellular Pathology (ESACP), aneuploidy is defined as “those types of DNA 
distributions which are different at a statistically significant level from those 
of normal cell populations. DNA aneuploidy can either be seen as DNA 
stem-line aneuploidy, or can be indicated by rare events” (Haroske et al., 
1997). Occurrence of rare events is defined by cells that exceed the 5c on 
an image cytometry histogram (Haroske et al., 1997). 
According to Boveri‘s theory of malignancy, the consequence of 
chromosomal instability results from multipolar mitosis of an abnormal single 
somatic cell (centrosome), and may cause aneuploidy, a constant mark of 
cancers (Pathak and Multani, 2006). 
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Numerical chromosomal aberrations (aneuploidy) and structural 
chromosomal alterations can lead to cancer development (Teixeira et al., 
2014). Indeed, some researchers believe that aneuploidy seems to be an 
early genetic change in cancer transformation (Visscher et al., 1996, 
Padilla-Nash et al., 2013, Michor et al., 2005). Therefore, the presence of 
aneuploidy in early stages of disease suggests that abnormal DNA content 
and its underlying cause may play a key role in tumour transformation and 
progression. However, it is still a long standing issue whether aneuploidy is 
essential for transformation and progression of cancer. Such genetic 
instability is frequently responsible for heterogeneity and progression of 
tumours (Lengauer et al., 1998). Abnormal DNA content (aneuploidy) is 
associated with poor prognosis, metastasis, and resistance to 
chemotherapy drugs (Gao et al., 2007, Choi et al., 2009, McClelland et al., 
2009, Swanton et al., 2009). In contrast, diploid tumours often exhibit a 
better prognosis (Sinicrope et al., 2006, Hicks et al., 2006, Belien et al., 
2009). 
Several investigators have suggested that the presence of aneuploidy is the 
main characteristic of cancer cells and is associated with aggressive 
behaviour and poor prognosis (Bowen et al., 2009, Kristensen et al., 2003, 
Gawrychowski et al., 2003). 
Laboratory experiments in human and animal cells suggest that aneuploidy 
appears to be required for malignant transformation (Schvartzman et al., 
2010, Hanks et al., 2004, Gordon et al., 2012). In this concept, aneuploidy 
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has been proposed to promote and inhibit immortalisation, depending on 
which chromosomes are affected (Weaver and Cleveland, 2008). Moreover, 
defects in telomerase function, DNA damage response, chromosomal 
segregation and cell cycle regulation, may lead to chromosomal instability 
(reviewed by (Bakhoum and Compton, 2012)). 
Interestingly, Fujiwara and colleagues (Fujiwara et al., 2005) found that cells 
with aneuploid DNA content (tetraploid) grown, in vitro, developed 
malignancies and genetic alterations in 10 out of 39 mice without 
carcinogen exposure. DNA aneuploidy in oral squamous cell carcinoma 
provided a good prognostic indicator for lymph node metastasis and 
recurrence (Seethalakshmi, 2013). In a recent study, it was reported that 
aneuploid oral dysplasia progressed to oral squamous cell carcinoma in 
74% of cases compared to only 42% of diploid lesions (Torres-Rendon et 
al., 2009b). In contrast, higher incidence of aneuploidy (90%) was reported 
in malignant head and neck lesions (Abou-Elhamd and Habib, 2007). 
Finally, it is important to mention that recent studies have shown no 
correlation between ploidy status and histopathological grade in either 
precancerous or cancerous lesions (Diwakar et al., 2005, Torres-Rendon et 
al., 2009b). 
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1.9.1 Causes of aneuploidy  
In human tissue, many cell divisions occur every minute; accurate 
chromosome segregation with every cell division is crucial to maintain the 
normal karyotype. Unequal chromosome segregations can lead to cancer 
transformation. Importantly, some of the genes that regulate chromosome 
segregation have been found to be mutated in human cancer (Jiang et al., 
2014). Aneuploidy arises through chromosomal instability caused by the 
continual loss and gain of whole chromosomes during cell division 
(Thompson and Compton, 2011). Such disruption has been implicated in 
numerical chromosome abnormality (aneuploidy) in cancer cells (Gordon et 
al., 2012, Holland and Cleveland, 2012). 
There are a number of possible mechanisms (Figure 1.8) by which a 
human cell might gain or lose chromosomes during cell division. Some of 
these mechanisms are discussed briefly below.  
1.9.1.1 Chromosomal missegregation 
According to some authors, continual chromosomal missegregation is 
believed to contribute to or accelerate malignant transformation by 
facilitating the accumulation of chromosomes with oncogenes (growth 
promoting genes) and deletion of chromosomes with tumour suppressor 
genes. This would lead to heterogeneous DNA content of tumour cells. 
Aneuploidy could result from genetic changes, such as mutations at 
nucleotide level and alteration of apoptotic genes (Loeb and Loeb, 2000, 
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Sen, 2000, Panigrahi and Pati, 2009). Thus far, it has been debated 
whether aneuploidy contributes to malignant transformation rather than 
being a discrete event. Recent evidence strongly indicates that alterations in 
genes that control chromosomal segregation, DNA damage response, 
telomere function and cell cycle regulatory proteins are the main causes for 
chromosomal instability (Holland and Cleveland, 2009). There has been 
more attention directed towards the causes and consequences of 
chromosomal instability, since it is a common feature of many aneuploid 
cancer cells and generates tumour heterogeneity (Thompson and Compton, 
2011, Chandhok and Pellman, 2009). 
1.9.1.2 Mitotic checkpoint defects 
A large number of mitosis genes have been mutated in human tumour cells. 
Not surprisingly, altered or mutated checkpoint genes could lead to 
chromosome missegregation, and subsequently, aneuploidy and tumour 
growth (Hanks et al., 2004, Holland and Cleveland, 2009, Snape et al., 
2011). Over-expression of proteins that regulate spindle checkpoints, such 
as Mad2 (mitotic arrest deficient 2) and Kinetochore protein (encoded by 
NDC80 gene), have been observed in human cancer and are often 
associated with a poor prognosis (Holland and Cleveland, 2009). 
Nevertheless, the frequency of such mutations or defects is rare in human 
tumours (Thompson et al., 2010, Holland and Cleveland, 2012). 
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1.9.1.3 Chromosome cohesion defects  
In an attempt to identify other pathways that stimulate chromosomal 
instability, researchers have suggested that mutations in genes that control 
sister chromatid cohesion may participate in aneuploidy (Holland and 
Cleveland, 2009, Chandhok and Pellman, 2009). Inactivation in the STAG2 
gene results in chromatid cohesion or attachment defects and leads to 
aneuploidy in human cancer (Solomon et al., 2011). 
1.9.1.4 Merotelic attachments 
Merotelic attachment is another mechanism that probably contributes to 
chromosome missegregation. By this mechanism inappropriate attachment 
of kinetochores to spindle microtubules may occur when a single 
kinetochore binds to microtubules that arise from both poles of the spindle 
(Thompson and Compton, 2011). Centrosome amplification is likely to 
increase the incidence of merotelic attachments, and strongly associates 
with chromosomal instability (Nigg, 2006, Gordon et al., 2012). Extra 
centrosomes are reported to be common in many aneuploid human cancers 
(Nigg, 2002). 
Another popular hypothesis suggested as a cause of aneuploidy proposes 
that replication of genetic content in the absence or failure of cell division 
(Endoreduplication) can result in tetraploidy or polyploidy (Fujiwara et al., 
2005, Zimmet and Ravid, 2000, Holland and Cleveland, 2009). However, 
tetraploid cells can arise by several pathways, including cytokinesis failure, 
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mitotic slippage, and cell fusion (Ganem et al., 2007). In this way, it has 
been proposed that Aurora B dependent kinase acts as a No Cut pathway 
“abscission inhibitor” to ensure that all chromosomes have been pulled out 
from the midzone during cell mitosis (Holland and Cleveland, 2009). 
However, there is strong evidence suggesting that tetraploidy can trigger 
malignant transformation (Ganem et al., 2007). This evidence came from an 
in-vitro study which showed that tetraploid p53 mouse cells promote 
malignant transformation after mutagen exposure (Fujiwara et al., 2005). 
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1.9.2 Aneuploidy as a cause of tumourigenesis 
Hansemann (Hansemann, 1890) and Boveri (Boveri, 1914) proposed that 
aneuploidy was the cause of malignant development, and others have 
suggested that it is a necessary step for carcinogenesis (Knauss and Klein, 
2012). However, the aneuploidy hypothesis has been underestimated by 
many researchers since the discovery of genes, and demonstration of 
mutagenic agents such as X-rays and alkylating agents (Pihan and Doxsey, 
1999). Consistent with this concept, other studies revealed that chemical 
carcinogens such as dimethylbenzanthracene, cytosine arabinoside and 
methylcholanthrene have been shown to impede mitosis in embryonic cells. 
Such disturbance during cell division leads to asymmetric cell mitosis and 
causes so called preneoplastic aneuploidy. Cells with the preneoplastic 
phenotype may result in immortal cell aneuploidy (Duesberg et al., 2000).  
In general, aneuploidy roles are largely unknown in some tissues. However, 
according to some genetic concepts, aneuploidy might be a driver or a 
passenger (context dependent) in the tumourigenesis transformation. 
Aneuploidy may depend on particular interactions of the karyotype with the 
microenvironment in different human tissues (reviewed by (Gordon et al., 
2012)). Recently, data has shown that aneuploidy has a role in promotion of 
and/or inhibition of carcinogenesis in certain circumstances (Weaver et al., 
2007, Weaver and Cleveland, 2008). These findings show that a high rate of 
abnormal DNA content (aneuploidy) in chemically and genetically induced 
tumours can act as an inhibitor rather than a motivator of tumour formation 
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(Weaver et al., 2007), depending on the specific genetic changes in distinct 
environments. The effects of aneuploidy on tumour cell fate are influenced 
by the gain or loss of specific chromosomes (Williams et al., 2008). These 
different effects refer to three possible relevant factors: firstly, the presence 
of specific combinations of gain or loss of chromosomes in aneuploid cells; 
secondly, the stability of aneuploid cells as additional chromosomal 
missegregations occurred; thirdly, further mutations in oncogenes and 
tumour suppressor genes in a given cell (Weaver and Cleveland, 2008). 
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Figure 1.8: Possible pathways by which the human cell may develop 
aneuploidy. (A) Mitotic checkpoint signalling defect. (B) Chromosome 
attachment defects. (C) Amplification of centrosome resulting in multipolar 
mitotic spindle (Adapted from Holland and Cleveland, 2012). 
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1.10 DNA image cytometry (ICM) 
A variety of techniques have been used to detect alterations in DNA content 
(aneuploidy) in tumour cell populations. These include flow cytometry, 
spectral karyotyping, fluorescence in situ hybridisation and image cytometry. 
Flow cytometry (FCM) has been the most popular method for evaluation of 
DNA ploidy in tumour cells. However, FCM has some limitations, and 
therefore DNA image cytometry (ICM) has become a more popular 
technique (Massimo, 2013). Different systems have been introduced in this 
field, the semi-automated cell analysis system (CAS) (Khan et al., 1994), 
and more recently the automated cellular imaging system (ACIS) (Huang et 
al., 2005, Huang et al., 2008, Santos‐Silva et al., 2011, Gouvêa et al., 
2013). Some OSCC studies have been carried out using various techniques 
of DNA image cytometry (Santos‐Silva et al., 2011, Torres-Rendon et al., 
2009b).  
DNA image cytometry (ICM) is widely used as a diagnostic and prognostic 
method for quantification of DNA content by means of integrated optical 
density (IOD). It can be performed using different systems (Huang et al., 
2005) incorporating a microscope with a motorised scanning stage attached 
to a digital camera. This microscope is connected to a computer with a 
software program able to scan and categorise the nuclei of interest 
according to the IOD, and to translate the results into DNA histograms. 
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The principle behind DNA image cytometry for evaluation of tumour cells is 
that normal human cells have diploid DNA content. The criteria to 
distinguish the cell cycle stages on the DNA histogram are as follows: cells 
with normal DNA content (diploid cell) have 2n DNA content; this is decoded 
as 2c (copies of the chromosomes) on the histogram. The nuclei at 2c on 
the histogram belong to a G0/G1 phase representing a diploid peak (Figure 
1.9). Cells with double DNA content located in the 4c area (tetraploid cells) 
represent cells in the G2 phase (Figure 1.9), thus the tetroploid peak is 
positioned in the duplication region of the G0/G1 phase fraction (Böcking 
and Nguyen, 2004). Cells with polyploid DNA content represent the 
multiploids of a 2c peak, so these cells are located at 4c, 8c…etc. 
Additionally, cells between 2c and 4c are in S phase (Figure 1.9). 
Aneuploidy cells with abnormal DNA content are observed at 3c and 5c 
areas on the histogram (Baak and Janssen, 2004). When using an image 
cytometry system, a 2c (normal diploid) peak is generated from selected 
normal cells as an internal control. When analysing tumour tissue, 
lymphocytes are usually selected as the normal cell population. 
In summary, DNA image cytometry systems are capable of identifying cells 
or stem-lines with aneuploid content. They also provide information about 
the polyploidisation of euploid or aneuploid DNA stem-lines (Böcking and 
Nguyen, 2004). The pre-established statistical parameters can be calculated 
to increase the cell nuclei data, and therefore improve the sample 
evaluation.  
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Recently, the evaluation of DNA content by automated image cytometry has 
been shown to be a valuable diagnostic tool in cytological diagnosis, and in 
oesophageal and oral cancer screening (Meng et al., 2013, Zhao et al., 
2012, Bradley et al., 2010). 
In the present study, ploidy analysis was undertaken using an automated 
cell imaging system (ACIS III, Automated Cellular Imaging System; Dako, 
Glostrup, Denmark) on tissue sections to increase the analysis sensitivity, 
with high-fidelity DNA histograms generated by the system.  
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Figure 1.9: DNA content represented in the cell cycle. The nuclei that 
belong to a G1 peak (2c) do not represent a duplication region. Cells in 
G2/M phase (tetraploid cells) are located in the duplication region (4c) of the 
G0/G1 fraction. 
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1.10.1 DNA index  
According to the European Society of Analytical and Cellular Pathology 
(ESACP), the DNA index is defined as the quotient of the modal value of a 
DNA stemline divided by the modal value of a G0/G1 peak of reference cells 
(Haroske et al., 2001). A DNA index of 1 means that the DNA content of 
analysed cells does not differ from that of the reference diploid cells (control 
cells). Normal diploid cells have double strands of chromosomes and a DNA 
index of 1. This means that tumour cells with a DNA index of 1 are the same 
as reference diploid cells in G1 phase (Huang et al., 2005).  
According to some authors, cells with a DI value between 0.9 and 1.05 are 
considered as diploid samples, however, others regard cells as diploid when 
the DI is less than 1.1 (Huang et al., 2005, Gschwendtner et al., 1999). This 
may vary according to the study, author, and DNA image cytometry system 
used (Huang et al., 2005). 
1.10.2 Coefficient of variation (CV) 
One of the most used statistical parameters in DNA cytometry analysis is 
the coefficient of variation (CV). The CV is the quotient of the standard 
deviation of the IOD values divided by the mean of the IOD values of the 
reference cells in the G0/G1 phase fraction as defined by the European 
Society of Analytic Cellular Pathology (ESACP). It is given as a percentage, 
and should typically be less than 5% (Baak and Janssen, 2004). However, 
others have considered that less than 10% is acceptable (Santos‐Silva et 
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al., 2011). The ESACP formula is CV=SD/Mean ×100 (Haroske et al., 2001, 
Haroske et al., 1997). 
In fact, the CV value indicates the width of the reference peak (G0/G1 
peak). The narrower the reference peak, the lower the CV and hence the 
greater the accuracy and reliablility of the analysis. Therefore, in practice 
the CV parameter indicates the quality of the analysis but does not provide 
any discriminatory information. Nevertheless, the CV is an important 
parameter to identify the aneuploidy and estimation of S phase.  
1.10.3 Cells that exceed 5c  
Besides the DNA index, cells with a DNA content of more than 5c (5cER) 
provide another DNA cytometry parameter. Some investigators suggest that 
if only one single cell exceeds 5c it would be considered as aneuploid (Baak 
and Janssen, 2004). Cells with 5cER are known as non-proliferating cells 
with abnormal nuclear content (aneuploid) and a large chromosome 
population (Haroske et al., 2001). 
Normal cell populations do not show a 5cER, but when it is present in more 
than 1% of the gross nuclei analysed it is considered as an indicator of 
aneuploidy. Thus, a 5cER of more than 1% is regarded as a criterion to 
classify a lesion as aneuploid (Kristensen et al., 2003, Palmeira et al., 2010, 
Torres-Rendon et al., 2009b, Gockel et al., 2006, Pektaș et al., 2006, 
Santos‐Silva et al., 2011). 
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1.10.4 DNA image cytometry versus flow cytometry  
Image and flow cytometry have both been commonly used for DNA 
analysis; in both techniques stoichiometric staining of the nuclei is needed 
to quantify the DNA content. ICM generally measures the DNA content by 
light optical density (LOD). Samples are prepared by either cytospin 
preparations of extracted and dispersed cell nuclei or by examination of 
whole tissue sections, in which the nuclei are stained with Feulgen stain. 
FCM measures the DNA content of single tumour cells by cell dispersion. 
The nuclei are stained with fluorescent dyes, and the cells are passed 
through a flow cytometer. Using FCM, it is not possible to visualise or check 
the nuclei before analysis. 
DNA image cytometry has some advantages over flow cytometry, as the 
latter has some limitations. Lack of standardisation in assays is the most 
important drawback of flow cytometry (Jahan-Tigh et al., 2012). Also, it is 
not possible to choose individual cells from specific areas of tissue, or 
exclude any artefacts from the measurements. A small number of cells with 
abnormal DNA content (aneuploid) can be undetected in the presence of a 
large number of cells with a diploid content. Cells of interest that need to be 
analysed can be easily mixed with tumour stromal cells (Jahan-Tigh et al., 
2012, Rygiel et al., 2008). Therefore, accuracy of the results can be 
compromised and be less reliable compared with ICM. 
In contrast to FCM, DNA image cytometry allows direct visual detection and 
selection of cells of interest. The standardisation of DNA measurements is a 
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well-defined algorithm and it has been reported as having well established 
diagnostic validity and reproducibility (Böcking and Nguyen, 2004). 
Therefore, DNA imaging systems are more accurate for the detection of 
DNA ploidy abnormalities than flow cytometry (Dunn et al., 2010, Belien et 
al., 2009). 
1.10.5 DNA cytometry and diagnosis of tumours  
The potential prognostic value of DNA ploidy analysis using ICM from 
paraffin embedded oral precancerous samples was reignited by J.Sudbø 
(Sudbø et al., 2001, Sudbø et al., 2004, Sudbø and Reith, 2005). His 
promising work raised the theory of aneuploidy as an early stage in oral 
cancer transformation. Unfortunately, these studies have been retracted 
from the literature due to fictional data (Couzin and Schirber, 2006, Curfman 
et al., 2006). Nonetheless, his work suggested that aneuploidy was a good 
prognostic indicator in oral epithelial dysplasia. 
Many studies have analysed different solid tumours using DNA image 
cytometry, for instance, in oesophageal lesions (Fang et al., 2004, Gockel et 
al., 2006, Dunn et al., 2010), ovarian and urothelial tumours (Flezar et al., 
2003, Baak and Janssen, 2004), oral premalignant lesions (Torres-Rendon 
et al., 2009b, Brouns et al., 2012, Van Zyl et al., 2012), gastric cancer and 
lung cancer (D'Urso et al., 2010). More recent studies have shown the 
predictive value of DNA image cytometry (ICM) as an adjunct method in 
cytological analysis, such as in malignant effusions and cervical cancer 
lesions (Meng et al., 2013, Demirel et al., 2013). Results from these studies 
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indicated that ICM was considerably more predictive and sensitive than flow 
cytometry. It can also predict late relapse in Barrett’s oesophagus; patients 
with residual aneuploid tumours have a higher chance to develop cancer 
than those who become diploid. DNA aneuploidy by image cytometry is 
considered to be a good prognostic marker in patients with Barrett’s 
oesophagus (Dunn et al., 2010).  
DNA abnormalities detected by image cytometry can predict recurrence and 
stage of progression. In oral epithelial dysplastic lesions, 74% of studied 
samples with an abnormal DNA content (aneuploidy) showed malignant 
progression, compared to only 42% of the diploid lesions. 52.6% of patients 
with aneuploid content progressed to carcinoma within the first 5 years. In 
contrast, 25.3% of the diploid lesions progressed within the first 5 years 
(Torres-Rendon et al., 2009b). Similarly, in urothelial carcinomas, abnormal 
DNA content and a high S phase fraction appeared to predict malignant 
progression (Baak and Janssen, 2004).  
According to some authors, DNA cytometry should be combined with 
tumour proliferation markers to improve the prognostic evaluation of some 
cancers (Zhu et al., 2005, D'Urso et al., 2010). 
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1.10.6 DNA cytometry in oral squamous cell carcinoma 
Measurement of DNA content has been evaluated extensively using DNA 
FCM and ICM (Abou-Elhamd and Habib, 2007, Fleskens et al., 2010, 
Torres-Rendon et al., 2009b, Santos‐Silva et al., 2011, El-Deftar et al., 
2012, Diwakar et al., 2005). Although good correlation between prognosis 
and DNA status has been shown, no correlation between genomic content 
and histological differentiation has been found (Das et al., 2005, Torres-
Rendon et al., 2009b, El-Deftar et al., 2012). However, it has been shown 
that there is a clear association between severity of aneuploidy and 
histological grade of dysplastic lesions (Yu et al., 2007). Significant 
correction between ploidy status (aneuploidy) and lymph node involvement 
has been detected (Das et al., 2005, Seethalakshmi, 2013). In addition, 
multiple genetic alterations, such as losses or gains of chromosomes, have 
been correlated with disease outcome in head and neck tumours (Gollin, 
2014). It is also clinically relevant that aneuploid cases are more sensitive to 
radiotherapy than diploid tumours (Xiaoyan et al., 2005). 
On the other hand, Saiz-Bustillo (Saiz-Bustillo et al., 2005) and co-workers 
reported that there is no significant correlation between tumour free survival 
and DNA content, measured by flow cytometry . Some studies have shown 
that oral squamous cell carcinoma cases are frequently diploid by DNA 
image cytometry (Pektaș et al., 2006, Torres-Rendon et al., 2009b) or flow 
cytometry, despite the fact that the vast majority of patients had advanced 
disease (El-Deftar et al., 2012). The incidence of DNA aneuploidy evaluated 
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by FCM among primary OSCC ranges from about 20% to 90%. Donadini et 
al (Donadini et al., 2010) reported that the incidence of abnormal DNA 
content (aneuploidy) in OSCC was 92%. In addition, El-Deftar et al. (El-
Deftar et al., 2012) examined the DNA status in primary OSCC and 
matched metastatic lymph nodes; aneuploidy was recorded in only 19% of 
cases, and all metastatic lesions were diploid. These variations in values 
may relate to tissue material (paraffin embedded or frozen) used or to 
resolution of the FCM system. 
In 2005, Diwakar et al. (Diwakar, et al., 2005) published a paper in which 
they noticed a high incidence of heterogeneity of ploidy in samples of OSCC 
(using ICM on cytospins of dispersed nuclei to study ploidy). The authors 
suggested that this may be due to sampling error and contamination, or 
increased genomic instability in tumour clones, although the cause of this 
instability is still unclear (Gordon et al., 2012, Holland and Cleveland, 2009). 
Other authors have started to investigate ploidy status along with the 
cytomorphometric pattern of tumour cells in tissue and smear samples 
(Pektaș et al., 2006). 
Diwakar et al. (Diwakar et al., 2005) reported an aneuploid rate of 52% in 42 
OSCC cases. Twenty-two were uniformly aneuploid, one uniformly 
tetraploid and three uniformly diploid, but 16 cases were heterogeneous in 
their DNA content. This low percentage of aneuploid lesions may be due to 
sampling error as a result of the heterogeneity of tumour contents. 
Generally, heterogeneity amongst malignant cells with significant biological 
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differences within the same tumour is not uncommon (Sipos et al., 2014). 
Multiple samples analysed for DNA ploidy using an image system are 
recommended. Additionally, the recent study by Torres-Rendon et al. 
(Torres-Rendon et al., 2009b) found 11 aneuploid lesions (52%) out of 22 
OSCC. This data suggested that DNA abnormalities are not essential for 
malignant progression. In this regard, Santos-Sliva et al. (Santos‐Silva et 
al., 2011) studied two groups of patients affected by OSCC of the tongue. In 
the group of young patients (less than 40 years) they found 86.5% of the 
samples were aneuploid compared to only 64.3% of the older group. This 
rate of aneuploidy is higher than shown in other studies (Diwakar et al., 
2005, Torres-Rendon et al., 2009b). However, these studies used dispersed 
cell nuclei in cytospin preparations, while Santos-Silva et al.(Santos‐Silva et 
al., 2011) and colleagues analysed tissue sections with an ACIS system as 
used in the present study. This suggests that using tissue sections and an 
automated system (ACIS) allows better selection of relevant tissues, without 
contamination from stromal and diploid normal cells.  
Image cytometry has been reported to be a sensitive technique to examine 
DNA aneuploidy of OSCC (Yu et al., 2007, Torres-Rendon et al., 2009b, 
Santos‐Silva et al., 2011) and this technique can predict recurrence and 
clinical outcome (Böcking et al., 2010). 
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1.11 Summary 
Early diagnosis of OSCC can improve the patient’s quality of life and 
decrease mortality rates. So far, no single predictive marker can assess 
OSCC. Several markers have been suggested to have prognostic value in 
cancerous lesions, including minichromosome maintenance proteins 
(MCM2), geminin, cyclin and other cell cycle regulatory biomarkers. These 
could help in understanding the cell cycle kinetics of OSCC, and may be 
useful markers in lesion metastasis. There is a strong suggestion in the 
literature that aneuploidy is associated with malignant transformation and is 
a hallmark of solid malignant tumours. DNA image cytometry has been 
shown to be a valuable method for measurement of gross genomic damage 
in single cells or stemlines. Determination of DNA content could also be a 
predicative marker of tumour metastasis in OSCC lesions. 
Assessment of nuclear content (DNA ploidy) as a surrogate measure of 
gross genomic aberrations in malignant populations has provided promising 
data. Confirmatory studies are needed for further evaluation of the efficiency 
of DNA image cytometry as a predictive adjunctive method. 
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2. AIMS AND OBJECTIVES 
2.1 Hypotheses 
 Alterations in cell cycle regulatory proteins can be found in oral 
squamous cell carcinoma and may predict prognosis. 
 DNA aneuploidy may indicate high risk of progression of oral cancer. 
 DNA image cytometry analysis of oral cancer may be a useful 
diagnostic and prognostic tool. 
2.2 Aims and objectives  
The aims of this project were to: 
1. Determine the expression patterns of a range of potential biomarkers 
in oral cancers (squamous cell carcinoma) including cell cycle 
regulatory proteins (e.g. MCM2 and cyclins). 
2. Evaluate DNA content (ploidy) as a diagnostic and prognostic marker 
in these lesions. 
3. Investigate the relationship between gross genomic aberrations 
(abnormal DNA content) and expression of cell cycle proteins. 
4. Assess heterogeneity of lesions by means of cell cycle proteins 
expression and DNA ploidy status.  
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Specific objectives were to: 
1. Determine the expression of potential biomarkers in oral cancer using 
immunocytochemistry. Analyse the expression of Minichromosome 
maintenance (MCM2) protein and other biomarkers including cell 
cycle proteins and proliferation markers in the same cases, and 
correlate expression to stage of disease (including lymph node 
metastases), conventional histological grade, and to grading by DNA 
status (diploid or aneuploid). 
2. Determine the ploidy status of oral cancers using an automated 
system of image cytometry. Ploidy will be correlated to the histological 
grade, and outcome in terms of metastatic disease. 
3. Determine heterogeneity of ploidy status in lesions of oral cancer using 
samples from different regions of squamous cell carcinomas (surface 
and advancing front). For each region the DNA content and 
expression of biomarkers will be investigated. 
.............................................................
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3.  MATERIALS AND METHODS 
3.1 Health and Safety and Ethics 
All tissue samples, materials and chemicals were handled according to 
university health and safety guidelines. Any chemical reagents producing 
toxic fumes were processed in a fume cupboard. The requirements and 
precautions recommended in Control of Substances Hazardous to Health 
were followed before starting any laboratory work. 
Ethical approval for the project was obtained from South Sheffield Research 
Ethics Committee (08/S0709/70).  
3.2 Tissue Specimens 
The archive of pathology specimens in the Unit of Oral and Maxillofacial 
Pathology, School of Clinical Dentistry, University of Sheffield, was searched 
for specimens which had been histologically diagnosed as oral squamous cell 
carcinoma. Pathology records were reviewed to identify cases that had 
metastasised and cases that had not. Metastatic cases were defined as 
histologically proven metastastic lesions in a cervical lymph node. Only cases 
which had been treated by primary surgery were included, cases that had 
received radiotherapy before surgical removal were excluded. The patient 
database was also searched for clinicopathological and demographic 
information, including age, gender and location. Disease stage was defined in 
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accordance with the TNM classification by the International Union Against 
Cancer (UICC) (Sobin and Wittekind, 2002). All sections and blocks were 
reviewed to confirm the diagnosis and to ensure that sufficient material was 
available for study. The grade of each tumour (differentiation) was retrieved 
from the histological reports and was confirmed on review. 
A total of one hundred and forty two cases were included in the study divided 
as follow: 
 17 cases of normal oral mucosa (NOM) 
 47 cases of OSCC that had not metastasised (OSCC NM) 
 39 cases of OSCC that had metastasised (OSCC M) 
 39 cases of matched metastatic lesions from cervical lymph nodes 
(OSCC LN) 
3.3 Tissue Microarrays 
For immunocytochemical studies, tissue specimens were prepared into tissue 
microarrays. This enabled more rapid analysis of markers associated with 
disease diagnosis and prognosis.  
Tissue microarrays of specimens were constructed using a Beecher manual 
micro-array system (The L.S. Starrett Company, USA), with array punches 
1.0 mm in diameter (Beecher instrument Inc., Sun Prairie, Wisconsin, USA) 
(Figure 3.1). This technique involves removing a core of tissue from the 
specimen (donor block) and transferring it into a new paraffin block (recipient 
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block). A recipient block may include up to a hundred or more cores, enabling 
staining and examination of many samples at the same time. 
For each sample a haematoxylin and eosin stained section was examined 
and representative areas of the tumour were selected and marked on the 
glass slide using a cytology slide marker (Nikon). Care was taken to select 
representative areas of tumour with minimal stroma, and avoiding areas of 
necrosis or ulcer. The marked slide was then superimposed on the paraffin 
block to identify and mark the sites on the donor block from where the TMA 
cores were to be taken. For each OSCC primary tumour sample, 3 areas 
were sampled: 
 The surface 
 The centre of the lesion 
 The advancing front 
Whenever possible three cores were taken from each of the three areas, 
giving a maximum of 9 samples per tumour. Some tumours were too small to 
obtain cores from all three areas, in which case two areas (6 cores) were 
sampled – the surface and the advancing front. For the metastatic lesions 
three representative cores were taken from each tumour. Each TMA block 
contained 48 to 60 cores (Figure 3.1). In each block, one core of a non-
relevant sample (epithelial tissue) was placed in the bottom right corner for 
orientation purposes.  
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Figure 3.1: Construction of Tissue Micro Arrays (TMA). Areas of interest 
were identified on an H&E stained slide and then punched from the donor 
block using a Beecher manual micro-array system. Cores were then inserted 
into a recipient paraffin wax block (Centre). Each block contained up to 60 
representative cores of the tissue specimens. 
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3.4 Immunohistochemistry 
3.4.1 Antibodies used in the IHC 
3.4.1.1 MCM2 
A rabbit polyclonal antibody raised against human MCM2 was provided by 
Sigma (Sigma-Aldrich, USA). MCM2, the presence of which has been 
determined with human homolog BM28, a protein of 250 amino acids that 
encodes the ATPase active site (Costa and Onesti, 2009). Its IgG1 subclass 
reacts with human MCM nuclear antigen. It has been reported that MCM2 is 
expressed throughout the G1 phase of the cell cycle and is gradually lost as S 
phase proceeds. However, its expression is very low in G0 phase. 
3.4.1.2 Ki-67 
Anti-human (clone MIB-1) monoclonal mouse antibody was obtained from 
Dako (Glostrup, Denmark). The Ki-67 nuclear antigen is differentially 
expressed as isotype IgG1 during all active phases of the cell cycle (late G1, 
S, M and G2), but absent in non-cycling cells (G0 phase).…………………... 
Immunohistochemical and flow cytometric analysis has shown that MIB-1 
reacts with Ki-67 antigen and is a valuable indicator of the growth fraction of 
cells undergoing active division in normal and neoplastic conditions. Thus, 
MIB-1 antibody has been recognised as the ideal monoclonal antibody for 
detecting the Ki-67 antigen in routinely formalin-fixed paraffin embedded 
specimens (Kubbutat et al., 1994). 
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3.4.1.3 Geminin  
Polyclonal rabbit anti-human geminin (clone ab12147) was provided by 
Abcam (Cambridge, UK). Geminin has a role in the governance of licensing in 
the G2 phase and is negatively regulated during S phase to prevent DNA re-
replication. This antibody has been previously detected in western blots of cell 
lysates from a human embryonic kidney cell line. Immunogen affinity purified 
antibody detected a band at 33 kDa (Hochegger et al., 2007); this band can 
be blocked by the immunising peptide. 
3.4.1.4 Cyclin D1  
Monoclonal rabbit anti-human cyclin D1 (clone EP12) was obtained from 
Dako (Glostrup, Denmark). This antibody reacts with cyclin D1 antigen 
encoded by the bcl-1 gene located on chromosome 11q13. Cyclin D1 is 
involved in normal cell cycle regulation and tumour transformation in 
mammalian cells. During the cell cycle cyclin D1 protein is responsible for 
progression from the G1 phase to the S phase by pRb phosphorylation. The 
corresponding antigen has been found useful for demonstration of cycling 
cells in mantle cell lymphomas (Donnellan and Chetty, 1998).  
3.4.1.5 p16INK4A  
Purified anti-p16INK4A mouse monoclonal antibody (obtained from Abcam, 
Cambridge, UK) is isotype IgG2b and is encoded by the gene CDKN2A. 
CDKN2A homozygous deletions or mutations are frequently seen in a variety 
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of malignant tumours, particularly melanoma and it is known to be an 
important tumour suppressor gene. This protein expression strongly 
correlates with infection by human papilloma virus (HPV) (Lewis et al., 2012). 
3.4.2 Immunohistochemical staining procedures 
Four-micrometre sections of the TMA paraffin blocks were cut and mounted 
on coated slides (Menzel Gläser, Germany) and used for IHC. Details of the 
antibodies used in IHC are listed in Table 3.1. Sections were dewaxed in 2 
changes of xylene (5 minutes each) and rehydrated in absolute alcohol 
(100% alcohol x 2, 5 minutes each). To suppress endogenous peroxidase 
activity, sections were treated with freshly prepared hydrogen peroxide in 
methanol (3% Met OH) for 30 minutes at room temperature. Then, a heat-
mediated antigen retrieval protocol was carried out using citrate buffer (pH 
6.0) (Appendix 1) in a steamer, for 30 minutes for MCM2, Ki-67, geminin and 
p16INK4A. For cyclin D1 protein, Tris-EDTA buffer (pH 9.0) was used for 30 
minutes (Appendix 1). Slides were then allowed to cool down and briefly 
washed with phosphate buffered saline (PBS) (Appendix 1) using a stirrer to 
ensure adequate washing.  
To prevent false positive and high background staining, sections were 
blocked by incubating for 60 minutes, with normal horse serum for mouse 
monoclonal antibodies, or goat serum for rabbit polyclonal antibodies. Primary 
antibodies were diluted and incubated as detailed in Table 3.1. Next, slides 
were washed with PBS buffer for 5 minutes. The visualisation system was the 
ABC Standard kit (Vector laboratories, US) that includes incubation with 
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secondary biotinylated antibody and with an appropriate substrate Vectastain 
for 30 minutes each at room temperature. Two washes of PBS were applied 
for 5 minutes each between secondary and Vectastain steps. Positive 
staining was detected after 6 minutes incubation with Vector Novared (Vector 
Laboratories, US). Finally, the slides were rinsed twice with distilled water to 
stop the hydrogen peroxide reaction, and then counterstained with Mayer`s 
haematoxylin (Appendix 1) before being dehydrated and mounted with low 
viscosity DPX mounting media. In order to ensure the specificity of antibodies 
and that there was no contamination, negative controls without primary 
antibody were run during the standardisation process. Sections of normal oral 
mucosa were used as positive controls and underwent the same procedure 
for MCM2, Ki-67, geminin and cyclin D1. Two sections of oropharyngeal 
carcinoma known to be positive for HPV were used as a positive control for 
p16INK4A. 
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Antibodies Clone Supplier Clonality 
Dilutions & incubation 
time 
MCM2  BM28  Sigma 
Rabbit polyclonal 
anti-human  
1:1000, overnight at 4°C  
Ki-67 MIB-1 Dako 
Monoclonal mouse 
anti-human  
1:75, overnight at 4°C 
Geminin ab12147 Abcam 
Rabbit polyclonal 
anti-human 
1:300, overnight at 4°C 
Cyclin D1 EP12 Dako 
Rabbit monoclonal 
anti-human 
1:100, overnight at 4°C 
p16INK4A 2D9A12 Abcam 
Mouse monoclonal 
antibody 
1:500, overnight at 4°C 
Table 3.1: Details of the antibodies used in immunohistochemistry. 
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3.4.3 Protein expression analysis  
3.4.3.1 Traditional cell counting method 
After the staining of the TMA sections the levels of expression of each protein 
were anaylsed by cell counting to determine a labelling index (LI). The 
number of positively and negatively stained epithelial cells were counted in 
eight to ten non-overlapping microscope fields using a x40 objective to give a 
final magnification of x400. Immunostaining for all cell cycle proteins was 
evaluated blindly without any knowledge of the clinical data. 
3.4.3.2 Determination of cell count  
The cumulative mean method was used (Williams, 1977) to estimate the total 
number of cells that needed to be counted to produce a consistent result. 
Malignant epithelial cells were counted in random fields and the number of 
positive and negative cells were recorded for each field in turn. After the 
second field was counted, the average of fields 1 and 2 was determined. This 
process continued for each field in turn and the cell counts in each 
subsequent field were included to produce a cumulative mean. The number of 
cell counts required to produce three consecutive running means within +/-5% 
of the final average is considered to be the minimum number of cells required 
to achieve a reliable result (Williams, 1977). The number of tumour cells that 
needed to be counted can then be determined. A total of 800 to 1500 cells 
need to be counted. Whenever possible the maximum number of cells was 
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counted (1500). However, in some cases the specimens were too small to 
count the maximum and fewer cells were counted (800). 
3.4.3.3 Cell Counting 
High power fields (x400 magnification) were identified using a stratified 
random sampling method. The first field was selected randomly and 
subsequent fields selected by moving the microscope stage one field 
horizontally or vertically as required. Usually ten fields were required to 
ensure that 800 to 1500 nuclei were counted and analysed. An eyepiece 
graticule was used to delineate the counting area and all cells that were 
inside the square of the graticule were counted. The positive, the negative 
and total number of cells were counted using a manual cell counter and 
recorded on an excel spread sheet. Positive expression was considered as 
nuclei with light to dark brown staining, negative cells showed counterstain 
only, as any shade of blue colour. The labelling index (LI) was calculated by 
dividing the total number of positive cells by the total number of cells counted 
per case and multiplied by 100. 
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3.5 DNA image cytometry 
3.5.1 Preparation for Feulgen-Schiff staining 
TMAs were not used for DNA analysis; instead, sections from paraffin blocks 
of each case were taken before the preparation of the TMAs. Seven 
micrometre thick sections were cut and mounted on coated slides (X-tra 
adhesive, Surgipath, USA). Sections were placed in slide boxes to dry and 
stored in a dust-free environment at room temperature. Sections were 
deparaffinised with three washes of xylene for 5 minutes each, and 
rehydrated with different concentrations of alcohol for 3 minutes (absolute 
alcohol, 95% and 70%) followed by distilled water (2 minutes).  
3.5.2 Feulgen-Schiff staining 
The slides were placed in a Coplin jar containing 5N hydrochloride acid (HCL) 
(Appendix 1) for 1 hour at room temperature in a fume hood; the jar was 
completely sealed with Parafilm during the incubation. Subsequently, the 
slides were rinsed with distilled water for 2 minutes, and immersed in blue 
Feulgen stain for 1 hour (Scy Tek Laboratories Kit, USA). Afterwards, the 
slides were washed in three changes of distilled water for 2 minutes. Next, 
they were placed in 3 changes of rinse solution (Scy Tek Laboratories Kit, 
USA) for 5 minutes followed by 3 washes of distilled water (2 minutes each). 
Finally, the slides were dehydrated with increasing concentrations of ethanol 
(70%, 95% and 100%) and fixed with xylene. A cover slip was mounted with 
low viscosity DPX on each slide.  
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3.5.3 Image cytometry for DNA analysis 
The intensity of Feulgen staining was measured using an Automated Cellular 
Imaging System, ACIS III (Dako, Glostrup, Denmark). This machine consists 
of a microscope unit (4, 10, 20, 40 and 60X objectives) with an automated X-
Y stage, a digital JAI camera 3-chip, 30 frames per second, connected to a 
CPU with Dual Xeon Intel, LCD monitor and label printer (InfoGlyph label) 
(Figure 3.2). For optimal function, a calibration kit provided by the 
manufacturer was run daily in the system. 
Briefly, ACIS III uses advanced colour detection software that is pre-
programmed for various parameters of analysis including microscope 
objective, stain colour and/or intensity of cellular objects. There are two main 
steps for ploidy anaylsis using ASCI III.  
Firstly, in the accessioning step (Figure 3.3), each stained slide is labelled 
with a unique barcode to create a unique patch that is used by the ACIS III 
database for reference and to track information and to analyse results, then 
labels are printed and stuck onto the slides. 
Secondly, in the analysis step, each slide is scanned by the automatic 
microscope to create a virtual image of the whole section (Figure 3.4). Based 
on morphometric characteristics of whole cells as measured by the software 
application, such as size, shape and integrated optical density (IOD), the 
application is then used to capture each field for recording data such as 
colour and chromogen intensity. 
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Figure 3.2: Automated Cellular Imaging System ACIS III (Dako, Denmark). 
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This process had to be repeated twice for the same slide in each group 
(except OSCC lymph node metastasis) and recorded with a different barcode 
and different patch name to be able to analyse different areas in the same 
sample (surface and advancing front). This was because the ACIS III does 
not provide multiple area measurements in a single section (same slide). 
The software algorithms built into the system were then used to allow the 
computer to automatically select, first, control cells, and then potential 
malignant cells. The system has different cutting levels (Figure 3.4) for 
tumour cell collection whereby sample level L5 has the most aggressive 
cutting algorithm and only selects separated cells. Once the slides were 
scanned the histological reconstructions were reviewed and the imaging 
system identified and the cells that had been automatically selected were 
outlined with a thin blue line (Figure 3.4). The histological reconstruction is a 
high resolution image that allows complete section to be reviewed for 
accurate selection of representative areas. The operator then reviews the 
image and confirms visually that the selected cells meet the criteria for control 
cells or malignant cells. Unwanted cells may be rejected, for example, 
incomplete sections of nuclei, overlapping nuclei or obvious cell debris can be 
selected and rejected. Once the control cells have been checked and 
selected, and the control peak (2c) assigned, tumour nuclei in the target area 
are collected and presented as montage images (Figure 3.5).  
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At least three hundred qualified malignant epithelial nuclei were selected and 
approximately 50 control nuclei (lymphocytes) in the same tissue were 
obtained at sample level 3 (L3). Cells can also be accepted or rejected by the 
operator from the montage window (Figure 3.5). The operator can also do 
further analysis by navigating between individual nuclei and their exact 
location on the histogram. The results are generated automatically by ACIS 
as a report, and displayed as a histogram, which contains assessment 
parameters such as DNA index, coefficient of variation (CV) and the 
proportion of nuclei that exceed 5C (5cER) (Figure 3.5). 
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Figure 3.3: Screen shot of ACIS III showing the first step of ploidy analysis 
(Accessioning). Firstly, assign a batch name, then give slide an accession 
number (labelled with a unique barcode). Next, select application name and 
add slide. Finally, labels print, and stuck onto the slide. 
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Figure 3.4: Screen shot of ACIS III showing the second step of ploidy 
analysis. Different cutting levels from L1 to L5 (red rectangle), where sample 
level L5 has the most aggressive cutting algorithm. On the left side is the high 
power view of the scanned image, which can be seen on the right. 
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Figure 3.5: ACIS III montage window of microscopically edited Feulgen-
stained nuclei (top). Once the DNA content histogram has been generated on 
the basis of integrated optical density (IOD), this montage window allows the 
operator to undertake further analyses (accepting or rejecting undesired 
cells). 
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3.5.4 Criteria for classification of DNA histograms  
DNA histograms were analysed by one observer (IZ). DNA histograms were 
evaluated according to the criteria proposed by Huang et al (Huang et al., 
2005) and Yu et al. (Yu et al., 2007) and previously used in our department 
(Santos-Sliva et al., 2011). The DNA index and coefficient of variation (CV) 
parameters were calculated for each sample. The CV was maintained at less 
than 5% to ensure the consistency of the cell selection. 
A diploid specimen was defined as only one peak at 2c (which presented at 
0.3 intervals on the ACIS histogram) during the G0/G1phase, and if the 
number of nuclei with a DNA content of more than 5c did not exceed 1% of 
the total (Figure 3.6). Aneuploidy was defined if separate aneuploid peaks 
were identified, located within 0.3, 0.6, 0.9….etc. intervals, or the number of 
cells exceeding 5c (pentaploid range) was more than 1% (Figure 3.7). Ploidy 
was also classified according to the value of the DNA index as follows: 
 Diploid (DI= 0.9 – 1.10) 
 Mild aneuploid (DI = 1.11 – 1.30) 
 Moderate aneuploid (DI = 1.31 – 1.80) 
 Severe aneuploid (DI = > 1.81) 
A lesion was characterised as tetraploid if the DI was between 1.81 and 2.20, 
which was considered to represent a subtype of severe aneuploidy. In the 
case of two peaks, the DI of the most prominent peak was considered 
(Figure 3.7). 
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Figure 3.6: An example of a diploid histogram generated by ACIS, with a 
single peak in c2 (represented as 3.00 interval in the histogram) and no cells 
that exceed 5c. CTRL indicates the control G1 peak and Dip-G1 indicates the 
diploid G1 peak. 
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Figure 3.7: Example of a moderate aneuploid histogram with two prominent 
peaks. In this case DI = 1.5 and more than 1% of cells exceed 5c. CTRL 
indicates the control G1 peak, An-G1 indicates the aneuploid G1 peak and 
An-G2 indicates the aneuploid G2 peak. 
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3.6 Statistical analysis  
Statistical analysis of all data in this study was undertaken using SPSS 
statistical software (Version 21.0). 
The Two-tailed Kolmogorov-Smirnov test was used to evaluate the 
distribution of data in each group (Appendix 2). Cross tabulation tables were 
created to show the age, gender and site distribution among groups. The 
labelling index (LI) of MCM2, Ki-67, geminin and cyclin D1 was normally 
distributed in all analysed groups (NOM, OSCC NM, OSCC M and OSCC 
LN). Therefore, these parameters were analysed using parametric tests. 
For the ploidy analysis, the DI and 5cER parameters were normally 
distributed in most of the groups with the exception of the DI in the OSCC LN 
and 5cER in OSCC M. Nominal data such as ploidy status were analysed by 
non-parametric tests. Non-parametric tests are often more powerful in 
detecting differences in given populations, therefore data were treated as not 
normally distributed. 
3.6.1 Evaluation of protein expression in NOM, OSCC NM, 
OSCC M and OSCC LN 
ANOVA and t-test were used to compare the mean LI of MCM2, Ki-67, 
geminin and cyclin D1 protein between groups (NOM, OSCC NM, OSCC M). 
Paired t-test was used to evaluate differences in proteins expression between 
OSCC M and their matched OSCC LN. 
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Bar charts and scatter plots were generated to demonstrate the protein 
distribution among the groups. A p value less than 0.05 was considered 
statistically significant. 
3.6.2 Evaluation of DNA image cytometry and ploidy status 
in OSCC NM, OSCC M and OSCC LN 
Mann-Whitney and Wilcoxon Signed tests were used to compare the DI, 
5cER and ploidy status among groups. Receiver operator characteristic 
(ROC) curves were plotted using the DNA index and 5cER values for each 
sample. Sensitivity, specificity, positive predictive value and negative 
predictive value were calculated to evaluate the DNA image cytometry as a 
prognostic method.  
3.6.3 Correlation of protein expression and ploidy status  
The Spearman rank correlation coefficient test was used to identify any 
correlation between protein expression (MCM2, Ki-67, geminin and cyclin D1) 
and ploidy status in OSCC lesions. 
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4. EXPRESSION OF CELL CYCLE PROTEINS IN 
OSCC AND MATCHED LYMPH NODE METASTASES 
4.1  Introduction 
The molecular mechanisms that control entry to the cell cycle are highly 
conserved processes. The precise events include the formation of the pre-
replication complex (pre-RC) by the origin recognition complex (ORC) in 
early G1 phase (Symeonidou et al., 2012). The ORC is required for the 
recruitment of cdc6, MCM2-7 and Cdt1 at the replication origin (Section 
1.3.1 and Figure 1.4). Subsequently, CDK and Dbf 4-dependent kinase are 
recruited to initiate the replication process. These, along with geminin (Cdt1 
inhibitor), impede loading of the MCM2–7 helicase at origin (Aparicio, 2013) 
and prevent another cell cycle round. Once mitosis is complete, the 
licensing proteins ensure the genomic stability in the cell cycle (Labib, 
2010). 
Expression of minichromosome maintenance proteins (MCM2-7) is required 
for DNA replication and cell cycle initiation (Symeonidou et al., 2012). MCM 
proteins are expressed throughout the cell cycle phases, including cells 
leaving the quiescent phase (G0) to enter into early G1 phase (licensed to 
proliferate). Notably, this characteristic is not found in other proliferation 
markers (Ki-67 or geminin), therefore, MCM2 in particular has been 
proposed as a sensitive prognostic marker that may indicate the presence 
of an increased growth fraction in malignant lesions. MCMs are emerging as 
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powerful cancer diagnostic tools (Torres-Rendon et al., 2009a, Kodani et al., 
2003, Gueiros et al., 2011, Szelachowska et al., 2006, Shalash et al., 2012). 
Due to its predominance as a potential proliferation marker in normal and 
malignant lesions, MCM2 will be the focus of this project. 
Ki-67 protein is expressed in all cell cycle phases except early G1 (Gerdes 
et al., 1984). It has been suggested that evaluation of this protein along with 
MCM2 and geminin may provide additional information about the 
proliferation rate in epithelial cells (Sections 1.4 and 1.5). The MCM2/Ki-67 
ratio has recently been used as a prognostic parameter to estimate the 
population of cells that are licensed to proliferate (Shetty et al., 2005, 
Torres-Rendon et al., 2009a). A high ratio indicates that many cells are in 
cycle, and could indicate a poor prognosis (Dudderidge et al., 2005).  
Geminin is a proliferation marker expressed only during the S-G2-M 
transition (Section 1.5 and Figure 1.5). It is believed to regulate the cell 
cycle initiation by preventing the second pre-RC assembly once replication 
has taken place (Guo and Sun, 2013). Geminin expression may be altered 
in cancer cells as it has been found to be over-expressed in several cancer 
cell lines (Xouri et al., 2004). The geminin/Ki-67 ratio estimates the relative 
length of G1, where a short G1 phase will approximate to a ratio of 1, cells 
with a prolonged G1 will approximate to a ratio of 0 (Wharton et al., 2004). 
The higher the ratio, the faster the rate of cell division, and the worse the 
prognosis (Torres-Rendon et al., 2009a). 
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p16INK4A is a tumour suppressor gene that plays an important role in cell 
cycle regulation during the G1 phase. Down-regulation or inactivation of this 
protein in human cancer may help to evaluate tumour progression, 
recurrence and survival (Dong et al., 2012, Kumar et al., 2008, Chen et al., 
2012). High expression of p16INK4A is seen in HPV-associated 
oropharyngeal cancer (Westra, 2015). p16INK4A over-expression has been 
considered as an HPV surrogate marker in OPC (Seiwert, 2014). However, 
high HPV positivity has been reported in OPC compared to OSCC (Laco et 
al., 2011). Therefore, OSCC and OPC cancers should be regarded as two 
entities (Auluck et al., 2014). Expression of p16INK4A was tested in this study 
to ensure that this cohort is confined to non-HPV associated OSCC. 
The cyclin D1 is a key regulatory protein required for transition from G1 to S 
phase by binding to cyclin-dependent kinases (CDK4 and CDK6). Its over-
expression has attracted significant attention because of its role in 
tumourgenesis. Cyclin D1 may be a valuable prognostic indicator for oral 
squamous cell carcinoma (Huang et al., 2012, Hanken et al., 2014), 
however, the exact role remains controversial. In addition, high levels of 
cyclin D1 were suggested to be associated with lymph node metastasis in 
OSCC (Huang et al., 2012).  
Generally, OSCC is characterised by a high rate of recurrence and 
metastasis to the regional lymph nodes. Nodal metastasis is considered to 
be a significant prognostic indicator (Noguti et al., 2012). However, tumour 
size, grade of differentiation and disease stage are also important factors 
which affect cervical metastasis and prognosis.  
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In summary, analysis of these bio-markers may help to evaluate the cell 
cycle phase distribution in OSCC NM, OSCC M and OSCC LN, and may 
provide additional prognostic information. 
The purpose of this study was to look at the heterogeneity observed in the 
oral squamous cell carcinoma lesions and to evaluate the expression levels 
of these proteins in OSCC NM, OSCC M and OSCC LN. Additionally, I 
sought to determine if altered expression could be used as a prognostic 
indicator of tumour progression and predict nodal metastasis in OSCC.  
4.2 Materials and methods  
Four micrometre (4µm) TMA sections were cut and immunostained with 
antibodies to MCM2, Ki-67, geminin, cyclin D1 and p16INK4A according to the 
protocol and methodology explained in Section 3.4.2. Dilutions and 
incubation times are summarised in Chapter 3 (Table 3.1). Oropharyngeal 
carcinoma sections were used as a posititive control to ensure antibody 
specificity for p16INK4A. Immunostaining of p16INK4A was considered positive 
if there was strong and diffuse nuclear and cytoplasmic staining in more 
than 70% of tumour cells (Lewis et al., 2012, Nankivell et al., 2014). Protein 
expression was analysed and labelling index (LI) was calculated in each 
area (surface, middle and front) for each case as previously described in 
section 3.4.3. The final analysis was based on all the TMA cores counted for 
each case and LI for the total was calculated. 
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4.2.1 Statistical analysis 
Statistical analysis was described in Chapter 3, Section 3.6. Parametric 
ANOVA and t-tests were used to evaluate the differences in the nuclear LI 
of MCM2, Ki-67, geminin and cyclin D1 in the NOM, OSCC NM, OSCC M 
and LN metastasis groups. Mean and standard deviations were calculated 
for the LI of all proteins. The general linear model (GLM) of repeated 
measures analyses was used to evaluate the differences in the LI of all 
proteins (MCM2, Ki-67, geminin and cyclin D1) in every group (e.g. NOM, 
OSCC NM, OSCC M, and OSCC LN). 
Bar-charts were generated to observe the differences in protein expression 
between groups. Scatter plots were prepared to illustrate the association 
between proteins (MCM2, Ki-67 and geminin). 
4.3 Results  
4.3.1 Patient information 
A total of one hundred and forty two samples were included in this study. In 
the OSCC NM group (n=47), TMA immunostaining was available in 40 
samples for MCM2, 44 samples for Ki-67, 47 samples for geminin, 47 
samples for p16INK4A and 47 samples for cyclin D1. In the OSCC M group 
(n=39), immunostaining was available in 37 samples for MCM2, 39 samples 
for Ki-67, 39 samples for geminin, 39 samples for p16INK4A and 39 samples 
for cyclin D1. In the LN metastasis group (n=39), 32 samples for MCM2, 26 
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samples for Ki-67, 33 samples for geminin, 32 samples for cyclin D1 and 35 
samples for p16INK4A were available for analysis.  
There were some missing cases due to missing TMA cores which were lost 
during the sectioning or during the immunostaining procedure. Additionally, 
some TMA cores did not show immuno reactivity and were therefore 
excluded from analysis. However, in all positive cases, LI was recorded 
from 6 to 9 TMA cores for each case.  
Demographic details for all 142 samples are shown in Table 4.1 and Table 
4.2. These include age, gender (Table 4.1) and lesion site (Table 4.2). The 
OSCC differentiation status was retrieved from the histological reports and 
is shown in Table 4.3. The OSCC NM and OSCC M were 
histopathologically graded by an expert pathologist (PMS). From the 47 
OSCC NM samples analysed for protein expression, 21 were well 
differentiated, 20 were moderately differentiated and 6 were poorly 
differentiated (Table 4.3). In OSCC M samples 13 were well differentiated, 
20 were moderately differentiated and 6 were poorly differentiated (Table 
4.3). In the metastatic samples (OSCC LN) 15 cases were well 
differentiated, 21 were moderate and 3 cases were poorly differentiated 
(Table 4.3). Tumour size (pT classification) and clinical stage of disease are 
shown in Table 4.3. 
The mean age of NOM was 51.55 years with a standard deviation of 15.71 
(range; 24.50-74.50). In the OSCC NM group the mean age of patients was 
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63.86 years (SD=12.58, range; 34.50-64.50) and was 61.67 (SD=12.55, 
range; 34.50-84.50) in the OSCC M group.  
Representative examples of immunoexpression of MCM2, Ki-67, geminin 
and cyclin D1 in NOM, OSCC NM, OSCC M and OSCC LN samples are 
shown in Figure 4.1, Figure 4.2, Figure 4.3 and Figure 4.4. p16INK4A 
negative and positive controls are shown in Figure 4.5. 
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 Groups   
 
NOM OSCC NM OSCC M Total 
Age 
(by decades) 
  
20-29 2 (12) 0 0 2 
30-39 1 (6) 1 2 4 
40-49 5 (29) 7 3 15 
50-59 4 (24) 7 13 24 
60-69 2 (12) 15 10 27 
70-79 3 (17) 13 8 24 
80-89 0 4 3 7 
Total 17 47 39 103 
Gender (%) 
  
Male 8 (47) 32 (70) 26 (67) 66 
Female 9 (53) 15 (30) 13 (33) 37 
Total 17 47 39 103 
NOM= Normal oral mucosa. 
OSCC M= Oral squamous carcinoma that had metastases. 
OSCC NM= Oral squamous carcinoma that did not metastasise. 
Table 4.1: Demographic data (age and gender) for all groups .  
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Groups Lesion sites Total 
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NOM 6 1 1 0 1 3 3 2 0 0 17 
OSCC 
M 
17 8 1 0 1 6 6 0 0 0 39 
OSCC 
NM 
16 8 1 1 2 8 7 1 2 1 47 
Total 39 17 3 1 4 17 16 3 2 1 103 
NOM= Normal oral mucosa 
OSCC M = Oral squamous carcinoma that had metastases. 
OSCC NM= Oral squamous carcinoma that did not metastasise.  
Table 4.2: Site of lesions from all patients in all groups. 
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 Groups Total 
 
OSCC NM 
n (%) 
OSCC M 
n (%) 
OSCC LN 
n (%) 
 
Tumour grad   
Well 21 (45) 13 (33) 15 (38) 49 
Moderate 20 (43) 20 (51) 21 (54) 61 
Poor 6 (13) 6 (15) 3 (8) 15 
Total 47 39 39 125 
Tumour stage (TNM)   
I 15 (32) 0 - 15 
II 15 (32) 0 - 15 
III 17 (36) 8 (21) - 25 
IV 0 27 (69) - 27 
NA - 4 (10) - 4 
Total  47 39  86 
Tumour size stage   
pT1 15 (32) 7 (18)  22 
pT2  15 (32) 10 (26)  25 
pT3  17 (36) 4 (10)  21 
pT4 0 18 (46)  18 
Total  47 39  86 
Extra capsular spread   
Yes  - - 16 (41) 16 
No - - 20 (51) 20 
NA - - 3 (8) 3 
Total    39 39 
OSCC NM= Oral squamous carcinoma that did not metastasise. 
OSCC M = Oral squamous carcinoma that had metastases. 
OSCC LN= Lymph node metastases. 
NA= Not available. 
Table 4.3: Distribution of OSCCs according to their clinicopathological 
parameters in all groups. 
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4.3.2 p16INK4A expression 
Sections of oropharyngeal carcinoma were used as a positive control of 
p16INK4A and showed strong nuclear and cytoplasmic staining in the 
malignant epithelial cells. Negative control sections showed no staining 
(Figure 4.5). The p16INK4A staining confirmed that all cases (NOM, OSCC 
M, OSCC NM and OSCC LN) were negative and therefore this cohort was 
not HPV associated OSCC. A second observer (PMS) examined all the 
cases for p16INK4A and found 100% agreement. 
4.3.3 Expression of proteins in normal oral mucosa 
The NOM samples showed positive nuclear staining of MCM2, Ki-67, 
geminin and cyclin D1 mainly in the basal and suprabasal cell layers 
(Figure 4.1). This group had the lowest LI expression (60.09) of MCM2, Ki-
67 and geminin when compared with OSCC M & OSCC NM groups (Table 
4.4). 
4.3.4 MCM2 expression 
Significant differences (p=0.007, ANOVA test) in MCM2 LI values were 
found among analysed groups (NOM, OSCC NM and OSCC M) (Table 4.4). 
The mean MCM2 LI values were slightly higher in the OSCC M than OSCC 
NM samples (Figure 4.6), but this did not reach statistical significance. 
Although there were no significant differences, the MCM2 LI was 73.58 in 
the OSCC M group, and 69.96 in OSCC NM group (Table 4.4). The positive 
nuclear staining of MCM2 showed variable expression in tumour areas; 
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however, whilst its expression was greater at the invasive front, this was not 
statistically significant in the OSCC NM and OSCC M groups (p=0.6, p= 0.1 
respectively, ANOVA test) (Table 4.5 and Figure 4.7). 
The mean MCM2 LI expression showed higher expression in the lymph 
nodes metastases than in the matched primary OSCC lesions, but the 
difference did not reach significance (p=0.8, Paired t-test) (Table 4.6 and 
Figure 4.7). 
4.3.5  Ki-67 expression  
The mean LI of Ki-67 showed high expression in the NOM samples. There 
was no difference in Ki-67 expression between OSCC NM and OSCC M 
(Table 4.4 and Figure 4.8). The mean LIs were 64.61 and 54.23 
respectively. There were no differences in Ki-67 expression when the 
different areas of tumours were compared (Table 4.5 and Figure 4.9). 
However, Ki-67 expression was higher in OSCC primary lesions (p=0.03, 
Paired t-test) than in the LN metastases (Table 4.6 and Figure 4.8). 
4.3.6 Geminin expression 
Overall, the mean geminin LI showed no differences in expression among 
the analysed groups (NOM, OSCC NM and OSCC M). The mean LI was 
27.34 in NOM, 34.23 in OSCC NM group and 31.16 in OSCC M (Table 4.4). 
There were no differences between the different areas of tumour in OSCC 
M and OSCC NM groups (Table 4.5). Differences in mean geminin 
expression were seen when primary tumours and nodal metastases (OSCC 
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LN) were compared (p=0.21, Paired t-test), but without reaching statistical 
significance (Table 4.6 and Figure 4.10). 
4.3.7 Cyclin D1 expression  
Overall, the mean LIs in NOM, OSCC NM and in OSCC M were 58.99, 
55.35 and 56.84 respectively (Table 4.4 and Figure 4.12). However, p 
values did not reach statistical significance. Cyclin D1 LI expression was 
slightly higher at the middle and invasive front than the surface when 
different parts of tumour were compared in OSCC M and OSCC NM groups 
(Figure 4.13); this was statistically significant (p=0.01, ANOVA test) (Table 
4.5). No significant difference was seen between the primary tumours and 
the nodal metastases (OSCC LN) (p=0.27, Paired t-test) (Table 4.6 and 
Figure 4.12). 
4.3.8 MCM2/Ki-67 and geminin/Ki-67 ratios 
The MCM2/Ki-67 ratio was higher than the geminin/Ki-67 ratio in all 
samples. There were no significant differences between the LIs of the 
MCM2 and Ki-67 LIs (determined by the MCM2/Ki-67 ratios) (Table 4.4 and 
Figure 4.16). The difference between geminin and Ki-67 (demonstrated by 
the geminin/Ki-67 ratio) increased significantly (p=0.02, t-test) when 
comparing OSCC NM to OSCC M samples (Table 4.4 and Figure 4.17). 
The MCM2/Ki-67 and geminin/Ki-67 ratios showed no intra-tumour 
differences in their LIs in OSCC NM and OSCCM (Table 4.5). Both ratios 
were proportionally lower in the nodal metastases than in the primary 
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lesions, and the difference was statistically significant (p=0.05, p=0.01 
respectively) (Table 4.6).  
4.3.9 MCM2, Ki-67, geminin and cyclin D1 as a proliferation 
marker in normal and oral SCC lesions (OSCC M & OSCC 
NM) 
Even though no differences were seen in the mean LIs of MCM2, Ki-67, 
geminin and cyclin D1 expression between OSCC NM and OSCC M 
samples (Table 4.4), the mean MCM2 LI gradually increased from NOM 
through OSCC NM to OSCC M (p=0.007, ANOVA test). The proteins LIs 
were increased in the nodal metastases compared to the primary lesions 
(Table 4.6). However, Ki-67 and geminin showed an increase from NOM to 
OSCC NM, but not in OSCC M. Cyclin D1 LI showed a tendency towards 
decreased expression from normal to OSCCs, although this was not 
statistically significant (Table 4.4). 
There was a positive linear association between MCM2 and Ki-67 in all 
analysed groups (Figure 4.14). Equally, there was also a strong positive 
linear association between geminin and Ki-67 in all analysed samples 
(Figure 4.15). 
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NOM 
(n=17) 
60.09 
(16.46) 
47.16 
(21.43) 
27.34 
(5.97) 
58.99 
(6.55) 
p<0.001 
1.55 
(0.67) 
0.58 
(0.23) 
OSCC NM 
(n=47) 
69.96 
(16.28) 
64.61 
(28.31) 
34.23 
(14.11) 
55.35 
(17.96) 
p<0.001 
1.35 
(1.00) 
0.66 
(0.27) 
OSCC M 
(n=39) 
73.58 
 (16.12) 
54.23 
(21.39) 
31.16 
(15.94) 
56.84 
(12.97) 
p<0.001 
1.58 
(0.84) 
0.68 
(0.30) 
ANOVA 
test 
p=0.007 NS NS NS  NS NS 
p* value  *NS *NS *NS *NS  *NS p*=0.02 
p*=t-test (OSCC NM vs OSCC M). 
NOM= Normal oral mucosa. 
OSCC NM= Oral squamous carcinoma that did not metastasise. 
OSCC M = Oral squamous carcinoma that had metastases. 
OSCC LN= Lymph node metastases. 
Stat GLM= General linear model. 
NS= Not significant. 
Table 4.4: Mean and standard deviation of MCM2, Ki-67, geminin and 
cyclin D1 Labelling index (LI) values, along with MCM2/Ki-67 and 
geminin/Ki-67 ratios for all groups. 
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OSCC NM  
Surface 
70.25 
(14.33) 
58.45 
(32.61) 
30.43 
(16.63) 
53.10 
(20.42) 
1.08 
(0.53) 
0.48 
(0.33) 
Middle 
70.25 
(14.33) 
18.85 
(30.39) 
28.29 
(25.90) 
59.24 
(21.46) 
1.46 
(0.83) 
0.66 
(0.28) 
Front 
72.47 
(21.13) 
50.93 
(28.79) 
31.23 
(18.74) 
57.35 
(21.23) 
2.73 
(7.60) 
0.75 
(1.12) 
ANOVA test p=0.6 p=0.7 p=0.1 p=0.1 p=0.2 p=0.5 
OSCC M  
Surface 
62.05 
(32.17) 
35.51 
(37.39) 
32.53 
(19.30) 
50.79 
(15.43) 
1.35 
(1.13)  
0.59 
(0.30) 
Middle 
61.43 
(30.74) 
35.51 
(37.39) 
24.47 
(16.96) 
60.42 
(16.36) 
1.04 
(0.71) 
0.41 
(0.23) 
Front 
72.84 
(23.63) 
37.94 
(28.74) 
28.26 
(22.56) 
57.98 
(17.56) 
5.40 
(20.29) 
1.29 
(4.04) 
ANOVA test p=0.1 p=0.6 p=0.2 p=0.01 p=0.3 p=0.6 
OSCC NM= Oral squamous carcinoma that did not metastasise. 
OSCC M = Oral squamous carcinoma that had metastases. 
Table 4.5: Mean and standard deviation of MCM2, Ki-67, geminin and 
cyclin D1 Labelling index (LI) values, along with MCM2/Ki-67 and 
geminin/Ki-67 ratios for tumour areas in all groups. 
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OSCC 
M 
(n=39) 
73.57 
 (16.20) 
54.22 
(21.38) 
31.16 
(15.94) 
56.84 
(12.97) 
p<0.001 
1.58 
(0.84) 
0.68 
(0.30) 
OSCC 
LN 
(n=39) 
79.88 
(12.66) 
49.66 
(36.04) 
20.75 
(21.90) 
59.20 
(20.81) 
p<0.001 
1.27 
(0.43) 
0.31 
(0.30) 
Paired  
t-test 
p=0.84 p=0.03 p=0.21 p=0.27  p=0.05 p=0.01 
OSCC M = Oral squamous carcinoma that had metastasise. 
OSCC LN= Lymph node metastases. 
Stat GLM= General linear model.  
 
Table 4.6: Mean and standard deviation of MCM2, Ki-67, geminin and 
cyclin D1 Labelling index (LI) values, along with MCM2/Ki-67 and 
geminin/Ki-67 ratios in primary tumours (OSCC M) and their lymph node 
metastasis (OSCC LN). 
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Figure 4.1: Representative immuno-staining illustrating the distribution of 
MCM2 (A), Ki-67 (B), geminin (C) and cyclin D1 (D) in NOM samples. The 
MCM2, Ki-67, geminin and cyclin D1 showed similar patterns of expression 
in NOM samples, mainly in basal and suprabasal cell layers. However, Ki-
67, geminin and cyclin D1 were expressed in fewer cells than MCM2. All 
images are at ×200 magnification. 
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Figure 4.2: Representative immuno-staining of MCM2 (A), Ki-67 (B), 
geminin (C) and cyclin D1 (D) proteins in samples of OSCC that did not 
metastasise. All images are at ×100 magnification. 
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Figure 4.3: Representative immuno-staining of MCM2 (A), Ki-67 (B), 
geminin (C) and cyclin D1 (D) proteins in samples of OSCC that did 
metastasise. All images are at ×100 magnification. 
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Figure 4.4: Representative immuno-staining of MCM2 (A), Ki-67 (B), 
geminin (C) and cyclin D1 (D) proteins in samples of lymph node 
metastases. All images are at ×100 magnification. 
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Figure 4.5: Oropharyngeal carcinoma sections showing negative (A) and 
positive (B) controls for p16INK4A. Images are at ×100 magnification. 
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Figure 4.6: Histogram showing the mean LI of MCM2 expression in NOM, 
OSCC NM, OSCC M and LN samples. There was a significant difference 
between groups (***p=0.007, ANOVA, Table 4.4). There was no significant 
difference between the primary OSCC M and the lymph node metastasis 
(red bar).  
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Figure 4.7: Histogram showing the mean LIs of MCM2 at different areas 
(surface, middle and invasive front) of tumours in OSCC M and OSCC NM 
groups. There were no significant differences between areas in OSCC M or 
OSCC NM. 
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Figure 4.8: Histogram showing the mean LI of Ki-67 expression in NOM, 
OSCC NM, OSCC M and LN samples. A significant difference (**p=0.03, 
Paired t-test, Table 4.6) was seen between the primary tumours and 
metastatic lymph node tumours.  
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Figure 4.9: Histogram showing the mean LIs of Ki-67 at different areas 
(surface, middle and invasive front) of tumours in OSCC M and OSCC NM 
groups. No significant differences were seen between areas.  
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Figure 4.10: Histogram showing the mean LI of geminin expression in 
NOM, OSCC NM, OSCC M and LN samples. Differences between OSCC M 
and OSCC NM were not significant. Similarly, differences between the 
primary OSCC M and their nodal metastases were not statistically 
significant.  
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Figure 4.11: Histogram showing the mean LIs of geminin at different areas 
(surface, middle and invasive front) of tumours in OSCC M and OSCC NM. 
There were no significant differences between areas in OSCC M or OSCC 
NM.  
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Figure 4.12: Histogram showing the mean LI of cyclin D1 expression in 
NOM, OSCC NM, OSCC M and LN samples. Differences between OSCC M 
and OSCC NM were not significant. Similarly, differences between the 
primary OSCC M and their nodal metastases were not statistically 
significant.  
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Figure 4.13: Histogram showing the mean LIs of cyclin D1 at different areas 
(surface, middle and invasive front) of tumours in OSCC M and OSCC NM 
groups. There were no significant differences between areas in analysed 
groups.  
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Figure 4.14: Scatter plot displaying the positive association between LI 
value of MCM2 and Ki-67 in NOM, OSCC M and OSCC NM groups. 
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Figure 4.15: Scatter plot displaying the positive association between LI 
value of Ki-67 and geminin in NOM, OSCC M and OSCC NM groups. 
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4.3.10 Protein expression and clinicopathological features 
The histopathological differentiation of OSCC was described in Section 
4.3.1. In the OSCC NM group there were no significant differences between 
the proteins LIs and ratios in well, moderately or poorly differentiated oral 
SCC (Table 4.7). Likewise, in OSCC M samples there were also no 
significant differences in protein expression associated with histological 
differentiation (Table 4.7), except for MCM2 expression, which showed 
significant differences (p=0.01, ANOVA test) associated with higher 
expression in moderately differentiated tumours in the OSCC LN samples 
(Table 4.7)  
The results showed that sixteen out of 39 cases (41%) of the nodal 
metastasis samples showed extra capsular spread, while 20 (51%) showed 
no spread (Table 4.3). The majority of samples in OSCC M group were 
stage IV (27/39), whereas the majority of OSCC NM samples were 
classified as stage III. Mean LI expression of MCM2, Ki-67, geminin and 
cyclin D1 did not show any significant association with clinicopathological 
features in either the metastatic or non-metastatic lesions (Appendix 2). 
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 Labelling index (LI) 
Mean (Standard deviation) 
 MCM2 Ki-67 Geminin Cyclin D1 
MCM2/Ki67 
ratio 
Geminin/Ki67 
ratio 
OSCC NM  
Well 
(n=21) 
68.76 
(16.77) 
61.20 
(21.27) 
34.68 
(16.82) 
52.72 
(17.54) 
1.33 
(0.98) 
0.77 
(0.23) 
Moderate 
(n=20) 
68.65 
(16.17) 
70.12 
(35.58) 
32.89 
(12.10) 
55.92 
(19.27) 
1.25 
(1.04) 
0.56 
(0.22) 
Poor 
(n=6) 
85.35 
(4.23) 
56.25 
(22.44) 
37.09 
(11.17) 
62.60 
(15.14) 
1.93 
(1.06) 
0.73 
(0.61) 
ANOVA p=0.82 p=0.40 p=0.69 p=0.58 p=0.29 p=0.20 
Correlation p=0.25 p=0.33 p=0.39 p=0.87 p=0.77 p=0.20 
OSCC M  
Well 
(n=13) 
79.68 
(10.24) 
52.65 
(23.71) 
34.90 
(23.55) 
58.43 
(14.88) 
1.84 
(0.77) 
0.73 
(0.24) 
Moderate 
(n=20) 
69.31 
(18.51) 
55.89 
(20.82) 
28.79 
(9.77) 
54.94 
(13.01) 
1.318 
(0.35) 
0.47 
(0.17) 
Poor 
(n=6)  
74.86 
(16.27) 
52.09 
(21.33) 
30.92 
(13.36) 
59.42 
(8.71) 
1.70 
(0.99) 
0.66 
(0.23) 
ANOVA NS NS NS NS NS NS 
Correlation p=0.70 p=0.55 p=0.58 p=0.57 p=0.66 p=0.22 
OSCC LN   
Well 
(n=15) 
78.78 
(11.64) 
57.75 
(30.83) 
23.89 
(16.83) 
61.45 
(22.92) 
1.31 
(0.45) 
0.36 
(0.24) 
Moderate 
(n=21)  
83.85 
(11.33) 
46.47 
(40.08) 
15.97 
(21.78) 
59.50 
(19.44) 
1.23 
(0.42) 
0.23 
(0.32) 
Poor 
(n=3) 
57.67 
(2.86) 
31.45 
(29.52) 
38.50 
(39.98) 
40.92 
(15.58) 
1.30 
(0.50) 
0.45 
(0.56) 
ANOVA p=0.01 p=0.36 p=0.87 p=0.28 p=0.99 p=0.69 
Correlation p=0.84 p=0.90 p=0.42 p=0.50 p=1.00 p=0.52 
OSCC NM= Oral squamous carcinoma that did not metastasise. 
OSCC M = Oral squamous carcinoma that had metastases. 
OSCC LN= Lymph node metastases 
NS= Not significant.  
Table 4.7: Mean and standard deviation of proteins labelling index 
according to the differentiation grad of OSCCs (NM, M & LN). 
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Figure 4.16: Scatter graph showing the MCM2/Ki-67 ratios for the NOM, 
OSCC NM and OSCC M groups. The horizontal bars indicate the mean 
values in each group. 
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Figure 4.17: Scatter graph showing the geminin/Ki-67 ratios for the NOM, 
OSCC NM and OSCC M groups. Differences were significant between 
OSCC NM and OSCC M (p=0.02, Paired t-test, Table 4.4). The horizontal 
bars indicate the mean values in each group. 
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4.4 Discussion and conclusions 
4.4.1 DNA replication licensing proteins in metastatic and 
non-metastatic oral squamous cell carcinoma and their 
corresponding lymph node metastatic lesions  
During the tumourigenesis process, dysregulation of cell cycle regulatory 
proteins is a pivotal event. Several studies have described the importance of 
pre-replication proteins as prognostic markers in oral and other human 
neoplasms (Going et al., 2002, Wharton et al., 2004, Kodani et al., 2003, 
Gonzalez et al., 2005, Eward et al., 2004, Dudderidge et al., 2005, Quaglia 
et al., 2006, Scott et al., 2006, Torres-Rendon et al., 2009a, Santos‐Silva et 
al., 2011, Gouvêa et al., 2013, Shalash et al., 2012). 
To our knowledge, this is the first time that heterogeneity of cell cycle 
protein expression has been determined in the same tumour with or without 
metastasis. This study reports the pattern of expression of these biomarkers 
in OSCCs. The aim was to identify markers associated with metastatic 
lesions, and to evaluate their value to predict lymph node metastasis. 
Overall, the mean LI for MCM2 was consistently higher than Ki-67, due to 
MCM2 being expressed during the whole cell cycle, including the G1 phase 
where Ki-67 is absent. Low labelling index in normal tissue has also been 
observed by others (Shomori et al., 2010, Torres-Rendon et al., 2009a). The 
OSCCs (NM & M) expressed MCM2 with variable levels when different 
areas of tumour were compared. Although, the advancing front showed 
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higher mean LIs, the difference was not significant. This would support the 
concept that there is greater cell proliferation at the advancing front of 
tumours, but further studies are needed to confirm this and to determine the 
degree of heterogeneity in tumours. 
The LI of MCM2 was higher in OSCC M than in OSCC NM, but this 
difference did not reach statistical significance, possibly because of the 
small sample size. This is in agreement with a previous study conducted by 
Kodani et al. (Kodani et al., 2003), in which neither MCM2 nor Ki-67 LIs 
were different in OSCC with or without metastasis. Since MCM2 expression 
increased from normal through OSCC NM to OSCC M (p=0.007, ANOVA 
test), this indicates the presence of a high number of cells licensed to 
proliferate. This in turn suggests that MCM2 may provide useful information 
about the growth fraction in normal and malignant cells. Further studies with 
a larger number of samples are needed to confirm this finding.  
The results of the present study indicated no significant difference in the cell 
cycle regulatory proteins between primary and matched lymph node 
metastsis, other than for Ki-67, with higher expression in primary tumours. A 
significant decrease in Ki-67 in the nodal metastases has been reported in 
breast cancer (Tawfik et al., 2013). The prognostic impact of MCM2 
expression has been assessed in primary oral carcinomas and their lymph 
node metastases. MCM2 LI showed greater mean protein LI in nodal 
metastases, however this was not statistically significant. Low Ki-67 and 
high MCM2 LIs in the nodal metastases may suggest that a majority of 
metastatic cells are in G0 phase, but are licensed to proliferate. This is in 
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keeping with the idea that nodal metastases are often better differentiated 
than the primary tumours. It may also suggest that high MCM2 LIs may 
reflect a cell proliferation capacity of OSCC in nodal metastases. This has 
also been observed in preivous reports evaluating MCM2 in OSCC (Shalash 
et al., 2012) and in colorectal cancer (Guzińska-Ustymowicz et al., 2009). 
In this study, geminin expression showed no significant difference between 
OSCC NM and OSCC M tumours. High expression of geminin in nodal 
metastases was observed, but did not reach significant levels. This 
relatively high expression may indicate that large numbers of tumour cells 
successfully progressed through the S-G2-M phases of the cell cycle. In 
accordance with previous reports, geminin LI values were smaller than the 
Ki-67 mean LIs in all analysed samples (Torres-Rendon et al., 2009a, 
Tamura et al., 2010).  
Surprisingly, Ki-67 showed lower mean LI value in OSCC M than OSCC 
NM. This decrease may be due to some tumours seeming to exhibit 
relatively high expression of geminin and relatively low expression of Ki-67 
for unknown mechanisms (Yamazaki et al., 2010). Additionally, Ki-67 
protein tended to show patchy staining in OSCC, which has been reported 
in previous studies (Birajdar et al., 2014). This may be another reason for 
divergent results. The statistical analysis revealed that Ki-67 did not show 
any correlation with histological differentiation of OSCC (NM or M); this was 
in accordance with a previous report (Deyhimi et al., 2013). 
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Cyclin D1 is a protein that controls the progression from G1 to S phase and 
controls the cellular proliferation rate. Alterations in cyclin D1 may result in 
loss of cell cycle regulation. High expression of cyclin D1 is a common event 
in squamous cell carcinoma (Hanken et al., 2014, Swaminathan et al., 
2012). Cyclin D1 results revealed no significant differences between OSCC 
NM and OSCC M. Similar to the findings presented in this study, no 
correlations between cyclin D1 overexpression and clinicopathological 
factors have previously been reported (Freier et al., 2003, Wang et al., 
2006, Kaminagakura et al., 2011). However, this is contradictory to a more 
recent finding by Zhao et al. (Zhao et al., 2014), who reported significant 
correlations with differentiation status, tumour size, lymph node metastasis 
and clinical stage of disease in OSCC. 
Histologically poorly differentiated carcinoma has been strongly correlated 
with a high expression of MCM2 and Ki-67 in OSCC (Shalash et al., 2012, 
Birajdar et al., 2014). However, in the current study there was no significant 
difference in protein expression between well, moderately or poorly 
differentiated tumours in OSCCs (NM & M). This finding is consistent with 
another previous study (Torres-Rendon et al., 2009). Positive correlation 
was only observed with MCM2 expression and moderately differentiated 
carcinoma in OSCC LN (p=0.01). These findings are in accordance with 
Kodani et al. (Kodani et al., 2003), who found a positive correlation between 
high MCM2 LI and moderate OSCC. More cells may have been in a 
proliferative phase and hence showed an increase in MCM LI.  
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No significant correlation was found between clinical parameters (such as, 
age, tumour size and stage) and cell cycle licensing proteins either in OSCC 
NM or in OSCC M. This is compatible with previous studies (Naderi et al., 
2014, Gouvêa et al., 2013). Further similar studies are recommended to 
investigate the heterogeneity of tumour cells in primary and metastatic 
lesions. 
In the case of the present study, instead of performing 
immunohistochemistry on tissue sections, the TMA technique was used so 
all staining could be achieved on only 15 slides of TMA sections. This was 
to save laboratory processing time and reagent cost, as well as to save 
valuable biological material. All TMAs were treated the same way to ensure 
consistent results. However, cores for the same case on the same TMA did 
not react similarly. Some tumour cores were lost and some did not show 
immune-reactivity within the same TMAs section It has been reported that 
about 10-15% of cores are expected to be lost during technical processing 
(Ilyas et al., 2013). Therefore, the TMA method appears to have some 
limitations. According to published data, there is no concordance in results 
obtained from whole tissue sections and TMA techniques (Kim et al., 2011); 
this could be a possible explanation for some unexpected results in this 
chapter. 
The findings in this chapter require confirmation from further analysis; using 
a larger number of samples of OSCC lesions. It may also be advisable to 
undertake staining on carefully prepared sections of individual cases since 
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the TMA cores showed variable staining and many sections were lost or 
were not interpretable. 
4.4.2 Conclusions  
The findings in this study suggest that: 
 It is possible to obtain cell cycle data by assessing the MCM2, Ki-
67, geminin and cyclin D1 protein expression by analysis of 
immune-staining in tissue microarrays. 
 There was no difference in cell cycle protein expression, in different 
areas of the tumours, nor between tumours which metastasised 
(M) or did not metastasise (NM). 
 There were no significant differences between primary lesions and 
their lymph node metastases for all cell cycle proteins, except for 
Ki-67. 
 An increase in MCM2 expression in OSCC LN suggests that this 
protein is a marker of proliferative capacity and that might be 
more useful for histological and prognostic evaluation. 
 This is the first time the MCM2/Ki-67 and geminin/Ki-67 ratios have 
been evaluated in primary and matched nodal metastases; the 
difference was significant but needs further confirmation. 
 The geminin/Ki-67 ratio was significantly different between 
metastatic and non-metastatic OSCC. 
 No correlation was noted between the immunohistochemical 
findings and clinicopathological features. 
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5. DNA PLOIDY ANALYSIS AS A PREDICTOR OF 
METASTASIS IN ORAL CANCER 
5.1 Introduction  
Despite recent improvements in diagnostic and therapeutic approaches to 
oral squamous cell carcinoma (OSCC), the survival rate has remained 
virtually unchanged for decades. Clinical and histopathological parameters 
are the most frequently used predictors of lesion progression, but to date 
these have lacked reliability. Thus objective methods are needed to 
distinguish lesions that may metastasise from those that may not. Research 
carried out over recent years has shown that most malignant neoplasms are 
clonal, although they may exhibit widespread heterogeneity with respect to 
phenotypic diversity in individual tumours (Marusyk and Polyak, 2010).  
Aneuploidy, as a measure of abnormal nuclear DNA content, is known to be 
an indicator of numerical chromosomal and DNA aberrations, and its 
emergence is often a crucial step in tumour transformation (associated with 
malignant and premalignant lesions). The literature shows that aneuploidy is 
seen in solid tumours (Holland and Cleveland, 2012) and is associated with 
a high risk of recurrence (Janisson‐Dargaud et al., 2008, Baak and Janssen, 
2004). Clinical studies have shown that up to 40% of patients with oral 
squamous cell carcinoma will develop lymph node metastases (Alkaisi et 
al., 2014) and the prognosis is unfavourable (Kowalski and Sanabria, 2007, 
Ganly et al., 2012). In practice, metastasis to lymph nodes is probably the 
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most important prognostic factor (Brannan et al., 2011). However, the 
incidence of aneuploidy has been shown to be higher in lymph node 
metastases than in primary lesions (Hemmer et al., 1997). This is consistent 
with previous findings that have shown that aneuploidy was found in 71% of 
metastatic tumours compared with 61% of primary lesions (Frankfurt et al., 
1984). 
Nuclear DNA status can be detected using robust and sensitive techniques, 
including flow cytometry (FCM) or image cytometry (ICM) (Brouns et al., 
2012). The latter has several advantages over FCM as it allows for visual 
control and selection of interesting cells or areas of tumour (Bremmer et al., 
2011). The DNA content of the tumour cell population can be measured by 
comparing integrated optical density (IOD) of control cells (usually 
lymphocytes) with nuclei of interest (Section 1.10). In addition, ICM provides 
two established parameters: the DNA index and the percentage of cells that 
exceed 5c (5cER), that may be used as quantitative measures of DNA 
alterations (Section 1.10.1 and 1.10.3). 
The prognostic importance of DNA ploidy in oral cancer remains uncertain 
(discussed in Chapter 1, Section 1.10.5). Therefore, the aim of this part of 
the project was to determine if DNA ploidy can be used as a useful 
prognostic marker in OSCC, and if it can predict which tumours may 
metastasise. 
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5.2 Material and methods  
5.2.1 Patient and tissue selection  
A total of 125 tumour samples were studied. The primary lesions in both 
groups (OSCC NM & OSCC M) were analysed twice for two different areas 
of each tumour (surface and advancing front). The inclusion criteria for 
ploidy analysis included adequate numbers of neoplastic epithelial cells 
(300 nuclei) and inflammatory cells (to be used as controls) in the same 
section. 
5.2.2 Tissue preparation for DNA image cytometry 
Paraffin sections (7µm) were cut and slides were stained with Feulgen-
Schiff stain (ScyTek Laboratories Kit, USA), as previously described in 
Section 3.5.2. 
5.2.3 Image cytometry for DNA analysis 
The Automated Cellular Imaging System, ACIS III (Dako, Glostrup, 
Denmark) was used to analyse Feulgen stained sections. Details of the 
equipment and the scanning process are described in Section 3.5.3. 
5.2.4 Criteria for classification of DNA content  
The criteria for diploid and aneuploid lesions are described in detail in 
Section 3.5.4 and are summarised in Table 5.1. These criteria are adapted 
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from a recent study in our laboratories (Santos‐Silva et al., 2011). In 
addition, all analyses were performed blind to the histopathological features. 
Ploidy status DI of peak on the histogram 5cER % 
Diploid 0.9 – 1.10 <1% 
Mild aneuploid 1.11 – 1.30 >1% 
Moderate aneuploid 1.31 – 1.80 >1% 
Severe aneuploid > 1.81 >1% 
DI = DNA index. 
5cER= Number of cells that exceed 5c. 
Table 5.1: Criteria used for ploidy status determination in the histograms of 
OSCC lesions. For diploid samples, the two characteristics must be 
identified. In the aneuploid samples, at least one of the two criteria should 
be present. 
 
5.2.5 Statistical analysis  
All Statistical analyses were performed using SPSS (v 21) software. Non-
parametric tests were used to compare the DI, 5cER and ploidy status 
between groups (described in Section 3.6.2). Spearman correlation tests 
were used to determine whether primary lesions with metastases and 
OSCC differentiation correlated with ploidy status. The ability of ploidy to be 
used as a test to differentiate lesions that metastasised from those that did 
not was determined by calculation of sensitivity, specificity, predictive values 
and receiver operating characteristic curves (ROC) (Section 3.6).  
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5.3 Results  
5.3.1 Patient data and ploidy 
The ploidy status of each case was taken as the ploidy value of the most 
severely aneuploid area (surface or advancing front). 
In the OSCC group that did not metastasise (OSCC NM, median age= 
64.50, range= 34.50-84.50), thirty two (68%) were males, of which 21 cases 
showed moderate aneuploidy and 11 exhibited severe aneuploidy (Table 
5.2). Fifteen cases were female (32%), 2 showed mild aneuploidy, 4 
moderate aneuploidy and 9 cases were severe (Table 5.2). The most 
commonly affected site was the tongue with 16 cases (34%); 11 were 
moderate, 2 exhibited severe aneuploidy and 3 cases showed mild 
aneuploidy. Floor of mouth and alveolar mucosa ranked second with 8 
cases each. Seven (15%) aneuploid cases were found in the buccal 
mucosa  (Table 5.3).  
In the OSCC group that had metastasised (OSCC M, median age= 64.50, 
range= 34.50-84.50) the incidence of moderate and severe aneuploidy was 
higher in males (Table 5.2). The majority of cases were located in the 
tongue and 10 cases (59%) showed moderate aneuploidy. Severe 
aneuploidy was seen in 7 cases (41%). Floor of mouth (8 cases) was the 
second most affected site, although only 2 cases showed severe aneuploidy 
(Table 5.3). The next most common sites were alveolar and buccal mucosa, 
with 6 cases each, of which 3 cases exhibited severe aneuploidy.  
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The quality of DNA histogram is assessed from the width of G1 peak, which 
is measured by the coefficient of variation (CV) across the peak.The 
coefficient of variance (CV) (explained in Section 1.10.2) was less than 5% 
in all cases, which complied with the recommendations of the ESACP 
guidelines (Haroske et al., 1997, Haroske et al., 2001). The median CV of 
the OSCC M group was 3.40 and in the OSCC NM group was 3.32 (Figure 
5.1 and Figure 5.2). 
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 OSCC NM  OSCC M  OSCC LN 
Median age 64.50  64.50  54.50 
Gender Male Female  Male Female  Male Female 
Total 32 15  26 13  26 13 
DNA status  
Diploid 0 0  0 0  0 0 
Mild aneuploidy 0 2  0 0  0 0 
Moderate aneuploidy 21 4  13 8  13 8 
Severe aneuploidy 11 9  13 5  13 5 
Total 47  39  39 
OSCC NM = Oral squamous cell carcinoma that had not metastasised. 
OSCC M = Oral squamous cell carcinoma that had metastasised. 
OSCC LN= metastasis in the lymph node. 
Table 5.2: Patient data and number of cases showing severe aneuploidy in 
each of the three patient groups.  
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 OSCC NM OSCC M 
 
DNA status  
No (%) 
DNA status 
No (%) 
Biopsy site N
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Tongue 16 
3 
(19) 
11 
(69) 
2 
(13) 
17 0 
10 
(59) 
7 
(41) 
Floor of mouth 8 
2 
(25) 
3 
(38) 
3 
(37) 
8 0 
6 
(75) 
2 
(25) 
Palatal mucosa 1 
1 
(100) 
0 0 1 0 0 
1 
(100) 
 Hard palate 1 0 0 
1 
(100) 
0 0 0 0 
Soft palate 2 
1 
(50) 
0 
1 
(50) 
1 0 
1 
(100) 
0 
Alveolar mucosa 8 
2 
(25) 
3 
(38) 
3 
(37) 
6 0 
3 
(50) 
3 
(50) 
Buccal mucosa 7 0 
4 
(57) 
3 
(43) 
6 0 
3 
(50) 
3 
(50) 
Tonsil area 1 0 
1 
(100) 
0 0 0 0 0 
Pharyngeal wall 2 
1 
(50) 
0 
1 
(50) 
0 0 0 0 
Retromolar area 1 0 
1 
(100) 
0 0 0 0 0 
Total 47 10 23 14 39 0 23 16 
p Value p=0.4 p=0.7 
OSCC NM = Oral squamous cell carcinoma that had not metastasised. 
OSCC M = Oral squamous cell carcinoma that had metastasised. 
P values= Chi-Square test. 
Table 5.3: Site of lesions and incidence of severe aneuploidy in all analysed 
samples. 
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Figure 5.1: DNA ploidy pattern of diploid histogram generated by ACIS III, 
this case had DI of 1.1, CV of 2.7% and 5cER of 0. CTRL indicates the 
control G1 peak and Dip-G1 indicates the G1 peak. 
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Figure 5.2: DNA ploidy pattern of severe aneuploid histogram with a 
tetraploid area. This case had DI of 2.0, CV of 1.5% and 5cER of 3.01%. 
CTRL indicates the control G1 peak, An-G1 represents the aneuploid G1 
peak and An-G2 represents the aneuploid G2 peak. 
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5.3.2 Ploidy status, DI and 5cER 
The ploidy data is summarised in Table 5.4. All cases of OSCC (n=86) 
showed abnormal DNA content in at least one of the analysed areas. In the 
OSCC group that had not metastasised (n=47), severe aneuploidy was 
observed in 20 cases (43%), moderate aneuploidy in 25 (53%), and mild 
aneuploidy was seen in 2 samples (4%) (Table 5.4).  
In the OSCC samples that had metastasised 46% (18/39) showed severe 
aneuploidy and 54% (21/39) were moderate (Table 5.4). There were no 
significant differences in ploidy status between OSCC that had 
metastasised and those that had not (p=0.5, Chi-Square test) (Table 5.4). 
The lymph node metastasis samples (OSCC LN) exhibited moderate 
(21/39) or severe aneuploidy (18/39) and no cases were mild or diploid 
(Table 5.4). There was no significant difference (p=0.2, Wilcoxon Signed 
Rank test) in the incidence of the DNA abnormality between the primary 
tumour lesions and lymph node metastases (Table 5.4 and Figure 5.3). 
Most of the studies using image cytometry for ploidy analysis consider a DI 
of 1.0 as the default value for normal tissue. No upper limit has been 
established definitively; whilst some authors use a cut-off point at 1.1 as the 
upper limit for normal tissue (Huang et al., 2005, Fang et al., 2004, 
Gschwendtner et al., 1999), other researchers have used cut off points at 
1.15 or 1.2 (Baak and Janssen, 2004, Furuya et al., 2000). It is worth 
mentioning that these studies employed different image cytometry systems 
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and different types of tumour tissue, and therefore, both cut off points were 
used to determine which of these had better prognostic results.  
The median DI for the OSCC NM group was 1.63 (Table 5.4). The 
differences in DI between the OSCC M group and their metastases were 
significant (p=0.05, Wilcoxon Signed Rank test); a median DI of 1.61 was 
seen in primary lesions compared to a DI of 1.70 in the matched lymph 
node metastases (Table 5.4).  
The 5cER cut-off point was selected at 1% as it has been shown to be an 
indicator of malignancy in image cytometry in several studies (Diwakar et 
al., 2005; Gockel et al., 2006; Pektaş et al., 2006). There was a significant 
difference (p=0.01, Wilcoxon Signed Rank test) in 5cER values between the 
primary lesions (OSCC M) and their metastases, where the lymph node 
lesions had higher values (Table 5.4).  
5.3.3 Heterogeneity in the OSCC tumours  
In the OSCC NM group there was a high incidence of moderate (23/47; 
49%) and severe aneuploidy (14/47; 30%) at the surface of the lesion; no 
diploid areas were detected. At the advancing front, moderate aneuploidy 
was detected in 30 cases (64%), while severe aneuploidy was seen in 11 
cases (23%) (Table 5.5). 
In the OSCC M group, although the same pattern of heterogeneity was 
observed, this group showed four tumour areas with diploid DNA content at  
the advancing front area. Severe aneuploidy was more frequently seen at 
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the surface of the lesions than at the invasive front, with 16 cases (41%) 
and 7 cases (18%) respectively. 
OSCC M showed more severe aneuploidy at the surface (41%) than the 
OSCC NM group (30%). The difference was significant (p=0.009, Chi-
Square test) (Table 5.5 and Figure 5.4). Overall, tumours showed 
heterogeneity within the same lesion; the surface cells showed more severe 
aneuploidy than the advancing front (Figure 5.5). 
5.3.4 Comparison of primary lesions (OSCC M) with 
metastases  
The ploidy status of OSCC primary lesions and their corresponding 
metastasis were compared. In 23 cases the degree of aneupoidy was the 
same in both lesions. In 8 of the 39 cases (21%) the changes were more 
severe in the lymph node metastases than in the primary lesion, and in a 
further 8 the changes were less severe (Table 5.6).  
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Groups 
Mild 
aneuploid 
n (%) 
Moderate 
aneuploid 
n (%) 
Severe 
aneuploid 
n (%) 
DI 
Median 
(25%-75%) 
5cER 
Median 
(25%-75%) 
OSCC NM 
(n=47) 
 
2 (4) 25 (53) 20 (43) 
1.63 
(1.44-1.91) 
5.06 
(2.60-10.79) 
OSCC M 
(n=39) 
0 21 (54) 18 (46) 
1.61 
(1.50-1.79) 
3.36 
(1.00-7.80) 
Chi-Square 
test 
p=0.5 p=0.82 p=0.17 
 
OSCC LN 
(n=39) 
0 21 (54) 18 (46) 
1.70 
(1.5-2.20) 
9.90 
(0.83-15.70) 
Wilcoxon 
Signed Rank 
Test 
p=0.2 p=0.05 p=0.01 
OSCC NM = Oral squamous cell carcinoma that had not metastasis. 
OSCC M = Oral squamous cell carcinoma that had metastasis. 
OSCC LN = Lymph node metastasis. 
DI = DNA index. 
5cER= Number of cells that exceed 5c. 
Table 5.4: Results of ploidy status, DI and 5cER in OSCC NM, OSCC M 
and OSCC LN. 
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Groups 
Ploidy status 
 n (%) 
 Diploid 
Mild 
aneuploid 
Moderate 
aneuploid 
Severe 
aneuploid 
Total 
OSCC NM 
(surface) 
0 10 (21) 23 (49) 14 (30) 47 
OSCC NM  
(advancing 
front) 
0 6 (13) 30 (64) 11 (23) 47 
 
OSCC M  
(surface) 
0 0 23 (59) 16 (41) 39 
OSCC M 
(advancing 
front) 
4 (10) 4 (10) 24 (62) 7 (18) 39 
 
P value indicating the difference between surface cells in OSCC M and 
OSCCNM 
p=0.009 
 
OSCC NM = Oral squamous cell carcinoma that had not metastasised. 
OSCC M = Oral squamous cell carcinoma that had metastasised. 
OSCC LN = Lymph node metastasis. 
Table 5.5: Ploidy results of OSCC M and OSCC NM at different areas of the 
tumours (surface and advancing front). 
 
 
 
 
 
 
                     Chapter 5: DNA ploidy analysis as a predictor of metastasis in oral cancer 
164 
 
Case No Lesion Site primary OSCCs 
lymph node 
metastasis 
1 Tongue Severe aneuploid Severe aneuploid 
2 Alveolar mucosa Moderate aneuploid Severe aneuploid 
3 Buccal mucosa Severe aneuploid Sever aneuploid 
4 Tongue Severe aneuploid Severe aneuploid 
5 Tongue Moderate aneuploid Moderate aneuploid 
6 Tongue Moderate aneuploid Moderate aneuploid 
7 Floor of mouth Moderate aneuploid Moderate aneuploid 
8 Buccal mucosa Severe aneuploid Severe aneuploid 
9 Tongue Severe aneuploid Severe aneuploid 
10 Alveolar mucosa Severe aneuploid Severe aneuploid 
11 Floor of mouth Moderate aneuploid Moderate aneuploid 
12 Tongue Severe aneuploid Moderate aneuploid 
13 Alveolar mucosa Severe aneuploid Severe aneuploid 
14 Alveolar mucosa Severe aneuploid Severe aneuploid 
15 Soft palate Moderate aneuploid Moderate aneuploid 
16 Floor of mouth Moderate aneuploid Severe aneuploid 
17 Palatal mucosa Severe aneuploid Moderate aneuploid 
18 Buccal mucosa Moderate aneuploid Moderate aneuploid 
19 Buccal mucosa Moderate aneuploid Severe aneuploid 
20 Tongue Moderate aneuploid Moderate aneuploid 
21 Floor of mouth Moderate aneuploid Moderate aneuploid 
22 Tongue Moderate aneuploid Severe aneuploid 
23 Buccal mucosa Severe aneuploid Moderate aneuploid 
24 Tongue Severe aneuploid Severe aneuploid 
25 Tongue Moderate aneuploid Moderate aneuploid 
26 Tongue Severe aneuploid Moderate aneuploid 
27 Tongue Moderate aneuploid Severe aneuploid 
28 Tongue Moderate aneuploid Severe aneuploid 
29 Tongue Severe aneuploid Moderate aneuploid 
30 Tongue Moderate aneuploid Moderate aneuploid 
31 Tongue Severe aneuploid Severe aneuploid 
32 Floor of mouth Moderate aneuploid Moderate aneuploid 
33 Alveolar mucosa Severe aneuploid Moderate aneuploid 
34 Floor of mouth Moderate aneuploid Moderate aneuploid 
35 Floor of mouth Severe aneuploid Moderate aneuploid 
36 Alveolar mucosa Moderate aneuploid Moderate aneuploid 
37 Buccal mucosa Moderate aneuploid Severe aneuploid 
38 Floor of mouth Severe aneuploid Moderate aneuploid 
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Case No Lesion Site primary OSCCs 
lymph node 
metastasis 
39 Tongue Moderate aneuploid Severe aneuploid 
Table 5.6: Ploidy status and site of the lesions in OSCC that had 
metastasised. Comparing the primary lesion to its corresponding 
metastasis, there were 8 cases in which the changes were more severe in 
the metastases (Red) and 8 cases where they were less severe (Green). 
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Figure 5.3: Bar-chart showing the incidence of aneuploidy in the lymph 
node metastases when compared to the matched OSCC (p=0.2, Wilcoxon 
Signed Rank test). 
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Figure 5.4: The incidence of severe aneuploidy at the surface area in 
OSCC with metastases (M) compared to OSCC without (NM). Differences 
among groups were highly significant (p=0.009, Chi-Square test). 
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Figure 5.5: Bar-chart showing the incidence of aneuploidy in OSCC M and 
OSCC NM. 
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5.3.5 Correlation of clinical and histopathological grading 
with ploidy status 
In the OSCC NM group, 21 cases were well differentiated OSCC, of which 
13 showed moderate aneuploidy and 8 were severe (Table 5.7). Among the 
moderately differentiated OSCC the majority were moderate (n=11) or 
severely aneuploid (n=7) compared to only 2 cases (10%) which showed 
mild aneuploidy. Five of the six (83%) poorly differentiated OSCC samples 
showed severe aneuploidy (Table 5.7 and Figure 5.6). 
In the OSCC M group, all OSCC lesions showed moderate (21/39) or 
severe (18/39) aneuploidy. There was an almost even distribution of 
moderate and severe aneuploidy regardless of differentiation (Table 5.7 and 
Figure 5.7). In the OSCC LN category one of 3 poorly differentiated 
carcinomas showed severe aneuploid (Table 5.7 and Figure 5.8), but 
overall the results showed no significant correlations between DNA status 
and histological differentiation. 
Correlation of the clinical and pathological parameters was performed by 
grouping T1 with T2 tumours, and T3 with T4 tumours in order to avoid 
dispersing data. Similarly, patients with clinical stages I and II were 
considered as a single group, as were stage III and IV patients, for 
comparing to DNA status (Table 5.8). Among OSCC NM samples, small or 
less advanced tumours (T1 and T2, stage I and II) tended to show more 
severe aneuploidy than the large tumours but this was not significant. In 
OSCC M specimens, larger or advanced stage tumours showed more 
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severe aneuploidy, but without significance (Table 5.9). Nine out of 16 
cases with extra-capsular spread showed severe aneuploidy and 7 were 
moderate (Table 5.9).  
Generally, none of the clinical parameters (gender, tumour site, 
histopathological grade, and clinical stage) showed any significant 
correlation to DNA content in either primary OSCC or metastatic LN lesions. 
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OSCC 
differentiation 
DNA status 
n (%) 
 
Mild 
aneuploid  
Moderate 
aneuploid 
Severe 
aneuploid 
Total 
OSCC NM  
Well 0 13 (62) 8 (38) 21 
Moderate 2 (10) 11 (55) 7 (35) 20 
Poor 0 1 (17) 5 (83) 6 
Total (%) 2 (4) 25 (53) 20 (42) 47 
Spearman 
correlation 
p=0.31  
OSCC M  
Well 0 7 (54) 6 (46) 13 
Moderate 0 11 (55) 9 (45) 20 
Poor 0 3 (50) 3 (50) 6 
Total 0 21 (54) 18 (46) 39 
Spearman 
correlation 
p=0.36  
OSCC LN  
Well 0 6 (40) 9 (60) 15 
Moderate 0 13 (62) 8 (38) 21 
Poor 0 2 (67) 1 (33) 3 
Total (%) 0 21 (54) 18 (46) 39 
Spearman 
correlation 
p=0.36  
OSCC NM = Oral squamous cell carcinoma that had not metastasised. 
OSCC M = Oral squamous cell carcinoma that had metastasised. 
OSCC LN = Lymph node metastasis. 
Table 5.7: Descriptive data showing the DNA ploidy status according to the 
differentiation of the tumours. 
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Figure 5.6: Bar-chart illustrating the distribution of the ploidy status of 
OSCC NM group according to their differentiation. 
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Figure 5.7: Bar-chart illustrating the distribution of the ploidy status of 
OSCC M group according to their differentiation. 
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Figure 5.8: The distribution of the ploidy status of OSCC nodal metastases 
according to their differentiation. 
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 DNA status (OSCC NM)   
 Mild Moderate severe Total p value 
Gender    
Male 0 21 11 32 
p=0.74 
female 2 4 9 15 
Tumour size 
(pT) 
 
 
 
T1+T2 0 16 14 30 
p=0.29 
T3+T4 2 9 6 17 
Clinical Stage    
I+II 0 16 14 30 
p=0.64 
 III+IV 2 9 6 17 
OSCC NM = Oral squamous cell carcinoma that had not metastasised. 
Table 5.8: Correlation between clinical parameters in OSCC NM. No 
correlation was detected. 
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 DNA status (OSCC M) 
  
 Mild Moderate severe Total p value 
Gender    
Male 0 13 13 26 
p=0.73 
female 0 8 5 13 
Tumour size 
(pT) 
   
T1+T2 0 8 9 17 
p=0.52 
T3+T4 0 13 9 22 
Stage    
I+II 0 0 0 0 
p=0.29 
II+IV 0 19 16 35 
Extra-capsule 
spread 
   
Yes 0 7 9 16 
p=0.50 
No 0 12 8 20 
OSCC M = Oral squamous cell carcinoma that had metastasised. 
Table 5.9: Correlation between clinical parameters in OSCC M. No 
significant correlation was detected. 
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5.3.6 Sensitivity, specificity and predictive values (PPV & 
NPV)  
To evaluate DNA image cytometry analysis as a prognostic test, sensitivity 
(true positives correctly identified) and specificity (true negatives correctly 
identified) were calculated. The ploidy status of OSCC was evaluated as 
either diploid or aneuploid as a marker of progression, and showed a 
sensitivity and specificity of 100% and 0% respectively (Table 5.10). This 
was expected, as all OSCC cases showed aneuploidy. Similarly, using a cut 
off value of >1.1 or >1.2 for the DI, resulted in a high sensitivity and low 
specificity. Additionally, the 5cER parameter had sensitivity of 26% and 
specificity of 15%. To assess the predictive ability of DNA image analysis, 
positive and negative predictive values are measured, depending on the 
prevalence of the disease. Positive predictive value (PPV) is defined as: 
true positives divided by the total number of population tested positively, 
multiplied by 100. Whereas, negative predictive value (NPV) is defined as: 
true negatives divided by the total number of population tested negatively, 
multiplied by 100. The PPV ranged from 45% to 59% and NPV from 0% to 
58% (Table 5.10). A low PPV indicates a high false positive rate, and tests 
with a high PPV are preferred. 
In order to visualise the efficacy of ploidy as a prognostic test in the oral 
squamous cell carcinoma lesions, DI and 5cER values were plotted in 
receiver operating characteristic curves (ROC curve) (Figure 5.9 and 
Figure 5.10). For diagnostic accuracy of ROC, the area under the curve 
was determined for each tested variable. A value of 1 under the ROC curve 
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represents a perfect test and an area of 0.5 or less represents a worthless 
test. The area under the ROC curve using the DI values was 0.514 (Figure 
5.9) and for 5cER values was 0.415 (Figure 5.10). In this statistical test the 
DI was the parameter with the largest area under the curve, suggesting that 
this was the most effective. However, the two curves had areas nearer to 
0.5 than to 1 meaning neither was very useful as a discriminating test. It is 
not surprising that this analysis has limitations (Halligan et al., 2015), as it 
does not take into consideration the prevalence of the disease to be tested. 
Nonetheless, it is still a good test to visualise the sensitivity and specificity 
values of any diagnostic or prognostic analysis.  
 
Table 5.10: Sensitivity, specificity, PPV and NPV results for progression of 
OSCC. Prognostic parameters in DNA image cytometry analysis were: 
Ploidy status (diploid or aneuploid), DI> 1.1, DI> 1.2, 5cER >1%. 
 
 Sensitivity specificity PPV NPV 
Ploidy status 100% 0% 45% 0% 
DI> 1.1 100% 0% 45% 0% 
DI> 1.2 100% 0% 45% 0% 
5cER >1% 26% 15% 59% 58% 
DI = DNA index 
5cER= Number of cells that exceed 5c 
PPV= Positive predictive value 
NPV= Negative predictive value 
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Figure 5.9: DI index value of the OSCC M and OSCC NM plotted in the 
ROC curve. The area under the curve was 0.514. 
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Figure 5.10: 5cER index value of the OSCC M and OSCC NM plotted in the 
ROC curve. The area under the curve was 0.415. 
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5.4 Discussion  
5.4.1 Ploidy status in oral carcinomas and nodal 
metastases  
Aneuploidy indicates the presence of abnormal genetic content and is 
associated with worsening clinical prognosis as the DNA index increases. 
The association between DNA ploidy status of primary tumours and their 
nodal metastases and disease free survival is frequently debated. The aim 
of this study was to explore the DNA ploidy status by image cytometry in 
metastatic and non-metastatic OSCC; in addition, to look at tumour 
heterogeneity with regard to ploidy status. High-fidelity DNA histograms 
generated by ACIS III, incorporate two important parameters, DI and 5cER, 
that may indicate poor clinical outcome (Yu et al., 2007, Haroske et al., 
1997).  
In the present study, all OSCC cases showed abnormal DNA content in at 
least one area of each tumour. Only four areas were found to be diploid. A 
low rate of aneuploidy incidence in OSCC has previously been observed 
(El-Deftar et al., 2012, Torres-Rendon et al., 2009b), but in agreement with 
our results, a high incidence of aneuploidy has been reported by others 
(Abou-Elhamd and Habib, 2007, Santos‐Silva et al., 2011). This variation 
may be due to differences in the ploidy system, cell nuclei preparation and 
techniques used in the various studies. In the present study ICM was used, 
which has the advantage that tumour areas can be accurately selected, 
ensuring representative sampling and removal of stromal contamination. 
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Additionally, DNA ploidy is known to be heterogeneous within OSCC and 
the rate of abnormal content (aneuploidy) is higher when multiple samples 
are analysed in each tumour (Baretton et al., 1995, Diwakar et al., 2005). In 
the current study, tumours showed heterogeneity within the same lesion. 
More severe aneuploidy was seen in the surface cells of OSCC lesions 
(34%) than cells at the advancing front (21%). Interestingly, there was a 
highly significant difference in ploidy severity at the surface between the 
OSCC M (40%) and OSCC NM groups (30%), suggesting an increase in 
aberrant nuclear DNA content in tumours that metastasise. One explanation 
for this observation could be that tumours behave differently at different 
stages, depending on ploidy status. Diploid cells detected at the front area 
may reflect a decrease in aneuploidy with tumour progression. It may be 
that tumours need to be more severe at the surface to provide a good 
environment for growth at the start of the lesion and to allow more genetic 
alterations. Additionally, probably tumour cells may shift down their ploidy 
alterations to endorse other changes at the advancing front. As this is the 
first time that both sites have been compared, further analysis with a larger 
number of samples is needed. 
The results also revealed that the lymph node metastases were more 
severely aneuploid in some cases (n=8) compared to the matched primary 
lesions (Table 5.6). This suggests that more malignant and aggressive cells 
in primary lesions have an ability to migrate into lymph nodes. In contrast, 
other studies did not find any association between incidence of aneuploidy 
and high rates of metastasis (Saiz-Bustillo et al., 2005).  
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5.4.2 High DI and 5cER are associated with nodal 
metastasis  
The DI values (Table 5.4) were significantly higher in the lymph node 
metastatic lesions than the matched primary lesions (p=0.05). Similarly, in 
other cytometric studies increases in the DNA index indicated an increased 
risk of disease progression (Isharwal et al., 2008, Hoofnagle Jr et al., 1995). 
This was also the case for 5cER values (p=0.01), which were higher in the 
metastatic lesions. This could indicate that metastatic cells with high levels 
of aneuploidy could be a characteristic of progression of disease. 
Taken together, our findings of increased aneuploidy in metastatic OSCC 
and in lymph nodes suggest that aberrant DNA content is associated with 
aggressive tumours and that DNA ploidy analysis may be a useful 
prognostic indicator. However, the results indicate that confirmatory studies 
on quantitative evaluation of DI and 5cER are needed if these parameters 
are to have any prognostic value. 
5.4.3 DNA image cytometry as a prognostic test in OSCC  
Even though the specificity of aneuploidy to predict disease progression 
was 0% the sensitivity was high (100%) and the positive predictive value 
was 45%. Similarly, other studies which have evaluated aneuploidy in 
patients with cervical cancer have shown high sensitivity (92%) and low 
specificity (54%) values (Tong et al., 2009). 
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When the DNA index and 5cER values were evaluated as independent 
prognostic factors, the 5cER showed 26% sensitivity and 15% specificity 
(Table 5.10). 
This suggests that DNA ploidy may not be a good tool to evaluate tumour 
prograssion; however, it may be useful if considered along with 
histopathological findings and other clinical and molecular prognostic 
factors. 
5.4.4 Correlation of ploidy status with tumour 
differentiation and clinicopathological parameters 
In the present cohort, OSCC differentiation and ploidy status were not 
associated (Table 5.7). This was in agreement with finding of other studies 
(Diwakar et al., 2005, Torres-Rendon et al., 2009b, Santos‐Silva et al., 
2011) which also reported no correlation between ploidy and differentiation 
in OSCC. In line with previous studies, no significant association was found 
between DNA ploidy of either primary or metastatic samples with age, lesion 
site, tumour size and tumour stage (El-Deftar et al., 2012, Das et al., 2005, 
Santos‐Silva et al., 2011). However, the association between DNA ploidy 
status and clinicopathological factors is controversial. In accordance with 
previous studies (Bueno et al., 1998), incidence of moderate and severe 
aneuploidy was more frequent in men and advanced stages (III & IV) in 
OSCC M samples. 
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5.4.5 DNA ploidy imaging system 
DNA image cytometry has become a common method for evaluation of 
DNA ploidy in tumour cells. It has been reported that image cytometry is 
more accurate than flow cytometry (Dunn et al., 2010, Belien et al., 2009) 
since the former system allows visual selection of tumour areas and cells of 
interest, and artefacts or areas which are not relevant can be discarded 
either semi-automatically or manually. In addtion, DNA ICM has well 
established diagnostic validity and reproducibility (Böcking et al., 2010, 
Böcking and Nguyen, 2004). The principles of DNA analysis consist of 
measuring of the DNA content in a large number of individual cells and 
construction of a histogram representing the distribution of the cell 
population. Even though image cytometry provides a more precise analysis, 
it has been reported that image cytometry systems may vary and some 
could be more accurate than others (Huang et al., 2005, Bremmer et al., 
2011). 
In this study, the Dako Automated Cell Imaging System (ACIS III) was used 
to undertake image cytometry on tissue sections, although we identified a 
number of technical limitations with this system. This is a semi-automatic 
system where the operator helps with the selection of the cells to be 
analysed. However, according to our experience with the ACIS III, too many 
sample cells (not originally selected by the system) need to be selected 
manually by the operator. The only option for selecting cells is to draw 
around the nuclei of each cell that was not originally pre-selected by the 
software. This is laborious and lacks accuracy. Additionally, ACIS III does 
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not provide multiple area measurements in a single section (on the same 
slide), and each area has to be rescanned and measured again. This is also 
very laborious and increases the operator time for every ploidy analysis. 
While the system may currently have flaws, future improvements in the 
analysis software and cheaper components will address these limitations. 
5.4.6 Conclusions  
 DNA ploidy is a common feature of OSCC as aneuploidy was found 
in all 86 cases (100%) and in 168 of 172 tumour areas analysed 
(98%). 
 Primary OSCC lesions show heterogeneity, suggesting that cancers 
are polyclonal. 
 Aneuploidy may only be useful as a tool to evaluate prognosis when 
used along with histopathological analysis and other clinical and 
molecular factors.  
 A dichotomous division of diploid/aneuploid may not be accurate 
enough for use as a marker, and calculation of DI and 5cER 
provides a more sensitive parameter. 
 There is no association between DNA status and histological 
differentiation.  
 Even though it is unlikely that the ploidy status alone can accurately 
predicate OSCC progression, further studies are needed to 
determine the ideal test parameters and conditions under which it 
should be used, as well as the cost-effectiveness.  
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6. CORRELATION OF CELL CYCLE REGULATORY 
PROTEIN EXPRESSION WITH PLOIDY STATUS  
6.1 Introduction  
MCM2 is a key regulatory protein of the cell cycle and is recruited as part of 
the replicative helicase to initiate eukaryotic DNA synthesis. In fact, it has 
been reported that down-regulation of MCM proteins leads to a loss of 
proliferative capacity in human cells (Zhang et al., 2015). Nuclear 
expression of this protein is seen not only in cycling cells, but also in cells 
which are licensed or enabled to proliferate (Torres-Rendon et al., 2009a). 
This property makes MCM proteins ideal as diagnostic proliferation markers 
in various tissues (Williams and Stoeber, 2012a, Tamura et al., 2010) 
Ki-67 protein identifies cells in active phases (late G1-S-G2-M) of the cell 
cycle, but not cells in early G1 or quiescent (G0) phases. Thus, evaluation 
of this antigen may serve as a marker of growth (Dudderidge et al., 2005, 
Gonzalez-Moles et al., 2010). At the same time, Ki-67 is not co-expressed 
with other G1 markers, suggesting that MCM2 protein is a superior 
proliferation marker over Ki-67. When combined with other cell cycle 
proteins it may help to define cells with different cell cycle kinetics. 
Geminin has been identified as a novel proliferation marker. It is mainly 
present in the S-G2-M transition stage of the cell cycle. Geminin helps to 
regulate cell cycle entry and functions by down regulating MCM complex 
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recruitment and preventing re-replication in mammalian cells. When geminin 
is evaluated along with Ki-67, the geminin/Ki-67 ratio gives information 
about the length of the G1 phase (Section 1.5.1). The geminin/Ki-67 ratio 
has been proposed as a prognostic marker, as shown in oligodendroglial 
tumours (Wharton et al., 2004). The higher the geminin/Ki-67 ratio, the 
poorer the prognosis.  
The MCM2/Ki-67 ratio defines the proportion of cells that are licensed to 
proliferate. The difference between MCM2 and Ki-67 is important as it may 
help to identify the cell kinetics of a lesion (Quaglia et al., 2006). The higher 
the ratio, the greater the proportion of cells that reside in a licensed 
proliferative state (Wharton et al., 2004, Shetty et al., 2005).  
Cyclin D1 is a crucial cell cycle regulator of the G1 phase. Various studies 
have been conducted to evaluate cyclin D1 in premalignant and malignant 
lesions. Studies have shown that cyclin D1 over-expression may be 
involved in the early stages of tumorigenesis (Wilkey et al., 2009, Shintani et 
al., 2002).  
DNA ploidy abnormalities are considered important indicators of genomic 
instability and correlate with worse prognosis in a variety of cancers (Blanco 
et al., 2013, Santos‐Silva et al., 2011, Torres-Rendon et al., 2009b). 
Dysregulation of the cell cycle, particularly during cell division (mitosis) and 
DNA synthesis events, is believed to generate aneuploidy and can promote 
tumorigenesis (Weaver and Cleveland, 2008). 
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Interestingly, a recent study carried out by Torres-Rendon et al. (Torres-
Rendon et al., 2009b) showed that aneuploid oral epithelial dysplasia 
lesions have a higher risk of malignant progression than cases with normal 
DNA content (diploid). Other studies showed aneuploidy in approximately 
87% of OSCC (Santos‐Silva et al., 2011). Aneuploidy has been proposed to 
help identify cases that develop cancer in Barrett`s oesophagus (Bird–
Lieberman et al., 2012). Therefore, it is important to investigate possible 
relations with prognostic biomarkers within aneuploid lesions.  
As mentioned in Chapter 1 (Section 1.10.1), the nuclear DNA index (DI) has 
been established as an important parameter of DNA image cytometry. The 
upper limit of DI for a diploid sample among DNA image cytometry studies 
has usually been 1.1 (Huang et al., 2005, Gschwendtner et al., 1999, 
Pentenero et al., 2009, Santos‐Silva et al., 2011). A DI of 1.2 has also been 
used as the upper limit in diploid cases (Furuya et al., 2000, Fang et al., 
2004). The proportion of cells that exceed 5c (5cER) in image cytometry 
analysis has been proposed as a reliable parameter of malignant 
progression when the value is more than 1% of the total number of analysed 
nuclei (Gockel et al., 2006, Pektaș et al., 2006). 
This chapter explores whether there is any correlation of cell cycle 
regulatory proteins (MCM2, Ki-67, geminin and cyclin D1) with ploidy status 
in non-metastatic and metastatic oral squamous cell carcinomas. 
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6.2 Material and methods 
A total of 125 paraffin blocks were analysed for both ploidy content and 
expression of the cell cycle regulatory proteins, MCM2, Ki-67, geminin and 
cyclin D1. Forty-seven were oral squamous cell carcinomas that had not 
metastasised (OSCC NM) and 39 cases were primary oral squamous cell 
carcinoma that had metastasised (OSCC M), with their matched lymph node 
metastases (39 samples). 
The cases that were used for the correlation analyses were the biopsy 
samples that had been analysed for DNA ploidy and also had sections 
available for immunohistochemistry staining (Table 6.1). Quantitative 
analysis of protein expression was previously explained in Chapter 3, 
section 3.4.3. The DNA analysis by image cytometry of the paraffin sections 
was also described in sections 3.5.1, 3.5.2, 3.5.3 and.3.5.4 
Spearman’s rank correlation coefficient was the statistical test used to 
evaluate the strength of the correlations. All correlation coefficient values 
are in Appendix 2. 
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 OSCC NM OSCC M OSCC LN Total 
MCM2 - Ploidy analysis 40 37 31 108 
 
Ki-67 - Ploidy analysis 44 39 36 119 
 
Geminin - Ploidy analysis 47 39 36 122 
 
Cyclin D1 - Ploidy analysis 47 38 31 116 
 
MCM2/Ki-67 ratio - Ploidy analysis 39 37 26 102 
 
Geminin/Ki-67 ratio - Ploidy analysis 22 23 27 72 
OSCC NM = Oral squamous cell carcinoma that had not metastasised. 
OSCC M = Oral squamous cell carcinoma that had metastasised. 
OSCC LN = Lymph node metastasis. 
Table 6.1: Number of cases that were available for the correlation analyses 
between DNA ploidy and immunostaining of the different proteins.  
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6.3 Results  
6.3.1 Correlation between MCM2, Ki-67, geminin and cyclin 
D1 expression and ploidy status in OSCC NM  
6.3.1.1  MCM2- Ploidy analysis 
There was no correlation between MCM2 and ploidy status in all analysed 
groups.  However, whilst the LI mean showed a significant correlation with 
DI (p=0.03) (Table 6.2), in contrast, the 5cER, showed no significant 
correlation in this group.  
6.3.1.2 Ki-67- Ploidy analysis  
There was no evident correlation between Ki-67 and ploidy status, and 
either, DI or 5cER in OSCC NM (Table 6.2). 
6.3.1.3 Geminin- Ploidy analysis 
Geminin showed no significant correlation with ploidy status. Likewise, the 
DI and 5cER were not significant (Table 6.2).  
6.3.1.4 Cyclin D1 - Ploidy analysis 
This protein showed no correlation with ploidy status, DI or 5cER (Table 
6.2) . 
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6.3.1.5 MCM2/Ki-67 ratio - Ploidy analysis 
The MCM2/Ki-67 value showed no correlation with ploidy statu in the OSCC 
NM group (Table 6.2).  
6.3.1.6 Geminin/Ki-67 ratio - Ploidy analysis 
There was no correlation between the geminin/Ki-67 ratio and the ploidy 
analysis in the OSCC NM group (Table 6.2). 
6.3.2 Correlation between MCM2, Ki-67, geminin and cyclin 
D1 expression and ploidy status in OSCC M 
With the exception of cyclin D1, which showed significant correlation with 
the DI value (Table 6.2), there was no correlation between the expression of 
cell cycle proteins (MCM2, Ki-67, geminin) and ploidy status in this group. 
Similarly, there was no correlation between the MCM2/Ki-67 and 
geminin/Ki-67 ratios and the ploidy status, DNA index or 5cER values 
(Table 6.2). 
6.3.3 Correlation between MCM2, Ki-67, geminin and cyclin 
D1 expression and ploidy status in OSCC LN 
No significant correlation between cell cycle proteins and ploidy status, DI or 
5cER was found in this cohort, except for Ki-67 LI, whcih was significantly 
correlated with ploidy status (p=0.04) (Table 6.2). 
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Protein / DNA status OSCC NM OSCC M OSCC LN 
 Spearman’s rank correlation test 
MCM2/ Ploidy status 0.23 0.10 0.42 
MCM2/ DI 0.03 0.20 0.79 
MCM2/ 5cER >1% 0.42 0.27 0.80 
    
Ki-67/ Ploidy status 0.09 0.71 0.04 
Ki-67/ DI 0.69 0.70 0.10 
Ki-67/ 5cER >1% 0.23 0.84 0.92 
    
Geminin/ Ploidy status 0.40 0.97 0.29 
Geminin/ DI 0.95 0.19 0.09 
Geminin/ 5cER >1% 0.67 0.55 0.09 
    
Cyclin D1/ Ploidy status 0.65 0.24 0.19 
Cyclin D1/ DI 0.64 0.02 0.41 
Cyclin D1/ 5cER >1% 0.78 0.16 0.80 
    
MCM2/Ki-67/ Ploidy status 0.05 0.78 0.07 
MCM2/Ki-67/DI 0.24 0.33 0.13 
MCM2/Ki-67/ 5cER >1% 0.35 0.68 0.55 
    
Geminin/Ki-67/ Ploidy status 0.17 0.59 0.12 
Geminin/Ki-67/ DI 0.68 0.19 0.09 
Geminin/Ki-67/ 5cER >1% 0.10 0.61 0.09 
OSCC NM = Oral squamous cell carcinoma that had not metastasised. 
OSCC M = Oral squamous cell carcinoma that had metastasised. 
OSCC LN = Lymph node metastasis. 
Ploidy status= Aneuploid or diploid. 
DI= DNA index. 
5cER= Abnormal cells that exceed 5c with a cut-off point at 1%. 
Table 6.2: Correlation of DNA content with MCM2, Ki-67, geminin, cyclin D1 
and MCM2/Ki-67 and geminin/Ki-67 ratios. P value of less than 0.05 was 
considered significant. 
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MCM2 
mean±SD 
Ki-67 
mean±SD 
Geminin 
mean±SD 
Cyclin D1 
mean±SD 
MCM2/Ki67 
mean±SD  
Geminin/Ki67 
mean±SD 
OSCCNM  
DI>1.2 69.96±16.28 64.61±28.3 34.23±14.11 55.35±17.96 1.35±1.00 0.66±0.27 
5cER>1% 70.39±16.84 62.29±18.51 34.98±14.08 54.89±18.22 1.33±0.87 0.69±0.25 
OSCC M  
DI>1.2 73.58±16.21 54.23±21.39 31.16±15.94 56.84±12.97  1.55±0.67 0.58±0.23 
5cER>1% 74.79±17.08 53.72±21.09 29.68±14.67 57.53±13.41 1.57±0.66 0.56±0.22 
OSCC LN  
DI>1.2 79.88±12.66 49.66±36.04 20.75±21.90 59.20±20.81 1.27±0.43 0.31±0.30 
5cER>1% 80.17±12.42 49.93±36.59 23.72±23.03 60.33±18.78 01.31±0.45 0.36±0.32 
SD= Standard deviation. 
OSCC NM = Oral squamous cell carcinoma that had not metastasised. 
OSCC M = Oral squamous cell carcinoma that had metastasised. 
OSCC LN = Lymph node metastasis. 
DI= DNA index. 
5cER >1%= Abnormal cells that exceed 5c. 
 
Table 6.3: DNA index and the 5cER mean and standard deviation of MCM2, 
Ki-67, geminin and cyclin D1 LIs in OSCC NM and OSCC M. 
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6.4 Discussion and conclusions  
The Spearman`s rank correlation coefficient is a non-parametric measure of 
correlation that is the most suitable to assess the relation between two 
variables (Altman, 1990). All analysed samples in OSCC were aneuploid 
and all had DI of 1.2 or more. Thus, correlation with different cut off points 
between groups was not applicable. 
6.4.1 High MCM2 expression is not correlated to ploidy 
status in OSCC NM and OSCC M  
In Chapter 4, it was shown that the OSCC M samples had slightly higher 
MCM2 LI values than the OSCC NM samples but this was not statistically 
significant (Table 4.4). However, in this chapter`s results the ploidy status of 
OSCC samples (NM & M) did not correlate with the MCM2 LI value (Table 
6.2), although, the mean LI values of cases with DI>1.2 and 5cER >1% 
were much higher in the OSCC M group (Table 6.3). 
The increase in expression of MCM2 in the OSCC M group may represent 
cells with an increased and steady proliferation rate but not necessarily with 
aberrant DNA content. 
6.4.2 Low Ki-67 expression is correlated with ploidy status 
in OSCC LN 
According to the Spearman rank correlation coefficient, Ki-67 expression 
showed a significant correlation (Table 6.2) with ploidy status (p=0.04). The 
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results in Chapter 4 showed that the mean Ki-67 LI value in the OSCC LN 
samples was significantly different (p=0.03) to the LI value in the primary 
tumours (OSCC M) (Table 4.5). One possible explanation for the lower Ki-
67 value in the aneuploid OSCC LN samples may be that aneuploid cases 
have a population of cells that are not in a proliferative state but are in the 
exit of G0 - early G1 phase.  
6.4.3 Low geminin expression is not correlated with ploidy 
status in OSCC M 
There was no significant correlation of low geminin and ploidy status 
(p=0.97) in the OSCC M samples (Table 6.2). This lack of significance was 
also observed between OSCC NM and OSCC M groups (Chapter 4, Table 
4.4).There was a tendency for geminin to be lower in OSCC M samples and 
in cases with a high DI value and 5cER ( Table 6.3). Moreover, the OSCC 
M and OSCC LN cases did not show any significant correlation. 
6.4.4 There is no correlation of high cyclin D1 expression 
with ploidy status  
Even though there was no significant correlation between OSCC NM and 
OSCC M samples (Chapter 4, Table 4.4), this study demonstrated a 
significant correlation (p=0.02) of high cyclin D1 with abnormal DNA content 
as shown by the DI parameter (Table 6.2).  
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6.4.5 MCM2/Ki-67 and geminin/Ki-67 ratios are not 
correlated with ploidy status  
In Chapter 4, geminin/Ki-67 ratio was significanly different when OSCC NM 
and OSCC M groups were cmpared (Table 4.4). Also, it was shown that 
differences between OSCC M and OSCC LN in MCM2/Ki-67 and 
geminin/Ki-67 ratios were statistically sgnificant (p=0.05, p=0.01, t-test, 
respectively). Reults from this Chapter showed no correlation (Table 6.2) 
between ploidy status and MCM2/Ki-67 or geminin/Ki-67 ratios in any of the  
OSCC samples (Table 6.3). 
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6.5 Conclusions  
 MCM2 LI correlated with abnormal DNA content as shown by DI in 
OSCC NM samples. 
 Ki-67 did not correlate with ploidy status or 5cER>1% values. 
However, Low Ki-67 LI correlated with aneuploidy in the OSCC 
LN group. 
 Cyclin D1 LI correlated with ploidy status in OSCC M, but not with 
DI or 5cER values in OSCC NM, OSCC M or OSCC LN. 
 MCM2/Ki-67 and geminin/Ki-67 ratios did not correlate with 
abnormal DNA content in any of the analysed groups. 
 In the OSCC LN group there was no correlation between 
aneuploidy with expression of the cell cycle regulatory proteins, 
MCM2, geminin and cyclin D1.  
 Ki-67 expression correlated with ploidy status in the OSCC LN 
group. 
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7. FINAL DISCUSSION 
7.1 Overview  
The final chapter of this dissertation discusses the findings which have 
emerged from the data and statistical analyses presented in the previous 
chapters. This project employed two different analytical methods that used 
paraffin embedded tissue blocks of oral squamous cell carcinoma lesions. 
The first method was immunohistochemical analysis of cell cycle regulatory 
proteins MCM2, Ki-67, geminin and cyclin D1. The objectives outlined in 
Chapter 4 of this thesis were met by performing an accurate quantification 
of positive and negative tumour cells in the TMA sections. It was considered 
that quantitative measures would usefully supplement and extend the 
qualitative analysis.The second method was DNA ploidy analysis by image 
cytometry. 
The following section provides a brief overview of the current literature, 
discusses shortcomings, and finally, suggestions for future work. 
7.2 MCM2, Ki-67, geminin and cyclin D1 expression in 
OSCC with and without metastasis and in lymph node 
metastases  
Squamous cell carcinoma is a common malignant tumour in the oral cavity 
characterised by complex genetic alterations, which may cause cell 
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dysregulation.  Alterations in cell cycle proteins, including licensing proteins 
and regulators, may contribute to the development and progression of 
OSCC. Cancer heterogeneity in the same tumour and between primary 
lesions and their nodal metastases has long been recognised (Greaves and 
Maley, 2012, Marte, 2013). The heterogeneity in tumour cells can be 
influenced by changes in the tumour microenvironment and the genomic 
divergence in the tumour itself. These changes are likely to be the reason 
for the intra and inter-tumour heterogeneity observed in cancer patients 
(Junttila and de Sauvage, 2013). 
This dissertation has investigated the heterogeneity of protein expression 
within the tumour. One of the findings to emerge from this study is that there 
were no differences in cell cycle protein expression in different areas of the 
tumours, nor between tumours which metastasised (M) or did not 
metastasise (NM). OSCC M had a higher mean of MCM2 LI than in OSCC 
NM, although this was not statistically significant. This may be attributable to 
the small sample size in this study and limitation of statistical power. In 
addition, MCM2 showed an increase from normal through OSCC NM to 
OSCC M, indicating the presence of a high number of cells licensed to 
proliferate.  
Overall, the present results showed greater proportion of cells that express 
MCM2 than Ki-67 or geminin in the NOM, OSCC NM and OSCC M groups. 
Moreover, MCM2 expression increased from normal through OSCC NM to 
OSCC M. This pattern of expression in NOM demonstrates that cells are in 
the G0 or in G0-G1 phase (established by MCM2 expression). These results 
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are in line with previous reports (Torres-Rendon et al., 2009a, Gouvêa et al., 
2013). 
The geminin/Ki-67, but not MCM2/Ki-67 ratio for OSCC M was significantly 
associated with nodal metastases. This finding could be investigated in 
future projects to determine if the geminin/Ki-67 ratio may be a reliable 
marker of metastasis in OSCC. 
Another finding in the current study was that there was no difference in the 
cell cycle regulatory proteins between primary and matched lymph node 
metastases, except for Ki-67, which had higher expression in primary 
tumours. Higher expression of Ki-67 in the primary lesions compared with in 
the lymph nodes may reflect a lower proliferative capacity of metastatic 
tumour cells (Tawfik et al., 2013). In contrast, MCM2 expression was 
greater in the nodal metastasis cells, but with no statistical significance. Low 
Ki-67 and high MCM2 LIs in the nodal metastases may suggest that a large 
population of metastatic cells are in G0 phase but are licensed to proliferate. 
High MCM2 LIs may reflect a cell proliferation capacity of OSCC in nodal 
metastases and supports the idea that metastatic lesions may be better 
differentiated (Park et al., 2007). However, no study has yet explored the 
proliferative activity of OSCC in lymph nodes. 
No significant associations between LI of MCM2, Ki-67, geminin and cyclin 
D1 and the TNM stages, lymph node metastases and differentiation grade 
were found. 
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7.3 DNA ploidy by image cytometry and prognosis of oral 
squamous cell carcinoma 
The main goal of the current study was to evaluate DNA content (ploidy) as 
a diagnostic and prognostic marker in oral cancers (squamous cell 
carcinoma). DNA image cytometry has become a common method for 
evaluation of DNA ploidy in tumour cells. Sensitivity, specificity, positive and 
negative predictive values were calculated for this diagnostic method.  
In OSCC that had metastasised, all cases (100%) showed an aneuploid 
DNA content. This result differed from previous studies which had recorded 
lower aneuploidy incidence in OSCC (Abou-Elhamd and Habib, 2007, 
Santos‐Silva et al., 2011). Such variation may be attributable to differences 
in methodology used in each study and possibly the tumour biology of our 
analysed samples. Likewise, all lymph node metastasis lesions (39 
samples) showed DNA abnormalities with varying degrees of severity. The 
ploidy parameters, DI and 5cER values, were significantly higher in the 
nodal metastasis samples than in the primary carcinomas. This suggests an 
aberrant or increase in the nuclear DNA content in metastatic tumour cells. 
In contrast, other studies did not find any association between high 
aneuploid incidence and high metastasis rates (Saiz-Bustillo et al., 2005). 
The sensitivity of aneuploidy to predict metastasis was very good (100%), 
however, specificity was 0% since all OSCC cases were aneuploid. Overall, 
these results indicate that DNA aneuploidy is a necessary feature for 
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metastasis progression in OSCC, but is not specific to lesions which 
progress. 
Thirty-one of the 39 cases which metastasised (Table 5.6) showed the 
same or more severe aneuploidy in their matched nodal metastasis. Taken 
together, these results suggest that there are aggressive primary cells that 
have the ability to migrate into the lymph nodes and cause tumour 
formation. The ability to metastasise may only be induced late in 
progression by a change in the tumour microenvironment allowing the clone 
to grow more (Chaffer and Weinberg, 2011). 
Most studies (Torres-Rendon et al., 2009b, Santos‐Silva et al., 2011, 
Gouvêa et al., 2013) in the field of DNA image cytometry analysis, have only 
focussed on the invasive front area. The present study has for the first time 
investigated heterogeneity of OSCC tumours in terms of DNA ploidy 
analysis; surface and invasive front areas were also compared. Tumour 
heterogeneity has previously been investigated, by examining multiple 
samples from OSCC at the invasive front area only (Diwakar et al., 2005). 
The most striking result to emerge from the data is that the surface more 
often showed severe aneuploidy (34%) than the invasive front (21%). 
Moreover, the incidence of abnormal DNA content was greater at the 
surface area in the OSCC M (40%) than OSCC NM (30%) (Table 5.5). This 
result may be related to the cellular heterogeneity found in malignant 
lesions, which is a common feature of all cancers (Greaves and Maley, 
2012). This genetic heterogeneity may be due to biological differences 
among malignant cells developed within the same clone (Marusyk and 
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Polyak, 2010). Another possible scenario for this may be that prestressing 
caused by aneuploidy leads to an increase in genomic imbalances (Torres 
et al., 2008), necessary for tumour formation in early stages. Subsequent 
malignant cells may then become less aneuploid as the tumour progresses 
but this has not yet been investigated. Understanding the cellular 
consequences of aneuploidy could offer a new insight into cancer therapy. 
7.4 Correlation of MCM2, Ki-67, geminin and cyclin D1 
expression with ploidy status in OSCCs and their matched 
lymph node metastasis  
To meet the objectives outlined in Chapter 6, expression of MCM2, Ki-67, 
geminin, cyclin D1, MCM2/Ki-67 and geminin/Ki-67 ratios were correlated 
with the DNA ploidy results.  
This study showed a significant correlation of low Ki-67 expression with 
abnormal DNA content in OSCC LN (Table 6.2). These results suggest that 
aneuploid metastatic tumours could have a population of cells that are not 
proliferating (in G0 or early G1) but are licensed to proliferate (demonstrated 
by MCM2 expression). In the OSCC group that had metastasis , MCM2, Ki-
67 and geminin, showed no correlation with ploidy status, DI or the 5cER 
values, Whereas cyclin D1 correlated with DI value. 
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7.5 Shortcomings  
1- The main limitation of this study was that the number of samples was 
relatively small. 
2- In this project, the first biopsy showing OSCC was retrieved for every 
patient that progressed to metastasis. The time of malignant nodal 
metastasis was not assessed at this stage.  
3- The TMA method appeared to have some limitations. Some cores 
were lost during immunohistochemistry processing and others did not 
show immune-reactivity within the same TMA section.  
4- One technical limitation was the ACIS III software, as this was only 
semi-automated. This system required too many sample cells to be 
selected by the operator, manually drawing around the cell nuclei of 
interest. This was very laborious and subjective. Nonetheless, the 
procedures for ploidy analysis were followed exactly according to 
standard protocols previously published and used in our laboratories. 
5- It is possible that, for some cases, the cells analysed for DNA ploidy 
may not be from the same area where the immunohistochemistry 
results were quantified. This was because for the immunostaining 
quantification, three representative samples from the surface, middle 
and advancing front were selected by the operator. 
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7.6 Future work  
1- Additional studies on OSCC evaluating MCM2, Ki-67 expression, along 
with their ratios, could be of great value to correlate with differentiation 
status, tumour size and disease outcome in term of disease free and overall 
survival. 
2- Evaluation of Ki-67 and MCM2 levels in metastatic tumour cells with a 
large sample size may identify subgroups of patients with low Ki-67 and 
high MCM2 expression in lymph nodes. Future work may include genomic 
comparisons between patient groups and control groups which may help in 
selection of treatment options. 
3- This is the first time that MCM2/Ki-67 and geminin/Ki-67 ratios have been 
calculated in OSCC with and without nodal metastases, but the differences 
in values were relatively small. However, as the sample size was small, 
these findings need to be confirmed in future similar studies.  
4- One of the most interesting findings of this work was the heterogeneity of 
cell cycle proteins. While this has been previously reported it remains highly 
complex and poorly understood. Further studies are recommended to 
investigate the relationship between tumour microenvironment and 
heterogeneity of cell cycle proteins within primary and metastatic tumours. 
5- In this thesis I reported for the first time a substantial difference in DNA 
status at the surface compared to the advancing front of OSCC. This finding 
should be confirmed in a large cohort of oral cancer and may indicate an 
increased risk of metastasis. Future studies could investigate the 
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differences between surface and advancing front cells. These cells could be 
isolated using laser capture microdissection (LCM) and analysed by single 
cell sequencing. This may identify important differences that could lead to 
new treatment options. 
7.7 General conclusions  
The conclusions that can be drawn from the present study are that altered 
expression of replication licensing proteins are found in oral squamous cell 
carcinoma. Therefore, the pre-replication MCM2 protein may serve as a 
diagnostic and prognostic tool for OSCC. 
DNA ploidy alone may not be a good diagnostic tool to evaluate OSCC 
progression in the oral cavity. However, aneuploidy is a common feature of 
OSCC and a highly sensitive parameter. Primary lesions showed 
heterogeneity in support of previous literature. Further studies on this may 
identify novel treatments. Finally, this is the first report showing differences 
in DNA status between the surface and advancing front within OSCC. This 
is a very interesting finding that requires further study.   
                                                                                                                   Chapter 8: References 
211 
 
8. REFERENCES 
ABOU-ELHAMD, K.-E. A. & HABIB, T. N. 2007. The flow cytometric 
analysis of premalignant and malignant lesions in head and neck squamous 
cell carcinoma. Oral oncology, 43, 366-372. 
ABRAHAO, A. C., BONELLI, B. V., NUNES, F. D., DIAS, E. P. & CABRAL, 
M. G. 2011. Immunohistochemical expression of p53, p16 and hTERT in 
oral squamous cell carcinoma and potentially malignant disorders. Brazilian 
oral research, 25, 34-41. 
AGARWAL, P., KABIR, F. M. L., DEINNOCENTES, P. & BIRD, R. C. 2012. 
Tumor suppressor gene p16/INK4A/CDKN2A and its role in cell cycle exit, 
differentiation, and determination of cell fate. Tumor suppressor genes. 
Rijeka, Croatia: InTech Open Access Pub, 1-34. 
AGOSTINIS, P., BERG, K., CENGEL, K. A., FOSTER, T. H., GIROTTI, A. 
W., GOLLNICK, S. O., HAHN, S. M., HAMBLIN, M. R., JUZENIENE, A., 
KESSEL, D., KORBELIK, M., MOAN, J., MROZ, P., NOWIS, D., PIETTE, J., 
WILSON, B. C. & GOLAB, J. 2011. Photodynamic therapy of cancer: an 
update. CA Cancer J Clin, 61, 250-81. 
AHN, J. H. & CHANG, H. K. 2010. Expression of minichromosome 
maintenance protein 7 and Smad 4 in squamous cell carcinoma of the 
esophagus. Korean Journal of Pathology, 44, 346-353. 
AI, L., STEPHENSON, K. K., LING, W., ZUO, C., MUKUNYADZI, P., SUEN, 
J. Y., HANNA, E. & FAN, C.-Y. 2003. The p16 (CDKN2a/INK4a) tumor-
suppressor gene in head and neck squamous cell carcinoma: a promoter 
methylation and protein expression study in 100 cases. Modern pathology, 
16, 944-950. 
AKHTER, M., HOSSAIN, S., RAHMAN, Q. B. & MOLLA, M. R. 2011. A 
study on histological grading of oral squamous cell carcinoma and its co-
relationship with regional metastasis. Journal of oral and maxillofacial 
pathology: JOMFP, 15, 168. 
ALKAISI, A., ZAIDAN, H. & AL KABTAN, I. 2014. The Predictive Value of 
Tumor Depth for Cervical Lymph Node Metastasis in Oral Squamous Cell 
Carcinoma; Prospective and Retrospective Study in Iraq. J Cancer Sci Ther, 
6, 253-257. 
ALTMAN, D. G. 1990. Practical statistics for medical research, CRC Press. 
ANG, K. K., HARRIS, J., WHEELER, R., WEBER, R., ROSENTHAL, D. I., 
NGUYEN-TAN, P. F., WESTRA, W. H., CHUNG, C. H., JORDAN, R. C., 
LU, C., KIM, H., AXELROD, R., SILVERMAN, C. C., REDMOND, K. P. & 
                                                                                                                   Chapter 8: References 
212 
 
GILLISON, M. L. 2010. Human papillomavirus and survival of patients with 
oropharyngeal cancer. N Engl J Med, 363, 24-35. 
ANG, K. K. & STURGIS, E. M. Human papillomavirus as a marker of the 
natural history and response to therapy of head and neck squamous cell 
carcinoma.  Seminars in radiation oncology, 2012. Elsevier, 128-142. 
ANNEROTH, G., BATSAKIS, J. & LUNA, M. 1987. Review of the literature 
and a recommended system of malignancy grading in oral squamous cell 
carcinomas. European Journal of Oral Sciences, 95, 229-249. 
ANSARY‐MOGHADDAM, A., HUXLEY, R. R., LAM, T. H. & WOODWARD, 
M. 2009. The risk of upper aero digestive tract cancer associated with 
smoking, with and without concurrent alcohol consumption. Mount Sinai 
Journal of Medicine: A Journal of Translational and Personalized Medicine, 
76, 392-403. 
APARICIO, O. M. 2013. Location, location, location: it's all in the timing for 
replication origins. Genes & development, 27, 117-128. 
ARGIRIS, A., KARAMOUZIS, M. V., RABEN, D. & FERRIS, R. L. 2008. 
Head and neck cancer. Lancet, 371, 1695-709. 
ARORA, S., AGGARWAL, P., PATHAK, A., BHANDARI, R., DUFFOO, F. & 
GULATI, S. C. 2012. Molecular genetics of head and neck cancer (Review). 
Molecular medicine reports, 6, 19-22. 
AULUCK, A., WALKER, B. B., HISLOP, G., LEAR, S. A., SCHUURMAN, N. 
& ROSIN, M. 2014. Population-based incidence trends of oropharyngeal 
and oral cavity cancers by sex among the poorest and underprivileged 
populations. BMC cancer, 14, 316. 
BAAK, J. & JANSSEN, E. 2004. DNA ploidy analysis in histopathology. 
Histopathology, 44, 603-620. 
BAKER, D. J., JIN, F., JEGANATHAN, K. B. & VAN DEURSEN, J. M. 2009. 
Whole chromosome instability caused by Bub1 insufficiency drives 
tumorigenesis through tumor suppressor gene loss of heterozygosity. 
Cancer cell, 16, 475-486. 
BAKHOUM, S. F. & COMPTON, D. A. 2012. Chromosomal instability and 
cancer: a complex relationship with therapeutic potential. The Journal of 
clinical investigation, 122, 1138. 
BARETTON, G., LI, X., STOLL, C., FISCHER-BRANDIES, E., SCHMIDT, 
M. & LÖHRS, U. 1995. Prognostic significance of DNA ploidy in oral 
squamous cell carcinomas: a retrospective flow and image cytometric study 
with comparison of DNA ploidy in excisional biopsy specimens and 
resection specimens, primary tumors, and lymph node metastases. Oral 
                                                                                                                   Chapter 8: References 
213 
 
Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and 
Endodontology, 79, 68-76. 
BARNES, L. 2005. Pathology & genetics: head and neck tumours, Lyon: 
IARC Press, World Health Organization. 
BARROS-ANGUEIRA, F. & GANDARA-VILA, P. 2015. The Loss of p16 
Expression Worsens the Prognosis of OSCC. carcinogenesis, 9, 13. 
BAUER, V. L., BRASELMANN, H., HENKE, M., MATTERN, D., WALCH, A., 
UNGER, K., BAUDIS, M., LASSMANN, S., HUBER, R. & WIENBERG, J. 
2008. Chromosomal changes characterize head and neck cancer with poor 
prognosis. Journal of molecular medicine, 86, 1353-1365. 
BELIEN, J., BUFFART, T., GILL, A., BROECKAERT, M., QUIRKE, P., 
MEIJER, G. & GRABSCH, H. 2009. Gross genomic damage measured by 
DNA image cytometry independently predicts gastric cancer patient survival. 
British journal of cancer, 101, 1011-1018. 
BESTER, A. C., RONIGER, M., OREN, Y. S., IM, M. M., SARNI, D., 
CHAOAT, M., BENSIMON, A., ZAMIR, G., SHEWACH, D. S. & KEREM, B. 
2011. Nucleotide deficiency promotes genomic instability in early stages of 
cancer development. Cell, 145, 435-446. 
BIRAJDAR, S. S., RADHIKA, M., PAREMALA, K., SUDHAKARA, M., 
SOUMYA, M. & GADIVAN, M. 2014. Expression of Ki-67 in normal oral 
epithelium, leukoplakic oral epithelium and oral squamous cell carcinoma. 
Journal of oral and maxillofacial pathology: JOMFP, 18, 169. 
BIRD–LIEBERMAN, E. L., DUNN, J. M., COLEMAN, H. G., LAO–SIRIEIX, 
P., OUKRIF, D., MOORE, C. E., VARGHESE, S., JOHNSTON, B. T., 
ARTHUR, K. & MCMANUS, D. T. 2012. Population-based study reveals 
new risk-stratification biomarker panel for Barrett's esophagus. 
Gastroenterology, 143, 927-935. e3. 
BLANCO, R., RENGIFO, C. E., CEDEÑO, M., FRÓMETA, M. & RENGIFO, 
E. 2013. Flow cytometric measurement of aneuploid DNA content correlates 
with high S-phase fraction and poor prognosis in patients with non-small-cell 
lung cancer. International Scholarly Research Notices, 2013. 
BLOW, J. J. & GILLESPIE, P. J. 2008. Replication licensing and cancer—a 
fatal entanglement? Nature Reviews Cancer, 8, 799-806. 
BOCHMAN, M. L. & SCHWACHA, A. 2007. Differences in the Single-
stranded DNA Binding Activities of MCM2-7 and MCM467 MCM2 AND 
MCM5 DEFINE A SLOW ATP-DEPENDENT STEP. Journal of Biological 
Chemistry, 282, 33795-33804. 
BOCHMAN, M. L. & SCHWACHA, A. 2008. The Mcm2-7 complex has in 
vitro helicase activity. Molecular cell, 31, 287-293. 
                                                                                                                   Chapter 8: References 
214 
 
BOCHMAN, M. L. & SCHWACHA, A. 2009. The Mcm complex: unwinding 
the mechanism of a replicative helicase. Microbiology and Molecular Biology 
Reviews, 73, 652-683. 
BÖCKING, A. & NGUYEN, V. Q. H. 2004. Diagnostic and prognostic use of 
DNA image cytometry in cervical squamous intraepithelial lesions and 
invasive carcinoma. Cancer Cytopathology, 102, 41-54. 
BÖCKING, A., SPROLL, C., STÖCKLEIN, N., NAUJOKS, C., DEPPRICH, 
R., KÜBLER, N. R. & HANDSCHEL, J. 2010. Role of brush biopsy and DNA 
cytometry for prevention, diagnosis, therapy, and followup care of oral 
cancer. Journal of oncology, 2011. 
BOVA, R. J., QUINN, D. I., NANKERVIS, J. S., COLE, I. E., SHERIDAN, B. 
F., JENSEN, M. J., MORGAN, G. J., HUGHES, C. J. & SUTHERLAND, R. 
L. 1999. Cyclin D1 and p16INK4A expression predict reduced survival in 
carcinoma of the anterior tongue. Clinical Cancer Research, 5, 2810-2819. 
BOVERI, T. 1914. Zur Frage der Entstenhung Maligner Tumoren. Jena, 
Germany: Gustav Fischer. Williams and Wilkins, Baltimore. 
BOWEN, D., GROVES, M., BURNETT, A., PATEL, Y., ALLEN, C., GREEN, 
C., GALE, R., HILLS, R. & LINCH, D. 2009. TP53 gene mutation is frequent 
in patients with acute myeloid leukemia and complex karyotype, and is 
associated with very poor prognosis. Leukemia, 23, 203-206. 
BRADLEY, G., ODELL, E., RAPHAEL, S., HO, J., LE, L., BENCHIMOL, S. 
& KAMEL-REID, S. 2010. Abnormal DNA content in oral epithelial dysplasia 
is associated with increased risk of progression to carcinoma. British journal 
of cancer, 103, 1432-1442. 
BRADLEY, K. T., BUDNICK, S. D. & LOGANI, S. 2006. 
Immunohistochemical detection of p16INK4a in dysplastic lesions of the oral 
cavity. Modern pathology, 19, 1310-1316. 
BRAILO, V., VUCICEVIC-BORAS, V., LUKAC, J., BIOCINA-LUKENDA, D., 
ZILIC-ALAJBEG, I., MILENOVIC, A. & BALIJA, M. 2012. Salivary and 
serum interleukin 1 beta, interleukin 6 and tumor necrosis factor alpha in 
patients with leukoplakia and oral cancer. Med Oral Patol Oral Cir Bucal, 17, 
e10-5. 
BRANDIZZI, D., GANDOLFO, M., VELAZCO, M. L., CABRINI, R. L. & 
LANFRANCHI, H. E. 2008. Clinical features and evolution of oral cancer: A 
study of 274 cases in Buenos Aires, Argentina. Age (in years), 40, 9. 
BRANNAN, A. G., JOHNSTONE, P. A. & COOPER, J. 2011. Extracapsular 
tumor extension in cervical lymph nodes: reconciling the literature and seer 
data. Head Neck, 33, 525-528. 
                                                                                                                   Chapter 8: References 
215 
 
BREMMER, J. F., BRAKENHOFF, R. H., BROECKAERT, M. A., BELIËN, J. 
A., LEEMANS, C. R., BLOEMENA, E., VAN DER WAAL, I. & BRAAKHUIS, 
B. J. 2011. Prognostic value of DNA ploidy status in patients with oral 
leukoplakia. Oral oncology, 47, 956-960. 
BRODERS, A. C. 1941. The microscopic grading of cancer. Surg Clin North 
Am, 21, 947-62. 
BROUNS, E., BLOEMENA, E., BELIEN, J., BROECKAERT, M., AARTMAN, 
I. & VAN DER WAAL, I. 2012. DNA ploidy measurement in oral leukoplakia: 
Different results between flow and image cytometry. Oral oncology, 48, 636-
640. 
BROWN, D. & GATTER, K. 1990. Monoclonal antibody Ki‐67: its use in 
histopathology. Histopathology, 17, 489-503. 
BRYNE, M., KOPPANG, H. S., LILLENG, R. & KJÆRHEIM, Å. 1992. 
Malignancy grading of the deep invasive margins of oral squamous cell 
carcinomas has high prognostic value. The Journal of pathology, 166, 375-
381. 
BUAJEEB, W., POOMSAWAT, S., PUNYASINGH, J. & SANGUANSIN, S. 
2009. Expression of p16 in oral cancer and premalignant lesions. Journal of 
oral pathology & medicine, 38, 104-108. 
BUBÁN, T., TÓTH, L., TANYI, M., KAPPELMAYER, J. & ANTAL-
SZALMÁS, P. 2009. Ki-67--new faces of an old player. Orvosi hetilap, 150, 
1059-1070. 
BUENO, P. R., GIAS, L. N., DELGADO, R. G., CEBOLLADA, J. D. & 
GONZÁLEZ, F. D. 1998. Tumor DNA content as a prognostic indicator in 
squamous cell carcinoma of the oral cavity and tongue base. Head & Neck, 
20, 232-239. 
BURY, J. & CROSS, S. 2003. Molecular biology in diagnostic 
histopathology: Part 1–The cell cycle. Current Diagnostic Pathology, 9, 266-
275. 
CAI, K., LUO, Y., LI, L. & LIU, Y. 2012. [Expression and significance of 
MCM2, Ki-67 and Rb protein in laryngeal squamous cell carcinomas]. Lin 
chuang er bi yan hou tou jing wai ke za zhi= Journal of clinical 
otorhinolaryngology, head, and neck surgery, 26, 425-428. 
CALIFANO, J., VAN DER RIET, P., WESTRA, W., NAWROZ, H., 
CLAYMAN, G., PIANTADOSI, S., CORIO, R., LEE, D., GREENBERG, B., 
KOCH, W. & SIDRANSKY, D. 1996. Genetic progression model for head 
and neck cancer: implications for field cancerization. Cancer Res, 56, 2488-
92. 
                                                                                                                   Chapter 8: References 
216 
 
CAMPO-TRAPERO, J., CANO-SÁNCHEZ, J., PALACIOS-SÁNCHEZ, B., 
SANCHEZ-GUTIERREZ, J., GONZÁLEZ-MOLES, M. & BASCONES-
MARTÍNEZ, A. 2008. Update on molecular pathology in oral cancer and 
precancer. Anticancer research, 28, 1197-1205. 
CANCER RESEARCH UK. 2010. Cancer research Available: 
http://www.cancerresearchuk.org/cancer-
info/cancerstats/types/oral/?script=true [Accessed Oct 2014]. 
CASPERSSON, T., FARBER, S., FOLEY, G. & KILLANDER, D. 1963. 
Cytochemical observations on the nucleolus-ribosome system: Effects of 
actinomycin D and nitrogen mustard. Experimental cell research, 32, 529-
552. 
CASTILLO, A., KORIYAMA, C., HIGASHI, M., ANWAR, M., BUKHARI, M. 
H., CARRASCAL, E., MANCILLA, L., OKUMURA, H., MATSUMOTO, M. & 
SUGIHARA, K. 2011. Human papillomavirus in upper digestive tract tumors 
from three countries. World journal of gastroenterology: WJG, 17, 5295. 
CHAFFER, C. L. & WEINBERG, R. A. 2011. A perspective on cancer cell 
metastasis. Science, 331, 1559-1564. 
CHANDARANA, S. P., LEE, J. S., CHANOWSKI, E. J., SACCO, A. G., 
BRADFORD, C. R., WOLF, G. T., PRINCE, M. E., MOYER, J. S., 
EISBRUCH, A. & WORDEN, F. P. 2013. Prevalence and predictive role of 
p16 and epidermal growth factor receptor in surgically treated 
oropharyngeal and oral cavity cancer. Head & neck, 35, 1083-1090. 
CHANDHOK, N. S. & PELLMAN, D. 2009. A little CIN may cost a lot: 
revisiting aneuploidy and cancer. Current opinion in genetics & 
development, 19, 74-81. 
CHARYCH, D. H., COYNE, M., YABANNAVAR, A., NARBERES, J., 
CHOW, S., WALLROTH, M., SHAFER, C. & WALTER, A. O. 2008. 
Inhibition of Cdc7/Dbf4 kinase activity affects specific phosphorylation sites 
on MCM2 in cancer cells. Journal of cellular biochemistry, 104, 1075-1086. 
CHATURVEDI, A. & GILLISON, M. L. 2010. Human papillomavirus and 
head and neck cancer. Epidemiology, Pathogenesis, and Prevention of 
Head and Neck Cancer. Springer. 
CHATURVEDI, A. K., ANDERSON, W. F., LORTET-TIEULENT, J., 
CURADO, M. P., FERLAY, J., FRANCESCHI, S., ROSENBERG, P. S., 
BRAY, F. & GILLISON, M. L. 2013. Worldwide trends in incidence rates for 
oral cavity and oropharyngeal cancers. Journal of Clinical Oncology, JCO. 
2013.50. 3870. 
CHEN, Q., LUO, G., LI, B. & SAMARANAYAKE, L. P. 1999. Expression of 
p16 and CDK4 in oral premalignant lesions and oral squamous cell 
                                                                                                                   Chapter 8: References 
217 
 
carcinomas: a semi‐quantitative immunohistochemical study. Journal of oral 
pathology & medicine, 28, 158-164. 
CHEN, Y. W., KAO, S. Y. & YANG, M. H. 2012. Analysis of p16INK4A 
expression of oral squamous cell carcinomas in Taiwan: Prognostic 
correlation without relevance to betel quid consumption. Journal of surgical 
oncology, 106, 149-154. 
CHIANG, W.-F., LIU, S.-Y., YEN, C.-Y., LIN, C.-N., CHEN, Y.-C., LIN, S.-C. 
& CHANG, K.-W. 2008. Association of epidermal growth factor receptor 
(EGFR) gene copy number amplification with neck lymph node metastasis 
in areca-associated oral carcinomas. Oral oncology, 44, 270-276. 
CHIEN, W., DOMENECH, C., CATALLO, R., KADDAR, T., MAGAUD, J., 
SALLES, G. & FFRENCH, M. 2011. Cyclin-dependent kinase 1 expression 
is inhibited by p16INK4a at the post-transcriptional level through the 
microRNA pathway. Oncogene, 30, 1880-1891. 
CHOI, C.-M., SEO, K. W., JANG, S. J., OH, Y.-M., SHIM, T.-S., KIM, W. S., 
LEE, D.-S. & LEE, S.-D. 2009. Chromosomal instability is a risk factor for 
poor prognosis of adenocarcinoma of the lung: Fluorescence in situ 
hybridization analysis of paraffin-embedded tissue from Korean patients. 
Lung Cancer, 64, 66-70. 
CHUANG, L.-C., TEIXEIRA, L. K., WOHLSCHLEGEL, J. A., HENZE, M., 
YATES, J. R., MÉNDEZ, J. & REED, S. I. 2009. Phosphorylation of Mcm2 
by Cdc7 promotes pre-replication complex assembly during cell-cycle re-
entry. Molecular cell, 35, 206-216. 
COOK, J. G. 2009. Replication licensing and the DNA damage checkpoint. 
Frontiers in bioscience (Landmark edition), 14, 5013. 
COOPER, J. S., PORTER, K., MALLIN, K., HOFFMAN, H. T., WEBER, R. 
S., ANG, K. K., GAY, E. G. & LANGER, C. J. 2009. National Cancer 
Database report on cancer of the head and neck: 10-year update. Head 
Neck, 31, 748-58. 
COSTA, A. & ONESTI, S. 2009. Structural biology of MCM helicases. 
Critical reviews in biochemistry and molecular biology, 44, 326-342. 
COUZIN, J. & SCHIRBER, M. 2006. Fraud upends oral cancer field, casting 
doubt on prevention trial. Science, 311, 448-449. 
CUEVAS, E., JONES, D. & WRIGHT, D. 1993. Immunohistochemical 
detection of tumour growth fraction (Ki‐67 antigen) in formalin‐fixed and 
routinely processed tissues. The Journal of pathology, 169, 477-478. 
CURFMAN, G. D., MORRISSEY, S. & DRAZEN, J. M. 2006. Retraction: 
Sudbo J et al. DNA content as a prognostic marker in patients with oral 
leukoplakia. N Engl J Med 2001;344:1270-8 and Sudbo J et al. The 
                                                                                                                   Chapter 8: References 
218 
 
influence of resection and aneuploidy on mortality in oral leukoplakia. N 
Engl J Med 2004;350:1405-13. N Engl J Med, 355, 1927. 
D'URSO, V., COLLODORO, A., MATTIOLI, E., GIORDANO, A. & 
BAGELLA, L. 2010. Cytometry and DNA ploidy: clinical uses and molecular 
perspective in gastric and lung cancer. Journal of cellular physiology, 222, 
532-539. 
DANAHEY, D. G., TOBIN, E. J., SCHULLER, D. E., BIER-LANING, C. M., 
WEGHORST, C. M. & LANG, J. C. 1999. p16 mutation frequency and 
clinical correlation in head and neck cancer. Acta oto-laryngologica, 119, 
285-288. 
DAS, M., PRASAD, S. B., YADAV, S. S., GOVARDHAN, H., PANDEY, L. 
K., SINGH, S., PRADHAN, S. & NARAYAN, G. 2013. Over expression of 
minichromosome maintenance genes is clinically correlated to cervical 
carcinogenesis. PloS one, 8, e69607. 
DAS, S. N., KHARE, P., PATIL, A., PANDEY, R. M., SINGH, M. K. & 
SHUKLA, N. K. 2005. Association of DNA pattern of metastatic lymph node 
with disease-free survival in patients with intraoral squamous cell 
carcinoma. INDIAN JOURNAL OF MEDICAL RESEARCH, 122, 216. 
DAVEY, M. J., INDIANI, C. & O'DONNELL, M. 2003. Reconstitution of the 
Mcm2-7p heterohexamer, subunit arrangement, and ATP site architecture. 
Journal of Biological Chemistry, 278, 4491-4499. 
DE OLIVEIRA, M. G., RAMALHO, L. M. P., GAIÃO, L., POZZA, D. H. & DE 
MELLO, R. A. 2012. Retinoblastoma and p53 protein expression in pre-
malignant oral lesions and oral squamous cell carcinoma. Molecular 
medicine reports, 6, 163-166. 
DEL SORDO, R. & SIDONI, A. 2008. MIB-1 cell membrane reactivity: a 
finding that should be interpreted carefully. Applied Immunohistochemistry & 
Molecular Morphology, 16, 568. 
DEMIREL, D., AKYÜREK, N. & RAMZY, I. 2013. Diagnostic and prognostic 
significance of image cytometric DNA ploidy measurement in cytological 
samples of cervical squamous intraepithelial lesions. Cytopathology, 24, 
105-112. 
DEMOKAN, S., CHUANG, A., SUOĞLU, Y., ULUSAN, M., YALNıZ, Z., 
CALIFANO, J. A. & DALAY, N. 2012. Promoter methylation and loss of 
p16INK4a gene expression in head and neck cancer. Head & neck, 34, 
1470-1475. 
DEYHIMI, P., TORABINIA, N. & TORABINIA, A. 2013. A comparative study 
of histological grade and expression of Ki67 protein in oral squamous cell 
carcinoma in young and old patients. Dental research journal, 10, 514. 
                                                                                                                   Chapter 8: References 
219 
 
DIFFLEY, J. F. 2011. Quality control in the initiation of eukaryotic DNA 
replication. Philosophical Transactions of the Royal Society B: Biological 
Sciences, 366, 3545-3553. 
DIWAKAR, N., SPERANDIO, M., SHERRIFF, M., BROWN, A. & ODELL, E. 
2005. Heterogeneity, histological features and DNA ploidy in oral carcinoma 
by image-based analysis. Oral oncology, 41, 416-422. 
DONADINI, A., MAFFEI, M., CAVALLERO, A., PENTENERO, M., 
MALACARNE, D., NALLO, E. D., TRUINI, M., NAVONE, R., MEREU, P. & 
SCALA, M. 2010. Oral cancer genesis and progression: DNA near-diploid 
aneuploidization and endoreduplication by high resolution flow cytometry. 
Analytical Cellular Pathology, 32, 373-383. 
DONALDSON, A. D. & BLOW, J. J. 1999. The regulation of replication 
origin activation. Current opinion in genetics & development, 9, 62-68. 
DONG, Y., WANG, J., DONG, F., WANG, X. & ZHANG, Y. 2012. The 
correlations between alteration of p16 gene and clinicopathological factors 
and prognosis in squamous cell carcinomas of the buccal mucosa. Journal 
of oral pathology & medicine, 41, 463-469. 
DONNELLAN, R. & CHETTY, R. 1998. Cyclin D1 and human neoplasia. 
Molecular Pathology, 51, 1. 
DUDDERIDGE, T. J., STOEBER, K., LODDO, M., ATKINSON, G., 
FANSHAWE, T., GRIFFITHS, D. F. & WILLIAMS, G. H. 2005. Mcm2, 
Geminin, and KI67 define proliferative state and are prognostic markers in 
renal cell carcinoma. Clin Cancer Res, 11, 2510-7. 
DUESBERG, P., LI, R., RASNICK, D., RAUSCH, C., WILLER, A., 
KRAEMER, A., YERGANIAN, G. & HEHLMANN, R. 2000. Aneuploidy 
precedes and segregates with chemical carcinogenesis. Cancer genetics 
and cytogenetics, 119, 83-93. 
DUNCAN, L. D., WINKLER, M., CARLSON, E. R., HEIDEL, R. E., KANG, E. 
& WEBB, D. 2013. p16 immunohistochemistry can be used to detect human 
papillomavirus in oral cavity squamous cell carcinoma. Journal of oral and 
maxillofacial surgery, 71, 1367-1375. 
DUNN, J., MACKENZIE, G., OUKRIF, D., MOSSE, C., BANKS, M., 
THORPE, S., SASIENI, P., BOWN, S., NOVELLI, M. & RABINOVITCH, P. 
2010. Image cytometry accurately detects DNA ploidy abnormalities and 
predicts late relapse to high-grade dysplasia and adenocarcinoma in 
Barrett's oesophagus following photodynamic therapy. British journal of 
cancer, 102, 1608-1617. 
EL-DEFTAR, M., EL GERZAWI, S., ABDEL-AZIM, A. & TOHAMY, S. 2012. 
Prognostic significance of ploidy and S-phase fraction in primary intraoral 
                                                                                                                   Chapter 8: References 
220 
 
squamous cell carcinoma and their corresponding metastatic lymph nodes. 
Journal of the Egyptian National Cancer Institute, 24, 7-14. 
EL‐NAGGAR, A. K. & WESTRA, W. H. 2012. p16 expression as a surrogate 
marker for HPV‐related oropharyngeal carcinoma: A guide for interpretative 
relevance and consistency. Head & neck, 34, 459-461. 
EWARD, K. L., OBERMANN, E. C., SHREERAM, S., LODDO, M., 
FANSHAWE, T., WILLIAMS, C., JUNG, H.-I., PREVOST, A. T., BLOW, J. J. 
& STOEBER, K. 2004. DNA replication licensing in somatic and germ cells. 
Journal of cell science, 117, 5875-5886. 
FANG, M., LEW, E., KLEIN, M., SEBO, T., SU, Y. & GOYAL, R. 2004. DNA 
abnormalities as marker of risk for progression of Barrett's esophagus to 
adenocarcinoma: image cytometric DNA analysis in formalin-fixed tissues. 
The American journal of gastroenterology, 99, 1887-1894. 
FERLAY, J., SHIN, H. R., BRAY, F., FORMAN, D., MATHERS, C. & 
PARKIN, D. M. 2010. Estimates of worldwide burden of cancer in 2008: 
GLOBOCAN 2008. Int J Cancer, 127, 2893-917. 
FLESKENS, S. J., TAKES, R. P., OTTE‐HÖLLER, I., VAN DOESBURG, L., 
SMEETS, A., SPEEL, E. J. M., SLOOTWEG, P. J. & VAN DER LAAK, J. A. 
2010. Simultaneous assessment of DNA ploidy and biomarker expression in 
paraffin‐embedded tissue sections. Histopathology, 57, 14-26. 
FLEZAR, M. S., BUT, I., KAVALAR, R. & US-KRASOVEC, M. 2003. Flow 
and image cytometric DNA ploidy, including 5c exceeding cells, of serous 
borderline malignant ovarian tumors. Correlation with clinicopathologic 
characteristics. Analytical and quantitative cytology and histology/the 
International Academy of Cytology [and] American Society of Cytology, 25, 
139-145. 
FRANKFURT, O., SLOCUM, H., RUSTUM, Y., ARBUCK, S., PAVELIC, Z., 
PETRELLI, N., HUBEN, R., PONTES, E. & GRECO, W. 1984. Flow 
cytometric analysis of DNA aneuploidy in primary and metastatic human 
solid tumors. Cytometry, 5, 71-80. 
FREIER, K., JOOS, S., FLECHTENMACHER, C., DEVENS, F., BENNER, 
A., BOSCH, F. X., LICHTER, P. & HOFELE, C. 2003. Tissue microarray 
analysis reveals site-specific prevalence of oncogene amplifications in head 
and neck squamous cell carcinoma. Cancer Res, 63, 1179-1182. 
FUJIWARA, T., BANDI, M., NITTA, M., IVANOVA, E. V., BRONSON, R. T. 
& PELLMAN, D. 2005. Cytokinesis failure generating tetraploids promotes 
tumorigenesis in p53-null cells. Nature, 437, 1043-1047. 
FUNG, C. & GRANDIS, J. R. 2010. Emerging drugs to treat squamous cell 
carcinomas of the head and neck. Expert Opin Emerg Drugs, 15, 355-73. 
                                                                                                                   Chapter 8: References 
221 
 
FURUYA, T., UCHIYAMA, T., MURAKAMI, T., ADACHI, A., KAWAUCHI, 
S., OGA, A., HIRANO, T. & SASAKI, K. 2000. Relationship between 
chromosomal instability and intratumoral regional DNA ploidy heterogeneity 
in primary gastric cancers. Clinical cancer research, 6, 2815-2820. 
GANEM, N. J., STORCHOVA, Z. & PELLMAN, D. 2007. Tetraploidy, 
aneuploidy and cancer. Current opinion in genetics & development, 17, 157-
162. 
GANGULY, N. & PARIHAR, S. P. 2009. Human papillomavirus E6 and E7 
oncoproteins as risk factors for tumorigenesis. Journal of biosciences, 34, 
113-123. 
GANLY, I., PATEL, S. & SHAH, J. 2012. Early stage squamous cell cancer 
of the oral tongue—clinicopathologic features affecting outcome. Cancer, 
118, 101-111. 
GAO, C., FURGE, K., KOEMAN, J., DYKEMA, K., SU, Y., CUTLER, M. L., 
WERTS, A., HAAK, P. & WOUDE, G. F. V. 2007. Chromosome instability, 
chromosome transcriptome, and clonal evolution of tumor cell populations. 
Proceedings of the National Academy of Sciences, 104, 8995-9000. 
GARZON, R., CALIN, G. A. & CROCE, C. M. 2009. MicroRNAs in Cancer. 
Annu Rev Med, 60, 167-79. 
GAWRYCHOWSKI, J., LACKOWSKA, B. & GABRIEL, A. 2003. Prognosis 
of the surgical treatment of patients with non-small cell lung cancer 
(NSCLC)–relation to DNA ploidy. European journal of cardio-thoracic 
surgery, 23, 870-877. 
GERDES, J., LEMKE, H., BAISCH, H., WACKER, H.-H., SCHWAB, U. & 
STEIN, H. 1984. Cell cycle analysis of a cell proliferation-associated human 
nuclear antigen defined by the monoclonal antibody Ki-67. The Journal of 
Immunology, 133, 1710-1715. 
GERDES, J., SCHWAB, U., LEMKE, H. & STEIN, H. 1983. Production of a 
mouse monoclonal antibody reactive with a human nuclear antigen 
associated with cell proliferation. International journal of cancer, 31, 13-20. 
GIAGINIS, C., GEORGIADOU, M., DIMAKOPOULOU, K., TSOUROUFLIS, 
G., GATZIDOU, E., KOURAKLIS, G. & THEOCHARIS, S. 2009. Clinical 
significance of MCM-2 and MCM-5 expression in colon cancer: association 
with clinicopathological parameters and tumor proliferative capacity. 
Digestive diseases and sciences, 54, 282-291. 
GIAGINIS, C., VGENOPOULOU, S., VIELH, P. & THEOCHARIS, S. 2010. 
MCM proteins as diagnostic and prognostic tumor markers in the clinical 
setting. Histology and histopathology, 25, 351-370. 
                                                                                                                   Chapter 8: References 
222 
 
GIBCUS, J., MASTIK, M., MENKEMA, L., DE BOCK, G., KLUIN, P. M., 
SCHUURING, E. & VAN DER WAL, J. 2008. Cortactin expression predicts 
poor survival in laryngeal carcinoma. British journal of cancer, 98, 950-955. 
GILLISON, M. L., BROUTIAN, T., PICKARD, R. K., TONG, Z.-Y., XIAO, W., 
KAHLE, L., GRAUBARD, B. I. & CHATURVEDI, A. K. 2012. Prevalence of 
oral HPV infection in the United States, 2009-2010. Jama, 307, 693-703. 
GOCKEL, I., KAMMERER, P., BRIEGER, J., HEINRICH, U., MANN, W., 
BITTINGER, F., ECKARDT, V. & JUNGINGER, T. 2006. Image cytometric 
DNA analysis of mucosal biopsies in patients with primary achalasia. World 
journal of gastroenterology: WJG, 12, 3020-3025. 
GOING, J. J., KEITH, W. N., NEILSON, L., STOEBER, K., STUART, R. C. 
& WILLIAMS, G. H. 2002. Aberrant expression of minichromosome 
maintenance proteins 2 and 5, and Ki-67 in dysplastic squamous 
oesophageal epithelium and Barrett's mucosa. Gut, 50, 373-7. 
GOLLIN, S. M. 2014. Cytogenetic alterations and their molecular genetic 
correlates in head and neck squamous cell carcinoma: A next generation 
window to the biology of disease. Genes, Chromosomes and Cancer, 53, 
972-990. 
GOLOGAN, O., BARNES, E. L. & HUNT, J. L. 2005. Potential diagnostic 
use of p16INK4A, a new marker that correlates with dysplasia in oral 
squamoproliferative lesions. The American journal of surgical pathology, 29, 
792-796. 
GONZALEZ-MOLES, M., RUIZ-AVILA, I., GIL-MONTOYA, J., ESTEBAN, F. 
& BRAVO, M. 2010. Analysis of Ki-67 expression in oral squamous cell 
carcinoma: why Ki-67 is not a prognostic indicator. Oral oncology, 46, 525-
530. 
GONZÁLEZ-MOLES, M., SCULLY, C., RUIZ-ÁVILA, I. & PLAZA-
CAMPILLO, J. 2013. The cancer stem cell hypothesis applied to oral 
carcinoma. Oral oncology, 49, 738-746. 
GONZALEZ, M. A., TACHIBANA, K. E., LASKEY, R. A. & COLEMAN, N. 
2005. Control of DNA replication and its potential clinical exploitation. Nat 
Rev Cancer, 5, 135-41. 
GORDON, D. J., RESIO, B. & PELLMAN, D. 2012. Causes and 
consequences of aneuploidy in cancer. Nature Reviews Genetics, 13, 189-
203. 
GOUVÊA, A. F., SANTOS SILVA, A. R., SPEIGHT, P. M., HUNTER, K., 
CARLOS, R., VARGAS, P. A., ALMEIDA, O. P. & LOPES, M. A. 2013. High 
incidence of DNA ploidy abnormalities and increased Mcm2 expression may 
predict malignant change in oral proliferative verrucous leukoplakia. 
Histopathology, 62, 551-562. 
                                                                                                                   Chapter 8: References 
223 
 
GREAVES, M. & MALEY, C. C. 2012. Clonal evolution in cancer. Nature, 
481, 306-313. 
GSCHWENDTNER, A., FEND, F., HOFFMANN, Y., KRUGMANN, J., 
KLINGLER, P. & MAIRINGER, T. 1999. DNA‐ploidy analysis correlates with 
the histogenetic classification of thymic epithelial tumours. The Journal of 
pathology, 189, 576-580. 
GUEIROS, L. A., COLETTA, R. D., KOWALSKI, L. P. & LOPES, M. A. 
2011. Clinicopathological features and proliferation markers in tongue 
squamous cell carcinomas. Int J Oral Maxillofac Surg, 40, 510-5. 
GUO, J. & SUN, N. 2013. Cell cycle regulator geminin is dispensable for the 
proliferation of vascular smooth muscle cells. Science China Life Sciences, 
56, 731-738. 
GUZIŃSKA-USTYMOWICZ, K., PRYCZYNICZ, A., KEMONA, A. & 
CZYŻEWSKA, J. 2009. Correlation between proliferation markers: PCNA, 
Ki-67, MCM-2 and antiapoptotic protein Bcl-2 in colorectal cancer. 
Anticancer research, 29, 3049-3052. 
HALL, M. & PETERS, G. 1996. Genetic alterations of cyclins, cyclin-
dependent kinases, and Cdk inhibitors in human cancer. Advances in 
cancer research, 68, 67-108. 
HALLIGAN, S., ALTMAN, D. G. & MALLETT, S. 2015. Disadvantages of 
using the area under the receiver operating characteristic curve to assess 
imaging tests: A discussion and proposal for an alternative approach. 
European radiology, 1-8. 
HANAHAN, D. & WEINBERG, R. A. 2011. Hallmarks of cancer: the next 
generation. Cell, 144, 646-74. 
HANKEN, H., GRÖBE, A., CACHOVAN, G., SMEETS, R., SIMON, R., 
SAUTER, G., HEILAND, M. & BLESSMANN, M. 2014. CCND1 amplification 
and cyclin D1 immunohistochemical expression in head and neck 
squamous cell carcinomas. Clinical oral investigations, 18, 269-276. 
HANKS, S., COLEMAN, K., REID, S., PLAJA, A., FIRTH, H., 
FITZPATRICK, D., KIDD, A., MÉHES, K., NASH, R. & ROBIN, N. 2004. 
Constitutional aneuploidy and cancer predisposition caused by biallelic 
mutations in BUB1B. Nature genetics, 36, 1159-1161. 
HANSEMANN, D. 1890. Ueber asymmetrische Zelltheilung in 
Epithelkrebsen und deren biologische Bedeutung. Virchows Archiv, 119, 
299-326. 
HARADA, H., NAKAGAWA, K., IWATA, S., SAITO, M., KUMON, Y., 
SAKAKI, S., SATO, K. & HAMADA, K. 1999. Restoration of wild-type p16 
                                                                                                                   Chapter 8: References 
224 
 
down-regulates vascular endothelial growth factor expression and inhibits 
angiogenesis in human gliomas. Cancer research, 59, 3783-3789. 
HAROSKE, G., BAAK, J., DANIELSEN, H., GIROUD, F., 
GSCHWENDTNER, A., OBERHOLZER, M., REITH, A., SPIELER, P. & 
BÖCKING, A. 2001. Fourth updated ESACP consensus report on diagnostic 
DNA image cytometry. Analytical Cellular Pathology, 23, 89-95. 
HAROSKE, G., GIROUD, F., REITH, A. & BÖCKING, A. 1997. 1997 
ESACP consensus report on diagnostic DNA image cytometry. Part I: basic 
considerations and recommendations for preparation, measurement and 
interpretation. European Society for Analytical Cellular Pathology. Analytical 
cellular pathology: the journal of the European Society for Analytical Cellular 
Pathology, 17, 189-200. 
HARRISON, L. B., SESSIONS, R. B. & HONG, W. K. 2009. Head and neck 
cancer: a multidisciplinary approach, Lippincott Williams & Wilkins. 
HEMMER, J., THEIN, T. & VAN HEERDEN, W. F. 1997. The value of DNA 
flow cytometry in predicting the development of lymph node metastasis and 
survival in patients with locally recurrent oral squamous cell carcinoma. 
Cancer, 79, 2309-2313. 
HICKS, J., KRASNITZ, A., LAKSHMI, B., NAVIN, N. E., RIGGS, M., LEIBU, 
E., ESPOSITO, D., ALEXANDER, J., TROGE, J. & GRUBOR, V. 2006. 
Novel patterns of genome rearrangement and their association with survival 
in breast cancer. Genome research, 16, 1465-1479. 
HOCHEGGER, H., DEJSUPHONG, D., SONODA, E., SABERI, A., 
RAJENDRA, E., KIRK, J., HUNT, T. & TAKEDA, S. 2007. An essential role 
for Cdk1 in S phase control is revealed via chemical genetics in vertebrate 
cells. The Journal of cell biology, 178, 257-268. 
HOLLAND, A. J. & CLEVELAND, D. W. 2009. Boveri revisited: 
chromosomal instability, aneuploidy and tumorigenesis. Nature reviews 
Molecular cell biology, 10, 478-487. 
HOLLAND, A. J. & CLEVELAND, D. W. 2012. Losing balance: the origin 
and impact of aneuploidy in cancer. EMBO reports, 13, 501-514. 
HOOFNAGLE JR, R., KANDZARI, S. & LAMM, D. 1995. Deoxyribonucleic 
acid flow cytometry of squamous cell carcinoma of the penis. The West 
Virginia medical journal, 92, 271-273. 
HUANG, Q., YU, C., KLEIN, M., FANG, J. & GOYAL, R. K. 2005. DNA 
index determination with Automated Cellular Imaging System (ACIS) in 
Barrett's esophagus: comparison with CAS 200. BMC clinical pathology, 5, 
7. 
                                                                                                                   Chapter 8: References 
225 
 
HUANG, Q., YU, C., ZHANG, X. & GOYAL, R. K. 2008. Comparison of DNA 
histograms by standard flow cytometry and image cytometry on sections in 
Barrett's adenocarcinoma. BMC clinical pathology, 8, 5. 
HUANG, S.-F., CHENG, S.-D., CHUANG, W.-Y., CHEN, I.-H., LIAO, C.-T., 
WANG, H.-M. & HSIEH, L.-L. 2012. Cyclin D1 overexpression and poor 
clinical outcomes in Taiwanese oral cavity squamous cell carcinoma. World 
J Surg Oncol, 10, 40. 
HUANG, S. H., HWANG, D., LOCKWOOD, G., GOLDSTEIN, D. P. & 
O'SULLIVAN, B. 2009. Predictive value of tumor thickness for cervical 
lymph‐node involvement in squamous cell carcinoma of the oral cavity. 
Cancer, 115, 1489-1497. 
HUANG, X., GOLLIN, S. M., RAJA, S. & GODFREY, T. E. 2002. High-
resolution mapping of the 11q13 amplicon and identification of a gene, 
TAOS1, that is amplified and overexpressed in oral cancer cells. 
Proceedings of the National Academy of Sciences, 99, 11369-11374. 
HUNT, J. L., BARNES, L., LEWIS JR, J. S., MAHFOUZ, M. E., 
SLOOTWEG, P. J., THOMPSON, L. D., CARDESA, A., DEVANEY, K. O., 
GNEPP, D. R. & WESTRA, W. H. 2014. Molecular diagnostic alterations in 
squamous cell carcinoma of the head and neck and potential diagnostic 
applications. European Archives of Oto-Rhino-Laryngology, 271, 211-223. 
HUNTER, K., PARKINSON, E. K. & THAKKER, N. 2011. An overview of the 
molecular pathology of head and neck cancer, and its clinical implications. 
Periodontol 2000, 57, 132-49. 
HUNTER, K. D., PARKINSON, E. K. & HARRISON, P. R. 2005. Profiling 
early head and neck cancer. Nature Reviews Cancer, 5, 127-135. 
ILYAS, M., GRABSCH, H., ELLIS, I. O., WOMACK, C., BROWN, R., 
BERNEY, D., FENNELL, D., SALTO‐TELLEZ, M., JENKINS, M. & 
LANDBERG, G. 2013. Guidelines and considerations for conducting 
experiments using tissue microarrays. Histopathology, 62, 827-839. 
ISAYEVA, T., XU, J., RAGIN, C., DAI, Q., COOPER, T., CARROLL, W., 
DAYAN, D., VERED, M., WENIG, B. & ROSENTHAL, E. 2014. The 
protective effect of p16INK4a in oral cavity carcinomas: p16INK4a dampens 
tumor invasion—integrated analysis of expression and kinomics pathways. 
Modern pathology. 
ISHARWAL, S., MILLER, M. C., EPSTEIN, J. I., MANGOLD, L. A., 
HUMPHREYS, E., PARTIN, A. W. & VELTRI, R. W. 2008. Prognostic value 
of Her‐2/neu and DNA index for progression, metastasis and prostate 
cancer‐specific death in men with long‐term follow‐up after radical 
prostatectomy. International Journal of Cancer, 123, 2636-2643. 
                                                                                                                   Chapter 8: References 
226 
 
ISHIMI, Y., OKAYASU, I., KATO, C., KWON, H. J., KIMURA, H., YAMADA, 
K. & SONG, S. Y. 2003. Enhanced expression of Mcm proteins in cancer 
cells derived from uterine cervix. Eur J Biochem, 270, 1089-101. 
JACKSON, S. P. & BARTEK, J. 2009. The DNA-damage response in 
human biology and disease. Nature, 461, 1071-1078. 
JAHAN-TIGH, R. R., RYAN, C., OBERMOSER, G. & 
SCHWARZENBERGER, K. 2012. Flow cytometry. Journal of Investigative 
Dermatology, 132, e1. 
JAKOBSSON, P., ENEROTH, C., KILLANDER, D., MOBERGER, G. & 
MÅRTENSSON, B. 1973. Histologic classification and grading of 
malignancy in carcinoma of the larynx. Acta Oncologica, 12, 1-8. 
JALOULI, J., JALOULI, M. M., SAPKOTA, D., IBRAHIM, S. O., LARSSON, 
P.-A. & SAND, L. 2012. Human papilloma virus, herpes simplex virus and 
epstein barr virus in oral squamous cell carcinoma from eight different 
countries. Anticancer research, 32, 571-580. 
JANISSON‐DARGAUD, D., DURLACH, A., LORENZATO, M., GRANGE, F., 
BERNARD, P. & BIREMBAUT, P. 2008. Aneuploidy, but not Ki‐67 or EGFR 
expression, is associated with recurrences in basal cell carcinoma. Journal 
of cutaneous pathology, 35, 916-921. 
JAYASURYA, R., SATHYAN, K., LAKSHMINARAYANAN, K., ABRAHAM, 
T., NALINAKUMARI, K., ABRAHAM, E. K., NAIR, M. K. & KANNAN, S. 
2005. Phenotypic alterations in Rb pathway have more prognostic influence 
than p53 pathway proteins in oral carcinoma. Modern pathology, 18, 1056-
1066. 
JEMAL, A., BRAY, F., CENTER, M. M., FERLAY, J., WARD, E. & 
FORMAN, D. 2011. Global cancer statistics. CA Cancer J Clin, 61, 69-90. 
JIANG, Y., LI, X., YANG, W., HAWKE, D. H., ZHENG, Y., XIA, Y., ALDAPE, 
K., WEI, C., GUO, F. & CHEN, Y. 2014. PKM2 regulates chromosome 
segregation and mitosis progression of tumor cells. Molecular cell, 53, 75-
87. 
JIN, Y., XIONG, A., ZHANG, Z., LI, S., HUANG, H., YU, T.-T., CAO, X. & 
CHENG, S. Y. 2014. MicroRNA-31 suppresses medulloblastoma cell growth 
by inhibiting DNA replication through minichromosome maintenance 2. 
Oncotarget, 5, 4821. 
JOHNSON, N. W., WARNAKULASURIYA, S., GUPTA, P., DIMBA, E., 
CHINDIA, M., OTOH, E., SANKARANARAYANAN, R., CALIFANO, J. & 
KOWALSKI, L. 2011. Global oral health inequalities in incidence and 
outcomes for oral cancer causes and solutions. Advances in dental 
research, 23, 237-246. 
                                                                                                                   Chapter 8: References 
227 
 
JORDAN, R. C., LINGEN, M. W., PEREZ-ORDONEZ, B., HE, X., 
PICKARD, R., KOLUDER, M., JIANG, B., WAKELY, P., XIAO, W. & 
GILLISON, M. L. 2012. Validation of methods for oropharyngeal cancer 
HPV status determination in US cooperative group trials. The American 
journal of surgical pathology, 36, 945-954. 
JUNTTILA, M. R. & DE SAUVAGE, F. J. 2013. Influence of tumour micro-
environment heterogeneity on therapeutic response. Nature, 501, 346-354. 
KAMINAGAKURA, E., WERNECK DA CUNHA, I., SOARES, F. A., 
NISHIMOTO, I. N. & KOWALSKI, L. P. 2011. CCND1 amplification and 
protein overexpression in oral squamous cell carcinoma of young patients. 
Head Neck, 33, 1413-1419. 
KARIMI, S., MOHAMMADI, F., KHODADAD, K., EMAMI, H. & 
SEYFOLLAHI, L. 2008. High expression of minichromosome maintenance 
protein 6 in classic Hodgkin's lymphoma points to a cell cycle arrest in G1 
phase. Arch Iran Med, 11, 532-8. 
KARIMI, S. & SADR, M. 2011. Mini-Chromosome Maintenance Protein 
Family: Novel Proliferative Markers-The Pathophysiologic Role and Clinical 
Application. 
KARNANI, N., TAYLOR, C. M., MALHOTRA, A. & DUTTA, A. 2010. 
Genomic study of replication initiation in human chromosomes reveals the 
influence of transcription regulation and chromatin structure on origin 
selection. Mol Biol Cell, 21, 393-404. 
KARSAI, S., ABEL, U., ROESCH‐ELY, M., AFFOLTER, A., HOFELE, C., 
JOOS, S., PLINKERT, P. & BOSCH, F. 2007. Comparison of p16INK4a 
expression with p53 alterations in head and neck cancer by tissue 
microarray analysis. The Journal of pathology, 211, 314-322. 
KESSENBROCK, K., PLAKS, V. & WERB, Z. 2010. Matrix 
metalloproteinases: regulators of the tumor microenvironment. Cell, 141, 52-
67. 
KHAN, M., BUI, H., DEL ROSARIO, A., ABDULLA, M., BALLOUK, F., SIM, 
Y. & ROSS, J. 1994. Role of DNA content determination by image analysis 
in confirmation of dysplasia in Barrett's esophagus. Modern pathology: an 
official journal of the United States and Canadian Academy of Pathology, 
Inc, 7, 169-174. 
KIM, J. K. & DIEHL, J. A. 2009. Nuclear cyclin D1: an oncogenic driver in 
human cancer. Journal of cellular physiology, 220, 292-296. 
KIM, K. C., KOH, Y. W., CHANG, H.-M., KIM, T. H., YOOK, J. H., KIM, B. 
S., JANG, S. J. & PARK, Y. S. 2011. Evaluation of HER2 protein expression 
in gastric carcinomas: comparative analysis of 1414 cases of whole-tissue 
                                                                                                                   Chapter 8: References 
228 
 
sections and 595 cases of tissue microarrays. Annals of surgical oncology, 
18, 2833-2840. 
KINGSBURY, S. R., LODDO, M., FANSHAWE, T., OBERMANN, E. C., 
PREVOST, A. T., STOEBER, K. & WILLIAMS, G. H. 2005. Repression of 
DNA replication licensing in quiescence is independent of geminin and may 
define the cell cycle state of progenitor cells. Experimental cell research, 
309, 56-67. 
KLOTZ-NOACK, K., MCINTOSH, D., SCHURCH, N., PRATT, N. & BLOW, 
J. J. 2012. Re-replication induced by geminin depletion occurs from G2 and 
is enhanced by checkpoint activation. Journal of cell science, 125, 2436-
2445. 
KNAUSS, S. & KLEIN, A. 2012. From aneuploidy to cancer: The evolution 
of a new species? Journal of biosciences, 37, 211-220. 
KODANI, I., OSAKI, M., SHOMORI, K., ARAKI, K., GOTO, E., RYOKE, K. & 
ITO, H. 2003. Minichromosome maintenance 2 expression is correlated with 
mode of invasion and prognosis in oral squamous cell carcinomas. Journal 
of oral pathology & medicine, 32, 468-474. 
KOWALSKI, L. & SANABRIA, A. 2007. Elective neck dissection in oral 
carcinoma: a critical review of the evidence. Acta Otorhinolaryngologica 
Italica, 27, 113. 
KRISTENSEN, G., KILDAL, W., ABELER, V., KAERN, J., VERGOTE, I., 
TROPE, C. & DANIELSEN, H. 2003. Large-scale genomic instability 
predicts long-term outcome for women with invasive stage I ovarian cancer. 
Annals of oncology, 14, 1494-1500. 
KRÜGER, M., PABST, A., WALTER, C., SAGHEB, K., GÜNTHER, C., 
BLATT, S., WEISE, K., AL-NAWAS, B. & ZIEBART, T. 2014. The 
prevalence of human papilloma virus (HPV) infections in oral squamous cell 
carcinomas: A retrospective analysis of 88 patients and literature overview. 
Journal of Cranio-Maxillofacial Surgery, 42, 1506-1514. 
KUBBUTAT, M., KEY, G., DUCHROW, M., SCHLÜTER, C., FLAD, H. & 
GERDES, J. 1994. Epitope analysis of antibodies recognising the cell 
proliferation associated nuclear antigen previously defined by the antibody 
Ki-67 (Ki-67 protein). J Clin Pathol, 47, 524-528. 
KUIPERS, M. A., STASEVICH, T. J., SASAKI, T., WILSON, K. A., 
HAZELWOOD, K. L., MCNALLY, J. G., DAVIDSON, M. W. & GILBERT, D. 
M. 2011. Highly stable loading of Mcm proteins onto chromatin in living cells 
requires replication to unload. The Journal of cell biology, 192, 29-41. 
KUMAR, B., CORDELL, K. G., LEE, J. S., WORDEN, F. P., PRINCE, M. E., 
TRAN, H. H., WOLF, G. T., URBA, S. G., CHEPEHA, D. B. & TEKNOS, T. 
N. 2008. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as 
                                                                                                                   Chapter 8: References 
229 
 
indicators of response to therapy and survival in oropharyngeal cancer. 
Journal of clinical oncology, 26, 3128-3137. 
KUO, M. Y. P., LIN, C. Y., HAHN, L. J., CHENG, S. J. & CHIANG, C. P. 
1999. Expression of cyclin D1 is correlated with poor prognosis in patients 
with areaca quid chewing‐related oral squamous cell carcinomas in Tiwan. 
Journal of oral pathology & medicine, 28, 165-169. 
LA VECCHIA, C., BOSETTI, C., LUCCHINI, F., BERTUCCIO, P., NEGRI, 
E., BOYLE, P. & LEVI, F. 2009. Cancer mortality in Europe, 2000–2004, 
and an overview of trends since 1975. Annals of Oncology, mdp530. 
LABIB, K. 2010. How do Cdc7 and cyclin-dependent kinases trigger the 
initiation of chromosome replication in eukaryotic cells? Genes & 
development, 24, 1208-1219. 
LACO, J., VOSMIKOVA, H., NOVAKOVA, V., CELAKOVSKY, P., 
DOLEZALOVA, H., TUCEK, L., NEKVINDOVA, J., VOSMIK, M., 
CERMAKOVA, E. & RYSKA, A. 2011. The role of high-risk human 
papillomavirus infection in oral and oropharyngeal squamous cell carcinoma 
in non-smoking and non-drinking patients: a clinicopathological and 
molecular study of 46 cases. Virchows Archiv, 458, 179-187. 
LAM, K. Y., NG, I. O., YUEN, A. P., KWONG, D. L. & WEI, W. 2000. Cyclin 
D1 expression in oral squamous cell carcinomas: clinicopathological 
relevance and correlation with p53 expression. Journal of oral pathology & 
medicine, 29, 167-172. 
LANG, J., BORCHERS, J., DANAHEY, D., SMITH, S., STOVER, D., 
AGRAWAL, A., MALONE, J., SCHULLER, D., WEGHORST, C. & 
HOLINGA, A. 2002. Mutational status of overexpressed p16 in head and 
neck cancer: evidence for germline mutation of p16/p14ARF. International 
journal of oncology, 21, 401-408. 
LASSEN, P., ERIKSEN, J. G., HAMILTON-DUTOIT, S., TRAMM, T., 
ALSNER, J. & OVERGAARD, J. 2009. Effect of HPV-associated p16INK4A 
expression on response to radiotherapy and survival in squamous cell 
carcinoma of the head and neck. Journal of Clinical Oncology, 27, 1992-
1998. 
LEEMANS, C. R., BRAAKHUIS, B. J. & BRAKENHOFF, R. H. 2010. The 
molecular biology of head and neck cancer. Nature Reviews Cancer, 11, 9-
22. 
LEI, M. 2005. The MCM complex: its role in DNA replication and 
implications for cancer therapy. Current cancer drug targets, 5, 365-380. 
LENGAUER, C., KINZLER, K. W. & VOGELSTEIN, B. 1998. Genetic 
instabilities in human cancers. Nature, 396, 643-649. 
                                                                                                                   Chapter 8: References 
230 
 
LEVIDOU, G., VENTOURI, K., NONNI, A., GAKIOPOULOU, H., BAMIAS, 
A., SOTIROPOULOU, M., PAPASPIROU, I., DIMOPOULOS, M. A., 
PATSOURIS, E. & KORKOLOPOULOU, P. 2012. Replication protein A in 
nonearly ovarian adenocarcinomas: correlation with MCM-2, MCM-5, Ki-67 
index and prognostic significance. International Journal of Gynecologic 
Pathology, 31, 319-327. 
LEWIS, J. S., CHERNOCK, R. D., MA, X.-J., FLANAGAN, J. J., LUO, Y., 
GAO, G., WANG, X. & EL-MOFTY, S. K. 2012. Partial p16 staining in 
oropharyngeal squamous cell carcinoma: extent and pattern correlate with 
human papillomavirus RNA status. Modern Pathology, 25, 1212-1220. 
LI, A. & BLOW, J. J. 2005. Cdt1 downregulation by proteolysis and geminin 
inhibition prevents DNA re‐replication in Xenopus. The EMBO journal, 24, 
395-404. 
LI, X. & ROSENFELD, M. G. 2004. Transcription: origins of licensing 
control. Nature, 427, 687-688. 
LI, Z., WANG, C., JIAO, X., KATIYAR, S., CASIMIRO, M. C., 
PRENDERGAST, G. C., POWELL, M. J. & PESTELL, R. G. 2008. Alternate 
cyclin D1 mRNA splicing modulates p27KIP1 binding and cell migration. 
Journal of Biological Chemistry, 283, 7007-7015. 
LIAN, M., FANG, J., HAN, D., MA, H., FENG, L., WANG, R. & YANG, F. 
2013. Microarray gene expression analysis of tumorigenesis and regional 
lymph node metastasis in laryngeal squamous cell carcinoma. PloS one, 8, 
e84854. 
LINGEN, M. W., KALMAR, J. R., KARRISON, T. & SPEIGHT, P. M. 2008. 
Critical evaluation of diagnostic aids for the detection of oral cancer. Oral 
oncology, 44, 10-22. 
LINGEN, M. W., XIAO, W., SCHMITT, A., JIANG, B., PICKARD, R., 
KREINBRINK, P., PEREZ-ORDONEZ, B., JORDAN, R. C. & GILLISON, M. 
L. 2013. Low etiologic fraction for high-risk human papillomavirus in oral 
cavity squamous cell carcinomas. Oral oncology, 49, 1-8. 
LIPPITZ, B. E. 2013. Cytokine patterns in patients with cancer: a systematic 
review. Lancet Oncol, 14, e218-28. 
LIU, Y., HE, G., WANG, Y., GUAN, X., PANG, X. & ZHANG, B. 2013. MCM-
2 is a therapeutic target of Trichostatin A in colon cancer cells. Toxicology 
letters, 221, 23-30. 
LOEB, K. R. & LOEB, L. A. 2000. Significance of multiple mutations in 
cancer. Carcinogenesis, 21, 379-385. 
                                                                                                                   Chapter 8: References 
231 
 
MACHIDA, Y. J. & DUTTA, A. 2005. Cellular checkpoint mechanisms 
monitoring proper initiation of DNA replication. Journal of Biological 
Chemistry, 280, 6253-6256. 
MAGATTI, M., MUNARI, S., VERTUA, E. & PAROLINI, O. 2012. Amniotic 
membrane‐derived cells inhibit proliferation of cancer cell lines by inducing 
cell cycle arrest. Journal of cellular and molecular medicine, 16, 2208-2218. 
MAHLER, M., MIYACHI, K., PEEBLES, C. & FRITZLER, M. J. 2012. The 
clinical significance of autoantibodies to the proliferating cell nuclear antigen 
(PCNA). Autoimmunity reviews, 11, 771-775. 
MAIORANO, D., LUTZMANN, M. & MECHALI, M. 2006. MCM proteins and 
DNA replication. Curr Opin Cell Biol, 18, 130-6. 
MAJCHRZAK, E., SZYBIAK, B., WEGNER, A., PIENKOWSKI, P., 
PAZDROWSKI, J., LUCZEWSKI, L., SOWKA, M., GOLUSINSKI, P., 
MALICKI, J. & GOLUSINSKI, W. 2014. Oral cavity and oropharyngeal 
squamous cell carcinoma in young adults: a review of the literature. Radiol 
Oncol, 48, 1-10. 
MALUMBRES, M. & BARBACID, M. 2009. Cell cycle, CDKs and cancer: a 
changing paradigm. Nature Reviews Cancer, 9, 153-166. 
MARIATOS, G., GORGOULIS, V. G., ZACHARATOS, P., KOTSINAS, A., 
VOGIATZI, T., RASSIDAKIS, G., FOUKAS, P., LILOGLOU, T., TINIAKOS, 
D. & ANGELOU, N. 2000. Expression of p16INK4A and alterations of the 
9p21‐23 chromosome region in non‐small‐cell lung carcinomas: 
Relationship with tumor growth parameters and ploidy status. International 
journal of cancer, 89, 133-141. 
MARTE, B. 2013. Tumour heterogeneity. Nature, 501, 327-327. 
MARUR, S., D'SOUZA, G., WESTRA, W. H. & FORASTIERE, A. A. 2010. 
HPV-associated head and neck cancer: a virus-related cancer epidemic. 
The lancet oncology, 11, 781-789. 
MARUR, S. & FORASTIERE, A. A. 2008. Head and neck cancer: changing 
epidemiology, diagnosis, and treatment. Mayo Clin Proc, 83, 489-501. 
MARUSYK, A. & POLYAK, K. 2010. Tumor heterogeneity: causes and 
consequences. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 
1805, 105-117. 
MASCOLO, M., SIANO, M., ILARDI, G., RUSSO, D., MEROLLA, F., ROSA, 
G. D. & STAIBANO, S. 2012. Epigenetic disregulation in oral cancer. 
International journal of molecular sciences, 13, 2331-2353. 
MASSANO, J., REGATEIRO, F. S., JANUÁRIO, G. & FERREIRA, A. 2006. 
Oral squamous cell carcinoma: review of prognostic and predictive factors. 
                                                                                                                   Chapter 8: References 
232 
 
Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and 
Endodontology, 102, 67-76. 
MASSIMO, O. 2013. The Prognostic Value of DNA Ploidy Determination in 
Endometrial Cancer. Journal of Clinical & Experimental Oncology. 
MCCLELLAND, S. E., BURRELL, R. A. & SWANTON, C. 2009. 
Chromosomal instability: a composite phenotype that influences sensitivity 
to chemotherapy. Cell Cycle, 8, 3262-3266. 
MCGARRY, T. J. & KIRSCHNER, M. W. 1998. Geminin, an inhibitor of DNA 
replication, is degraded during mitosis. Cell, 93, 1043-1053. 
MEHANNA, H., PALERI, V., WEST, C. M. & NUTTING, C. 2010. Head and 
neck cancer--Part 1: Epidemiology, presentation, and prevention. BMJ, 341, 
c4684. 
MELIXETIAN, M., BALLABENI, A., MASIERO, L., GASPARINI, P., 
ZAMPONI, R., BARTEK, J., LUKAS, J. & HELIN, K. 2004. Loss of Geminin 
induces rereplication in the presence of functional p53. The Journal of cell 
biology, 165, 473-482. 
MENG, Z., SHI, J., ZHU, C., GU, J. & ZHOU, C. 2013. Automated 
quantification of DNA aneuploidy by image cytometry as an adjunct for the 
cytologic diagnosis of malignant effusion. Analytical Cellular Pathology, 36, 
107-115. 
MICHOR, F., IWASA, Y., VOGELSTEIN, B., LENGAUER, C. & NOWAK, M. 
A. Can chromosomal instability initiate tumorigenesis?  Seminars in cancer 
biology, 2005. Elsevier, 43-49. 
MISHRA, R. 2010. Glycogen synthase kinase 3 beta: can it be a target for 
oral cancer. Molecular cancer, 9, 144. 
MITSUDOMI, T. & YATABE, Y. 2010. Epidermal growth factor receptor in 
relation to tumor development: EGFR gene and cancer. FEBS journal, 277, 
301-308. 
MIYAMOTO, R., UZAWA, N., NAGAOKA, S., HIRATA, Y. & AMAGASA, T. 
2003. Prognostic significance of cyclin D1 amplification and overexpression 
in oral squamous cell carcinomas. Oral oncology, 39, 610-618. 
MONTEBUGNOLI, L., CERVELLATI, F., COCCHI, R., FARNEDI, A., 
PENNESI, M. G., FLAMMINIO, F. & FOSCHINI, M. P. 2010. 
Immunohistochemical expression of p16INK4A protein as a helpful marker 
of a subset of potentially malignant oral epithelial lesions: study on a series 
with long‐term follow‐up. Histopathology, 57, 528-534. 
MOODY, C. A. & LAIMINS, L. A. 2010. Human papillomavirus oncoproteins: 
pathways to transformation. Nature Reviews Cancer, 10, 550-560. 
                                                                                                                   Chapter 8: References 
233 
 
MORAES, M. D., MAIA, C. A. D. M., ALMEIDA FREITAS, R. D. & GALVAO, 
H. C. 2012. Cell proliferation markers in oral squamous cell carcinoma. 
Journal of Molecular Biomarkers & Diagnosis. 
MOYER, S. E., LEWIS, P. W. & BOTCHAN, M. R. 2006. Isolation of the 
Cdc45/Mcm2–7/GINS (CMG) complex, a candidate for the eukaryotic DNA 
replication fork helicase. Proceedings of the National Academy of Sciences, 
103, 10236-10241. 
MUTTAGI, S. S., CHATURVEDI, P., GAIKWAD, R., SINGH, B. & PAWAR, 
P. 2012. Head and neck squamous cell carcinoma in chronic areca nut 
chewing Indian women: Case series and review of literature. Indian J Med 
Paediatr Oncol, 33, 32-5. 
MYOUNG, H., KIM, M.-J., LEE, J.-H., OK, Y.-J., PAENG, J.-Y. & YUN, P.-Y. 
2006. Correlation of proliferative markers (Ki-67 and PCNA) with survival 
and lymph node metastasis in oral squamous cell carcinoma: a clinical and 
histopathological analysis of 113 patients. International journal of oral and 
maxillofacial surgery, 35, 1005-1010. 
MYSTER, D. L. & DURONIO, R. J. 2000. Cell cycle: To differentiate or not 
to differentiate? Current Biology, 10, R302-R304. 
NADERI, N. J., TIRGARI, F., KHARAZIFARD, M. J. & PARSA, F. F. 2014. A 
study on the relationship between clinical features with Ki67 expression and 
eosinophil cells infiltration in oral squamous cell carcinoma. Medical journal 
of the Islamic Republic of Iran, 28, 115. 
NAKUCI, E., XU, M., PUJANA, M. A., VALLS, J. & ELSHAMY, W. M. 2006. 
Geminin is bound to chromatin in G2/M phase to promote proper 
cytokinesis. The international journal of biochemistry & cell biology, 38, 
1207-1220. 
NANKIVELL, P., WILLIAMS, H., WEBSTER, K., PEARSON, D., HIGH, A., 
MACLENNAN, K., SENGUVEN, B., MCCONKEY, C., RABBITTS, P. & 
MEHANNA, H. 2014. Investigation of p16INK4a as a prognostic biomarker 
in oral epithelial dysplasia. Journal of Oral Pathology & Medicine, 43, 245-
249. 
NAPIER, S. S. & SPEIGHT, P. M. 2008. Natural history of potentially 
malignant oral lesions and conditions: an overview of the literature. Journal 
of oral pathology & medicine, 37, 1-10. 
NASSER, W., FLECHTENMACHER, C., HOLZINGER, D., HOFELE, C. & 
BOSCH, F. X. 2011. Aberrant expression of p53, p16INK4a and Ki‐67 as 
basic biomarker for malignant progression of oral leukoplakias. Journal of 
Oral Pathology & Medicine, 40, 629-635. 
                                                                                                                   Chapter 8: References 
234 
 
NATIONAL CANCER INSTITUTE OF U.S.A. 2014. National Cancer 
Institute. Available: http://www.cancer.gov/cancertopics/types/oral 
[Accessed Nov 2014]. 
NEMES, J. A., DELI, L., NEMES, Z. & MÁRTON, I. J. 2006. Expression of 
p16 INK4A, p53, and Rb proteins are independent from the presence of 
human papillomavirus genes in oral squamous cell carcinoma. Oral 
Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and 
Endodontology, 102, 344-352. 
NEVILLE, B. W., DAMM, D. D., ALLEN, C. M. & BOUQUOT, J. E. 2009. 
Oral and maxillofacial pathology, Sunders, an imprint of Elsevier Inc. 
NEWLON, C. S. 1997. Putting it all together: building a prereplicative 
complex. Cell, 91, 717-720. 
NIEDUSZYNSKI, C. A., KNOX, Y. & DONALDSON, A. D. 2006. Genome-
wide identification of replication origins in yeast by comparative genomics. 
Genes & development, 20, 1874-1879. 
NIGG, E. A. 2002. Centrosome aberrations: cause or consequence of 
cancer progression? Nature Reviews Cancer, 2, 815-825. 
NIGG, E. A. 2006. Origins and consequences of centrosome aberrations in 
human cancers. International journal of cancer, 119, 2717-2723. 
NISHITANI, H. & LYGEROU, Z. 2002. Control of DNA replication licensing 
in a cell cycle. Genes to Cells, 7, 523-534. 
NISHITANI, H., LYGEROU, Z. & NISHIMOTO, T. 2004. Proteolysis of DNA 
replication licensing factor Cdt1 in S-phase is performed independently of 
geminin through its N-terminal region. Journal of Biological Chemistry, 279, 
30807-30816. 
NOGUTI, J., DE MOURA, C. F. G., DE JESUS, G. P. P., DA SILVA, V. H. 
P., HOSSAKA, T. A., OSHIMA, C. T. F. & RIBEIRO, D. A. 2012. Metastasis 
from oral cancer: an overview. Cancer Genomics-Proteomics, 9, 329-335. 
NORMANNO, N., DE LUCA, A., BIANCO, C., STRIZZI, L., MANCINO, M., 
MAIELLO, M. R., CAROTENUTO, A., DE FEO, G., CAPONIGRO, F. & 
SALOMON, D. S. 2006. Epidermal growth factor receptor (EGFR) signaling 
in cancer. Gene, 366, 2-16. 
OHTA, S., UEMURA, H., MATSUI, Y., ISHIGURO, H., FUJINAMI, K., 
KONDO, K., MIYAMOTO, H., YAZAWA, T., DANENBERG, K. & 
DANENBERG, P. V. 2009. Alterations of p16 and p14ARF genes and their 
9p21 locus in oral squamous cell carcinoma. Oral Surgery, Oral Medicine, 
Oral Pathology, Oral Radiology, and Endodontology, 107, 81-91. 
OKAMOTO, M., NISHIMINE, M., KISHI, M., KIRITA, T., SUGIMURA, M., 
NAKAMURA, M. & KONISHI, N. 2002. Prediction of delayed neck 
                                                                                                                   Chapter 8: References 
235 
 
metastasis in patients with stage I/II squamous cell carcinoma of the tongue. 
Journal of oral pathology & medicine, 31, 227-233. 
OLIVEIRA, L. & RIBEIRO-SILVA, A. 2011. Prognostic significance of 
immunohistochemical biomarkers in oral squamous cell carcinoma. 
International journal of oral and maxillofacial surgery, 40, 298-307. 
OLSON, E. N. 1992. Interplay between proliferation and differentiation 
within the myogenic lineage. Developmental biology, 154, 261-272. 
PADILLA-NASH, H. M., MCNEIL, N. E., YI, M., NGUYEN, Q.-T., HU, Y., 
WANGSA, D., MACK, D. L., HUMMON, A. B., CASE, C. & CARDIN, E. 
2013. Aneuploidy, oncogene amplification and epithelial to mesenchymal 
transition define spontaneous transformation of murine epithelial cells. 
Carcinogenesis, 34, 1929-1939. 
PALMEIRA, C., OLIVEIRA, P. A., LAMEIRAS, C., AMARO, T., SILVA, V. 
M., LOPES, C. & SANTOS, L. 2010. Biological similarities between murine 
chemical-induced and natural human bladder carcinogenesis. Oncology 
letters, 1, 373-377. 
PANDE, P., MATHUR, M., SHUKLA, N. & RALHAN, R. 1998. pRb and p16 
protein alterations in human oral tumorigenesis. Oral oncology, 34, 396-403. 
PANIGRAHI, A. K. & PATI, D. 2009. Road to the crossroads of life and 
death: Linking sister chromatid cohesion and separation to aneuploidy, 
apoptosis and cancer. Critical reviews in oncology/hematology, 72, 181-193. 
PARK, D., KÅRESEN, R., NOREN, T. & SAUER, T. 2007. Ki-67 expression 
in primary breast carcinomas and their axillary lymph node metastases: 
clinical implications. Virchows Archiv, 451, 11-18. 
PATHAK, S. & MULTANI, A. S. 2006. Aneuploidy, stem cells and cancer. 
Cancer: Cell Structures, Carcinogens and Genomic Instability. Springer. 
PEKTAȘ, Z. Ö., KESKIN, A., GÜNHAN, Ö. & KARSLIOĞLU, Y. 2006. 
Evaluation of nuclear morphometry and DNA ploidy status for detection of 
malignant and premalignant oral lesions: quantitative cytologic assessment 
and review of methods for cytomorphometric measurements. Journal of oral 
and maxillofacial surgery, 64, 628-635. 
PENTENERO, M., GIARETTI, W., NAVONE, R., DEMURTAS, A., 
ROSTAN, I., BERTOLUSSO, G., BROCCOLETTI, R., ARDUINO, P. G., 
MALACARNE, D. & GANDOLFO, S. 2009. DNA aneuploidy and dysplasia 
in oral potentially malignant disorders: association with cigarette smoking 
and site. Oral oncology, 45, 887-890. 
PÉREZ-SAYÁNS, M., SUÁREZ-PEÑARANDA, J. M., GAYOSO-DIZ, P., 
BARROS-ANGUEIRA, F., GÁNDARA-REY, J. M. & GARCÍA-GARCÍA, A. 
2011. p16 INK4a/CDKN2 expression and its relationship with oral 
                                                                                                                   Chapter 8: References 
236 
 
squamous cell carcinoma is our current knowledge enough? Cancer letters, 
306, 134-141. 
PESTELL, R. G. 2013. New roles of cyclin D1. The American journal of 
pathology, 183, 3-9. 
PIETSCH, E. C. & MURPHY, M. E. 2008. Low risk HPV-E6 traps p53 in the 
cytoplasm and induces p53-dependent apoptosis. Cancer Biol Ther, 7, 
1916-8. 
PIHAN, G. A. & DOXSEY, S. J. The mitotic machinery as a source of 
genetic instability in cancer.  Seminars in cancer biology, 1999. Elsevier, 
289-302. 
PITIYAGE, G., TILAKARATNE, W., TAVASSOLI, M. & 
WARNAKULASURIYA, S. 2009. Molecular markers in oral epithelial 
dysplasia: review. Journal of oral pathology & medicine, 38, 737-752. 
QUAGLIA, A., MCSTAY, M., STOEBER, K., LODDO, M., CAPLIN, M., 
FANSHAWE, T., WILLIAMS, G. & DHILLON, A. 2006. Novel markers of cell 
kinetics to evaluate progression from cirrhosis to hepatocellular carcinoma. 
Liver International, 26, 424-432. 
QUEIROZ, A. B., FOCCHI, G., DOBO, C., GOMES, T. S., RIBEIRO, D. A. & 
OSHIMA, C. T. 2010. Expression of P27, P21WAF/Cip1, and P16INK4a in 
normal oral epithelium, oral squamous papilloma, and oral squamous cell 
carcinoma. Anticancer research, 30, 2799-2803. 
REED, A. L., CALIFANO, J., CAIRNS, P., WESTRA, W. H., JONES, R. M., 
KOCH, W., AHRENDT, S., EBY, Y., SEWELL, D. & NAWROZ, H. 1996. 
High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck 
squamous cell carcinoma. Cancer Research, 56, 3630-3633. 
REMUS, D. & DIFFLEY, J. F. 2009. Eukaryotic DNA replication control: lock 
and load, then fire. Current opinion in cell biology, 21, 771-777. 
REUSCHENBACH, M., KANSY, K., GARBE, K., VINOKUROVA, S., 
FLECHTENMACHER, C., TOTH, C., PRIGGE, E.-S., THIELE, O. C., 
REINERT, S. & HOFFMANN, J. 2013. Lack of evidence of human 
papillomavirus-induced squamous cell carcinomas of the oral cavity in 
southern Germany. Oral oncology, 49, 937-942. 
RICKE, R. M., VAN REE, J. H. & VAN DEURSEN, J. M. 2008. Whole 
chromosome instability and cancer: a complex relationship. Trends Genet, 
24, 457-66. 
ROMAGOSA, C., SIMONETTI, S., LOPEZ-VICENTE, L., MAZO, A., 
LLEONART, M., CASTELLVI, J. & Y CAJAL, S. R. 2011. p16Ink4a 
overexpression in cancer: a tumor suppressor gene associated with 
senescence and high-grade tumors. Oncogene, 30, 2087-2097. 
                                                                                                                   Chapter 8: References 
237 
 
RYGIEL, A. M., MILANO, F., TEN KATE, F. J., DE GROOT, J. G., 
PEPPELENBOSCH, M. P., BERGMAN, J. J. & KRISHNADATH, K. K. 2008. 
Assessment of chromosomal gains as compared to DNA content changes is 
more useful to detect dysplasia in Barrett's esophagus brush cytology 
specimens. Genes, Chromosomes and Cancer, 47, 396-404. 
SAEB-PARSY, K., WILSON, A., SCARPINI, C., CORCORAN, M., 
CHILCOTT, S., MCKEAN, M., THOTTAKAM, B., RAI, B., NABI, G. & RANA, 
D. 2012. Diagnosis of bladder cancer by immunocytochemical detection of 
minichromosome maintenance protein-2 in cells retrieved from urine. British 
journal of cancer, 107, 1384-1391. 
SAILASREE, R., ABHILASH, A., SATHYAN, K., NALINAKUMARI, K., 
THOMAS, S. & KANNAN, S. 2008. Differential roles of p16INK4A and 
p14ARF genes in prognosis of oral carcinoma. Cancer Epidemiology 
Biomarkers & Prevention, 17, 414-420. 
SAIZ-BUSTILLO, R., CORCHERO-MARTIN, G., GARCIA-MONTESINOS-
PEREA, B., GONZALEZ-TERAN, T. & SANCHEZ-SANTOLINO, S. 2005. 
Oral squamous cell carcinoma. Cytometric parameters of prognostic 
interest. Med Oral Patol Oral Cir Bucal, 10, 462-7. 
SALAHSHOURIFAR, I., VINCENT-CHONG, V. K., KALLARAKKAL, T. G. & 
ZAIN, R. B. 2014. Genomic DNA copy number alterations from precursor 
oral lesions to oral squamous cell carcinoma. Oral oncology, 50, 404-412. 
SAMEL, S. A., FERNÁNDEZ-CID, A., SUN, J., RIERA, A., TOGNETTI, S., 
HERRERA, M. C., LI, H. & SPECK, C. 2014. A unique DNA entry gate 
serves for regulated loading of the eukaryotic replicative helicase MCM2-7 
onto DNA. Genes Dev, 28, 1653-66. 
SAMMAN, M., WOOD, H., CONWAY, C., BERRI, S., PENTENERO, M., 
GANDOLFO, S., CASSENTI, A., CASSONI, P., AL AJLAN, A. & BARRETT, 
A. W. 2014. Next-generation sequencing analysis for detecting human 
papillomavirus in oral verrucous carcinoma. Oral surgery, oral medicine, oral 
pathology and oral radiology, 118, 117-125. e1. 
SANTOS‐SILVA, A. R., RIBEIRO, A. C. P., SOUBHIA, A. M. P., 
MIYAHARA, G. I., CARLOS, R., SPEIGHT, P. M., HUNTER, K. D., 
TORRES‐RENDON, A., VARGAS, P. A. & LOPES, M. A. 2011. High 
incidences of DNA ploidy abnormalities in tongue squamous cell carcinoma 
of young patients: an international collaborative study. Histopathology, 58, 
1127-1135. 
SCHNEIDER, M. R. & WOLF, E. 2009. The epidermal growth factor 
receptor ligands at a glance. Journal of cellular physiology, 218, 460-466. 
SCHOLZEN, T. & GERDES, J. 2000. The Ki-67 protein: from the known and 
the unknown. Journal of cellular physiology, 311-22. 
                                                                                                                   Chapter 8: References 
238 
 
SCHVARTZMAN, J.-M., SOTILLO, R. & BENEZRA, R. 2010. Mitotic 
chromosomal instability and cancer: mouse modelling of the human 
disease. Nature Reviews Cancer, 10, 102-115. 
SCOTT, I., ODELL, E., CHATRATH, P., MORRIS, L., DAVIES, R., 
VOWLER, S., LASKEY, R. & COLEMAN, N. 2006. A minimally invasive 
immunocytochemical approach to early detection of oral squamous cell 
carcinoma and dysplasia. Br J Cancer, 94, 1170-1175. 
SCULLY, C. & BAGAN, J. 2009a. Oral squamous cell carcinoma overview. 
Oral Oncol, 45, 301-8. 
SCULLY, C. & BAGAN, J. 2009b. Oral squamous cell carcinoma: overview 
of current understanding of aetiopathogenesis and clinical implications. Oral 
Dis, 15, 388-99. 
SEETHALAKSHMI, C. 2013. Early Detection of Oral Squamous Cell 
Carcinoma (OSCC)–Role of Genetics: A Literature Review. Journal of 
clinical and diagnostic research: JCDR, 7, 1824. 
SEIWERT, T. Y. 2014. Ties That Bind: p16 As a Prognostic Biomarker and 
the Need for High-Accuracy Human Papillomavirus Testing. Journal of 
Clinical Oncology, JCO. 2014.57. 9268. 
SEN, S. 2000. Aneuploidy and cancer. Current opinion in oncology, 12, 82-
88. 
SENDEROWICZ, A. M. 2004. Targeting cell cycle and apoptosis for the 
treatment of human malignancies. Current opinion in cell biology, 16, 670-
678. 
SEO, S. & KROLL, K. L. 2006. Geminin's double life: chromatin connections 
that regulate transcription at the transition from proliferation to 
differentiation. Cell Cycle, 5, 374-379. 
SHACKNEY, S. E., SMITH, C. A., MILLER, B. W., BURHOLT, D. R., 
MURTHA, K., GILES, H. R., KETTERER, D. M. & POLLICE, A. A. 1989. 
Model for the genetic evolution of human solid tumors. Cancer research, 49, 
3344-3354. 
SHAH, J. P. & GIL, Z. 2009. Current concepts in management of oral 
cancer--surgery. Oral Oncol, 45, 394-401. 
SHAH, N. G., TRIVEDI, T. I., TANKSHALI, R. A., GOSWAMI, J. V., JETLY, 
D. H., SHUKLA, S. N., SHAH, P. M. & VERMA, R. J. 2009. Prognostic 
significance of molecular markers in oral squamous cell carcinoma: a 
multivariate analysis. Head & neck, 31, 1544-1556. 
SHAHNAVAZ, S., REGEZI, J., BRADLEY, G., DUBE, I. & JORDAN, R. 
2000. p53 gene mutations in sequential oral epithelial dysplasias and 
squamous cell carcinomas. The Journal of pathology, 190, 417-422. 
                                                                                                                   Chapter 8: References 
239 
 
SHALASH, H. N., DRAZ, A. I., EL-ROUBY, D. H. & MORSY, R. A. 2012. 
Immunohistochemical Evaluation of The Proliferation Marker Mcm-2 In Oral 
Squamous Cell Carcinoma. Australian Journal of Basic & Applied Sciences, 
6. 
SHERIN, N., SIMI, T., SHAMEENA, P. & SUDHA, S. 2008. Changing trends 
in oral cancer. Indian journal of cancer, 45, 93. 
SHETTY, A., LODDO, M., FANSHAWE, T., PREVOST, A., SAINSBURY, 
R., WILLIAMS, G. & STOEBER, K. 2005. DNA replication licensing and cell 
cycle kinetics of normal and neoplastic breast. British journal of cancer, 93, 
1295-1300. 
SHEU, J. J.-C., HUA, C.-H., WAN, L., LIN, Y.-J., LAI, M.-T., TSENG, H.-C., 
JINAWATH, N., TSAI, M.-H., CHANG, N.-W. & LIN, C.-F. 2009. Functional 
genomic analysis identified epidermal growth factor receptor activation as 
the most common genetic event in oral squamous cell carcinoma. Cancer 
research, 69, 2568-2576. 
SHINTANI, S., MIHARA, M., NAKAHARA, Y., KIYOTA, A., UEYAMA, Y., 
MATSUMURA, T. & WONG, D. T. 2002. Expression of cell cycle control 
proteins in normal epithelium, premalignant and malignant lesions of oral 
cavity. Oral oncology, 38, 235-243. 
SHOMORI, K., NISHIHARA, K., TAMURA, T., TATEBE, S., HORIE, Y., 
NOSAKA, K., HARUKI, T., HAMAMOTO, Y., SHIOMI, T. & NAKABAYASHI, 
M. 2010. Geminin, Ki67, and minichromosome maintenance 2 in gastric 
hyperplastic polyps, adenomas, and intestinal-type carcinomas: 
pathobiological significance. Gastric Cancer, 13, 177-185. 
SHREERAM, S. & BLOW, J. J. 2003. The role of the replication licensing 
system in cell proliferation and cancer. Progress in cell cycle research, 5, 
287. 
SINGHI, A. D. & WESTRA, W. H. 2010. Comparison of human 
papillomavirus in situ hybridization and p16 immunohistochemistry in the 
detection of human papillomavirus‐associated head and neck cancer based 
on a prospective clinical experience. Cancer, 116, 2166-2173. 
SINICROPE, F. A., REGO, R. L., HALLING, K. C., FOSTER, N., 
SARGENT, D. J., LA PLANT, B., FRENCH, A. J., LAURIE, J. A., 
GOLDBERG, R. M. & THIBODEAU, S. N. 2006. Prognostic impact of 
microsatellite instability and DNA ploidy in human colon carcinoma patients. 
Gastroenterology, 131, 729-737. 
SIPOS, F., CONSTANTINOVITS, M. & MŰZES, G. 2014. Intratumoral 
functional heterogeneity and chemotherapy. World journal of 
gastroenterology: WJG, 20, 2429. 
                                                                                                                   Chapter 8: References 
240 
 
SMITH, J., THO, L. M., XU, N. & GILLESPIE, D. A. 2010. The ATM-Chk2 
and ATR-Chk1 pathways in DNA damage signaling and cancer. Advances 
in cancer research, 73-112. 
SNAPE, K., HANKS, S., RUARK, E., BARROS-NÚÑEZ, P., ELLIOTT, A., 
MURRAY, A., LANE, A. H., SHANNON, N., CALLIER, P. & CHITAYAT, D. 
2011. Mutations in CEP57 cause mosaic variegated aneuploidy syndrome. 
Nature genetics, 43, 527-529. 
SOARES, A. B., ALTEMANI, A. & DE ARAUJO, V. C. 2011. Study of 
histopathological, morphological and immunohistochemical features of 
recurrent pleomorphic adenoma: an attempt to predict recurrence of 
pleomorphic adenoma. Journal of Oral Pathology & Medicine, 40, 352-358. 
SOBIN, L. & WITTEKIND, C. 2002. International Union Against Cancer 
(UICC). TNM Classification of Malignant Tumours, New York, John Wiley & 
Sons. 
SOBIN, L. H., GOSPODAROWICZ, M. K. & WITTEKIND, C. 2011. TNM 
classification of malignant tumours, John Wiley & Sons. 
SOLOMON, D. A., KIM, T., DIAZ-MARTINEZ, L. A., FAIR, J., ELKAHLOUN, 
A. G., HARRIS, B. T., TORETSKY, J. A., ROSENBERG, S. A., SHUKLA, N. 
& LADANYI, M. 2011. Mutational inactivation of STAG2 causes aneuploidy 
in human cancer. Science, 333, 1039-1043. 
SPEIGHT, P. M., FARTHING, P. M. & BOUQUOT, J. E. 1996. The 
pathology of oral cancer and precancer. Current Diagnostic Pathology, 3, 
165-176. 
SQUIER, C. A., NEWELL, W. J. & ROSAMUND, M. H. 1976. Human oral 
mucosa Oxford Blackwell scientific  
STADLER, M. E., PATEL, M. R., COUCH, M. E. & HAYES, D. N. 2008. 
Molecular biology of head and neck cancer: risks and pathways. Hematol 
Oncol Clin North Am, 22, 1099-124, vii. 
STOEBER, K., TLSTY, T. D., HAPPERFIELD, L., THOMAS, G. A., 
ROMANOV, S., BOBROW, L., WILLIAMS, E. D. & WILLIAMS, G. H. 2001. 
DNA replication licensing and human cell proliferation. Journal of cell 
science, 114, 2027-2041. 
SU, P.-F., HUANG, W.-L., WU, H.-T., WU, C.-H., LIU, T.-Y. & KAO, S.-Y. 
2010. P16INK4A promoter hypermethylation is associated with invasiveness 
and prognosis of oral squamous cell carcinoma in an age-dependent 
manner. Oral oncology, 46, 734-739. 
SUDBØ, J., KILDAL, W., RISBERG, B., KOPPANG, H. S., DANIELSEN, H. 
E. & REITH, A. 2001. DNA content as a prognostic marker in patients with 
oral leukoplakia. New England Journal of Medicine, 344, 1270-1278. 
                                                                                                                   Chapter 8: References 
241 
 
SUDBØ, J., LIPPMAN, S. M., LEE, J. J., MAO, L., KILDAL, W., SUDBØ, A., 
SAGEN, S., BRYNE, M., EL-NAGGAR, A. & RISBERG, B. 2004. The 
influence of resection and aneuploidy on mortality in oral leukoplakia. New 
England Journal of Medicine, 350, 1405-1413. 
SUDBØ, J. & REITH, A. 2005. Retracted: The evolution of predictive 
oncology and molecular‐based therapy for oral cancer prevention. 
International journal of cancer, 115, 339-345. 
SUN, J. & KONG, D. 2010. DNA replication origins, ORC/DNA interaction, 
and assembly of pre-replication complex in eukaryotes. Acta Biochim 
Biophys Sin (Shanghai), 42, 433-9. 
SUZUKI, H., SUGIMURA, H. & HASHIMOTO, K. 2006. p16 INK4A in Oral 
Squamous Cell Carcinomas—A Correlation With Biological Behaviors: 
Immunohistochemical and FISH Analysis. Journal of oral and maxillofacial 
surgery, 64, 1617-1623. 
SWAMINATHAN, U., JOSHUA, E., RAO, U. K. & RANGANATHAN, K. 
2012. Expression of p53 and Cyclin D1 in oral squamous cell carcinoma 
and normal mucosa: An Immunohistochemical study. Journal of oral and 
maxillofacial pathology: JOMFP, 16, 172. 
SWANTON, C., NICKE, B., SCHUETT, M., EKLUND, A. C., NG, C., LI, Q., 
HARDCASTLE, T., LEE, A., ROY, R. & EAST, P. 2009. Chromosomal 
instability determines taxane response. Proceedings of the National 
Academy of Sciences, 106, 8671-8676. 
SYMEONIDOU, I.-E., TARAVIRAS, S. & LYGEROU, Z. 2012. Control over 
DNA replication in time and space. FEBS letters, 586, 2803-2812. 
SYRJÄNEN, S. 2010. The role of human papillomavirus infection in head 
and neck cancers. Annals of oncology, 21, vii243-vii245. 
SZELACHOWSKA, J., DZIEGIEL, P., JELEN-KRZESZEWSKA, J., JELEN, 
M., MATKOWSKI, R., POMIECKO, A., SPYTKOWSKA, B., JAGAS, M., 
GISTEREK, I. & KORNAFEL, J. 2006. Mcm-2 protein expression predicts 
prognosis better than Ki-67 antigen in oral cavity squamocellular carcinoma. 
Anticancer Res, 26, 2473-2478. 
TACHIBANA, K. E., GONZALEZ, M. A. & COLEMAN, N. 2005. Cell-cycle-
dependent regulation of DNA replication and its relevance to cancer 
pathology. J Pathol, 205, 123-9. 
TAKES, R. P., RINALDO, A., SILVER, C. E., PICCIRILLO, J. F., 
HAIGENTZ, M., SUÁREZ, C., VAN DER POORTEN, V., HERMANS, R., 
RODRIGO, J. P. & DEVANEY, K. O. 2010. Future of the TNM classification 
and staging system in head and neck cancer. Head & neck, 32, 1693-1711. 
                                                                                                                   Chapter 8: References 
242 
 
TAMURA, T., SHOMORI, K., HARUKI, T., NOSAKA, K., HAMAMOTO, Y., 
SHIOMI, T., RYOKE, K. & ITO, H. 2010. Minichromosome maintenance‐7 
and geminin are reliable prognostic markers in patients with oral squamous 
cell carcinoma: immunohistochemical study. Journal of oral pathology & 
medicine, 39, 328-334. 
TAO, Y.-M., TAO, Y.-S. & MA, L. 2011. Expression of Ki-67 and MCM2 
protein and their comparison in esophageal squamous cell carcinoma [J]. 
Chinese Journal of Clinical and Experimental Pathology, 4, 014. 
TAWFIK, K., KIMLER, B. F., DAVIS, M. K., FAN, F. & TAWFIK, O. 2013. Ki-
67 expression in axillary lymph node metastases in breast cancer is 
prognostically significant. Human pathology, 44, 39-46. 
TEIXEIRA, J. H., SILVA, P. M., REIS, R. M., MOURA, I. M., MARQUES, S., 
FONSECA, J., MONTEIRO, L. S. & BOUSBAA, H. 2014. An overview of the 
spindle assembly checkpoint status in oral cancer. BioMed research 
international, 2014. 
THOMPSON, S. L., BAKHOUM, S. F. & COMPTON, D. A. 2010. 
Mechanisms of chromosomal instability. Current biology, 20, R285-R295. 
THOMPSON, S. L. & COMPTON, D. A. 2011. Chromosomes and cancer 
cells. Chromosome research, 19, 433-444. 
TOBIN, N. P., SIMS, A. H., LUNDGREN, K. L., LEHN, S. & LANDBERG, G. 
2011. Cyclin D1, Id1 and EMT in breast cancer. BMC cancer, 11, 417. 
TOJO, M. J. R., CANO, F. J. G., SÁNCHEZ, J. C. I., FERNANDEZ, E. V. & 
URÍZAR, J. M. A. 2005. Immunoexpression of p53, Ki-67 and E-cadherin in 
basaloid squamous cell carcinoma of the larynx. Clinical and Translational 
Oncology, 7, 110-114. 
TONG, H., SHEN, R., WANG, Z., KAN, Y., WANG, Y., LI, F., WANG, F., 
YANG, J. & GUO, X. 2009. DNA ploidy cytometry testing for cervical cancer 
screening in China (DNACIC Trial): a prospective randomized, controlled 
trial. Clinical Cancer Research, 15, 6438-6445. 
TORRES-RENDON, A., ROY, S., CRAIG, G. & SPEIGHT, P. 2009a. 
Expression of Mcm2, geminin and Ki67 in normal oral mucosa, oral 
epithelial dysplasias and their corresponding squamous-cell carcinomas. Br 
J Cancer, 100, 1128-1134. 
TORRES-RENDON, A., STEWART, R., CRAIG, G., WELLS, M. & 
SPEIGHT, P. 2009b. DNA ploidy analysis by image cytometry helps to 
identify oral epithelial dysplasias with a high risk of malignant progression. 
Oral oncology, 45, 468-473. 
TORRES, E. M., WILLIAMS, B. R. & AMON, A. 2008. Aneuploidy: cells 
losing their balance. Genetics, 179, 737-746. 
                                                                                                                   Chapter 8: References 
243 
 
TOYOKAWA, G., MASUDA, K., DAIGO, Y., CHO, H.-S., YOSHIMATSU, M., 
TAKAWA, M., HAYAMI, S., MAEJIMA, K., CHINO, M. & FIELD, H. I. 2011. 
Minichromosome Maintenance Protein 7 is a potential therapeutic target in 
human cancer and a novel prognostic marker of non-small cell lung cancer. 
Mol Cancer, 10, 1-11. 
TRUONG, L. N. & WU, X. 2011. Prevention of DNA re-replication in 
eukaryotic cells. J Mol Cell Biol, 3, 13-22. 
TSANTOULIS, P., KASTRINAKIS, N., TOURVAS, A., LASKARIS, G. & 
GORGOULIS, V. 2007. Advances in the biology of oral cancer. Oral 
oncology, 43, 523-534. 
TSUJI, T., FICARRO, S. B. & JIANG, W. 2006. Essential role of 
phosphorylation of MCM2 by Cdc7/Dbf4 in the initiation of DNA replication 
in mammalian cells. Mol Biol Cell, 17, 4459-72. 
VAN DEN HEUVEL, S. 2005. Cell-cycle regulation. WormBook  21, 1-16. 
VAN ZYL, A. W., VAN HEERDEN, M. B., LANGENEGGER, E. & VAN 
HEERDEN, W. F. 2012. Correlation between dysplasia and ploidy status in 
oral leukoplakia. Head and neck pathology, 6, 322-327. 
VERHEIJEN, R., KUIJPERS, H., VAN DRIEL, R., BECK, J., VAN 
DIERENDONCK, J., BRAKENHOFF, G. & RAMAEKERS, F. 1989. Ki-67 
detects a nuclear matrix-associated proliferation-related antigen. II. 
Localization in mitotic cells and association with chromosomes. Journal of 
cell science, 92, 531-540. 
VIJAYRAGHAVAN, S. & SCHWACHA, A. 2012. The eukaryotic Mcm2-7 
replicative helicase. The Eukaryotic Replisome: a Guide to Protein Structure 
and Function. Springer. 
VILEN, S.-T., SALO, T., SORSA, T. & NYBERG, P. 2013. Fluctuating roles 
of matrix metalloproteinase-9 in oral squamous cell carcinoma. The 
Scientific World Journal, 2013. 
VISSCHER, D. W., WALLIS, T. L. & CRISSMAN, J. D. 1996. Evaluation of 
chromosome aneuploidy in tissue sections of preinvasive breast carcinomas 
using interphase cytogenetics. Cancer, 77, 315-320. 
WANG, L., LIU, T., NISHIOKA, M., AGUIRRE, R. L., WIN, S. S. & OKADA, 
N. 2006. Activation of ERK1/2 and cyclin D1 expression in oral tongue 
squamous cell carcinomas: relationship between clinicopathological 
appearances and cell proliferation. Oral oncology, 42, 625-631. 
WANG, Y., LI, Y., ZHANG, W.-Y., XIA, Q.-J., LI, H.-G., WANG, R., YANG, 
L., SUN, X.-F. & ZHOU, Z.-G. 2009. mRNA expression of minichromosome 
maintenance 2 in colonic adenoma and adenocarcinoma. European Journal 
of Cancer Prevention, 18, 40-45. 
                                                                                                                   Chapter 8: References 
244 
 
WARNAKULASURIYA, S., MAK, V. & MÖLLER, H. 2007. Oral cancer 
survival in young people in South East England. Oral oncology, 43, 982-
986. 
WARNAKULASURIYA, S., REIBEL, J., BOUQUOT, J. & DABELSTEEN, E. 
2008. Oral epithelial dysplasia classification systems: predictive value, 
utility, weaknesses and scope for improvement. Journal of oral pathology & 
medicine, 37, 127-133. 
WATT, F. M. & HOGAN, B. 2000. Out of Eden: stem cells and their niches. 
Science, 287, 1427-1430. 
WEAVER, B. A. & CLEVELAND, D. W. 2008. The aneuploidy paradox in 
cell growth and tumorigenesis. Cancer cell, 14, 431-433. 
WEAVER, B. A., SILK, A. D., MONTAGNA, C., VERDIER-PINARD, P. & 
CLEVELAND, D. W. 2007. Aneuploidy acts both oncogenically and as a 
tumor suppressor. Cancer cell, 11, 25-36. 
WESTRA, W. H. 2014. Detection of human papillomavirus (HPV) in clinical 
samples: Evolving methods and strategies for the accurate determination of 
HPV status of head and neck carcinomas. Oral oncology, 50, 771-779. 
WESTRA, W. H. The pathology of HPV-related head and neck cancer: 
Implications for the diagnostic pathologist.  Seminars in diagnostic 
pathology, 2015. Elsevier, 42-53. 
WHARTON, S., HIBBERD, S., EWARD, K., CRIMMINS, D., JELLINEK, D., 
LEVY, D., STOEBER, K. & WILLIAMS, G. 2004. DNA replication licensing 
and cell cycle kinetics of oligodendroglial tumours. British journal of cancer, 
91, 262-269. 
WILKEY, J. F., BUCHBERGER, G., SAUCIER, K., PATEL, S. M., 
EISENBERG, E., NAKAGAWA, H., MICHAYLIRA, C. Z., RUSTGI, A. K. & 
MALLYA, S. M. 2009. Cyclin D1 overexpression increases susceptibility to 
4‐nitroquinoline‐1‐oxide‐induced dysplasia and neoplasia in murine 
squamous oral epithelium. Molecular carcinogenesis, 48, 853-861. 
WILLIAMS, B. R., PRABHU, V. R., HUNTER, K. E., GLAZIER, C. M., 
WHITTAKER, C. A., HOUSMAN, D. E. & AMON, A. 2008. Aneuploidy 
affects proliferation and spontaneous immortalization in mammalian cells. 
Science, 322, 703-709. 
WILLIAMS, G. H. & STOEBER, K. 2007. Cell cycle markers in clinical 
oncology. Current opinion in cell biology, 19, 672-679. 
WILLIAMS, G. H. & STOEBER, K. 2012a. The cell cycle and cancer. J 
Pathol, 226, 352-64. 
WILLIAMS, G. H. & STOEBER, K. 2012b. The cell cycle and cancer. J 
Pathol, 226, 352-364. 
                                                                                                                   Chapter 8: References 
245 
 
WILLIAMS, M. A. 1977. Quantitative methods in biology. 
WOHLSCHLEGEL, J. A., KUTOK, J. L., WENG, A. P. & DUTTA, A. 2002. 
Expression of geminin as a marker of cell proliferation in normal tissues and 
malignancies. The American journal of pathology, 161, 267-273. 
WOJNAR, A., KOBIERZYCKI, C., KROLICKA, A., PULA, B., PODHORSKA-
OKOLOW, M. & DZIEGIEL, P. 2010. Correlation of Ki-67 and MCM-2 
proliferative marker expression with grade of histological malignancy (G) in 
ductal breast cancers. Folia Histochem Cytobiol, 48, 442-6. 
WON, H. S., JUNG, C.-K., CHUN, S. H., KANG, J.-H., KIM, Y.-S., SUN, D.-
I. & KIM, M.-S. 2012. Difference in expression of EGFR, pAkt, and PTEN 
between oropharyngeal and oral cavity squamous cell carcinoma. Oral 
oncology, 48, 985-990. 
WOOLGAR, J. A. 2006. Histopathological prognosticators in oral and 
oropharyngeal squamous cell carcinoma. Oral Oncol, 42, 229-39. 
XIAOYAN, S., XIANGLIN, Y., DEDING, T., JIANPING, G. & GUOQING, H. 
2005. Analysis of DNA ploidy, cell cycle and Ki67 antigen in nasopharyngeal 
carcinoma by flow cytometry. Journal of Huazhong University of Science 
and Technology [Medical Sciences], 25, 198-201. 
XOURI, G., LYGEROU, Z., NISHITANI, H., PACHNIS, V., NURSE, P. & 
TARAVIRAS, S. 2004. Cdt1 and geminin are down‐regulated upon cell 
cycle exit and are over‐expressed in cancer‐derived cell lines. European 
Journal of Biochemistry, 271, 3368-3378. 
YAMAZAKI, M., FUJII, S., MURATA, Y., HAYASHI, R. & OCHIAI, A. 2010. 
High expression level of geminin predicts a poor clinical outcome in salivary 
gland carcinomas. Histopathology, 56, 883-892. 
YU, C., ZHANG, X., HUANG, Q., KLEIN, M. & GOYAL, R. K. 2007. High-
fidelity DNA histograms in neoplastic progression in Barrett's esophagus. 
Laboratory investigation, 87, 466-472. 
ZHANG, X., TENG, Y., YANG, F., WANG, M., HONG, X., YE, L.-G., GAO, 
Y.-N. & CHEN, G.-Y. 2015. MCM2 is a therapeutic target of lovastatin in 
human non-small cell lung carcinomas. Oncology reports. 
ZHAO, L., WEI, W.-Q., ZHAO, D.-L., HAO, C.-Q., LIN, D.-M., PAN, Q.-J., LI, 
X.-Q., LEI, F.-H., WANG, J.-W. & WANG, G.-Q. 2012. Population-based 
study of DNA image cytometry as screening method for esophageal cancer. 
World journal of gastroenterology: WJG, 18, 375. 
ZHAO, Y., YU, D., LI, H., NIE, P., ZHU, Y., LIU, S., ZHU, M. & FANG, B. 
2014. Cyclin D1 Overexpression Is Associated with Poor Clinicopathological 
Outcome and Survival in Oral Squamous Cell Carcinoma in Asian 
Populations: Insights from a Meta-Analysis. PLoS One, 9, e93210. 
                                                                                                                   Chapter 8: References 
246 
 
ZHOU, H., TANG, Y., LIANG, X., YANG, X., YANG, J., ZHU, G., ZHENG, 
M. & ZHANG, C. 2009. RNAi targeting urokinase‐type plasminogen 
activator receptor inhibits metastasis and progression of oral squamous cell 
carcinoma in vivo. International journal of cancer, 125, 453-462. 
ZHU, S.-C., LI, R., WANG, Y.-X., FENG, W., LI, J. & QIU, R. 2005. Impact 
of simultaneous assay, the PCNA, cyclinD1, and DNA content with 
specimens before and after preoperative radiotherapy on prognosis of 
esophageal cancer-possible incorporation into clinical TNM staging system. 
World journal of gastroenterology, 11, 3823. 
ZHU, W., CHEN, Y. & DUTTA, A. 2004. Rereplication by depletion of 
geminin is seen regardless of p53 status and activates a G2/M checkpoint. 
Molecular and Cellular Biology, 24, 7140-7150. 
ZHU, W. & PAMPHILIS, D. M. L. 2009. Selective killing of cancer cells by 
suppression of geminin activity. Cancer Res, 69, 4870-4877. 
ZIMMET, J. & RAVID, K. 2000. Polyploidy: occurrence in nature, 
mechanisms, and significance for the megakaryocyte-platelet system. 
Experimental hematology, 28, 3-16. 
 247 
 
 
 
 
APPENDIX 1 
Solution and Reagents 
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1.1 Buffers used in immunohistochemistry methodology  
Phosphate buffered saline (PBS)  
 
 
75.2g K2HPO4 
13.2G NaH2PO4 
72.0G NaCL 
800ml distal water 
Sodium citrate buffer pH 6 
 
Sodium citrate 2.94g 
Distilled water 1L 
1M HCL (add it until pH reached) 
Tris / EDTA pH 9.0 
 
1.21x5 Tris 
0.37X5 EDTA  
5 litres distal water 
 
Mayer`s haematoxylin 
 
1g Haematoxylin  
50g potassium alum 
0.2g sodium iodate 
50g chloral hydrate  
1g citric acid  
3% Hydrogen peroxide 
 
3ml H2O2 in 100ml distal water  
 
APES solution 
 
2ml APES in 100ml acetone 
 
0.1% Calcium Chloride (pH 7.8) 
 
1g Calcium chloride  
1 litre Distal water 
 0.1M Sodium hydroxide  
 
4g NaOH 
1 litre 
 
 
1.2 Solutions used in Feulgen-Schiff stain for ploidy analysis 
5N HCL (1000 ml) 
431 ml HCL 
569 ml deionised water 
 0.05 HCL (900 ML) 
 
9 ml 5N HCL 
891 ml deionised water 
Feulgen stain kit Scy Tek Lab , USA 
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Detailed Data from the Each Chapter 
 250 
 
Chapter 2  
 MCM2 Ki67 Geminin Cyclin D1 
MCM2/Ki67 
ratio 
geminin/Ki67 
ratio 
NOM 0.50 0.65 0.83 0.73 0.98 0.47 
OSCC 
NM 
0.52 0.49 0.22 0.91 0.85 0.99 
OSCC 
M 
0.94 0.14 0.92 0.930 0.93 0.44 
OSCC 
LN 
0.13 0.42 0.0034 0.20 0.40 0.90 
OSCC NM = Oral squamous cell carcinoma that had not metastasised. 
OSCC M = Oral squamous cell carcinoma that had metastasised. 
OSCC LN = Lymph node metastases. 
 
 DI 5cER CV 
OSCC NM 0.311 0.215 0.990 
OSCC M 0.060 0.018 0.162 
OSCC LN 0.051 0.301 0.015 
*The CV value was not used for any statistical analysis. 
DI= DNA index. 
5cER= Cells that exceed 5c. 
CV= Coefficient of variance. 
 
Tow-tailed Kolmogorov-Smirnov test values from the analysed LIs, DI, 5cER 
results. P values that are less than 0.05 are not normally distributed. 
 251 
 
Chapter 4 
Correlation of protein expression with clinicopathological features. 
Correlation was not available between proteins expression and stage of 
disease in the OSCC M group, as all cases were stage III and IV. 
 OSCC NM 
 
Gender 
Tumour size Disease stage 
MCM2 p=0.83 p=0.83 p=0.83 
Ki-67 p=0.41 p=0.89 p=0.89 
Geminin p=0.16 p=0.17 p=0.17 
Cyclin D1 p=0.25 p=0.52 p=0.52 
MCM2/Ki-67 p=0.80 p=0.32 p=0.32 
Geminin/Ki-67 p=0.25 p=0.46 p=0.46 
Gender: Male and female. 
Tumour size: (T1&T2) and (T3 &T4). 
*Correlation was performed by t-test. 
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 OSCC M 
 
Gender Tumour size Disease stage 
MCM2 p=0.58 p=0.61 NA 
Ki-67 p=0.58 p=0.57 NA 
Geminin p=0.48 p=0.38 NA 
Cyclin D1 p=0.93 p=0.66 NA 
MCM2/Ki-67 p=0.31 p=0.11 NA 
Geminin/Ki-67 p=0.53 p=0.83 NA 
Gender: Male and female. 
Tumour size: (T1&T2) and (T3 &T4). 
*Correlation was performed by t-test. 
NA: Not applicable.  
 
 
OSCC LN 
 
 Gender Tumour size Disease Stage 
Extra capsular 
spread 
MCM2 p=0.65 p=0.82 p=0.83 p=0.32 
Ki-67 p=0.09 p=0.80 p=0.89 p=0.70 
Geminin p=0.71 p=0.92 p=0.17 p=0.98 
Cyclin D1 p=0.28 p=0.40 p=0.52 p=0.54 
MCM2/Ki-67 p=0.36 p=0.94 p=0.32 p=0.53 
Geminin/Ki-67 p=0.74 p=0.41 p=0.46 p=0.52 
Gender:  Male and female. 
Tumour size: (T1&T2) and (T3 &T4). 
Stage: (I &II) and (III &IV). 
Extra capsular spread: Yes and no. 
*Correlation was performed by t-test.  
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Chapter 5 
Contingency tables of the ploidy status data that was analysed for the 
sensitivity, specificity, PPV and NPV calculation. 
 
Groups  Total 
 OSCC M OSCC NM 
Aneuploidy 39 (TP) 47(FP) 86 
Diploid 0 (FN) 0 (TN) 0 
 
 
Groups 
 
OSCC M OSCC NM 
DI> 1.2 39 (TP) 47 (FP) 86 
DI<1.2 0 (FN)  0 (TN) 0 
Total 39 47 86 
TP= True positive. 
FP= False positive. 
TN= True negative. 
FN= False negative. 
 
 
Groups  Total 
 OSCC M OSCC NM 
5cER >1 10 (TP) 7(FP)  17 
5cER <1 29 (FN) 40 (TN) 69 
Total 39 47 86 
TP= True positive.  
FP= False positive. 
TN= True negative. 
FN= False negative. 
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Chapter 6  
Correlation Coefficient values of DNA content (DI and 5cER) with MCM2, 
Ki-67, geminin, cyclin D1 and MCM2/Ki-67 and geminin/Ki-67 ratios. 
 Groups 
OSCC-M OSCC-NM OSCC LN 
DNA Status 
Correlation Coefficient 
Total.MCM2 0.268 0.194 -0.150 
Total.Ki-67 0.059 -0.254 -0.335* 
Total. Geminin 0.005 0.124 0.180 
Total.CD1 0.195 0.066 -0.238 
Total.MCM2/Ki-67 0.046 0.316 0.358 
Total. Geminin/Ki-67 -0.118 0.300 0.305 
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Groups 
OSCC M OSCC NM OSCC LN 
Correlation Coefficient 
Total.MCM2 
DI 0.219 0.336* -0.049 
5CER >1% 0.188 0.133 0.045 
Total.Ki-67 
DI -0.067 -0.065 -0.267 
5CER >1% 0.034 -0.196 -0.016 
Total. Geminin 
DI -0.221 0.010 0.269 
5CER >1% -0.102 0.069 0.272 
Total.CD1 
DI 0.377* 0.077 -0.148 
5CER >1% 0.238 -0.044 0.045 
Total.MCM2/Ki-67 
DI 0.164 0.193 0.303 
5CER >1% 0.071 0.152 0.122 
Total. Geminin/Ki-67 
DI -0.289 -0.100 0.318 
5CER >1% -0.113 0.387 0.323 
 
